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 ABSTRACT  
Advancements in capsule endoscopy technology allow it to image the upper 
gastrointestinal tract. Oesophagogastroduodenoscopy (OGD) is the gold standard 
examination, but it is often poorly tolerated and requires sedative premedication. This 
thesis examines how capsule endoscopy can improve the quality of an upper GI 
endoscopic examination.  
 
The first study examines the rate of, and factors affecting missed cancer occurrence 
after conventional OGD. In this retrospective study, a total of 48 (7.7%) of 627 patients 
with oesophagogastric cancer had OGDs up to three years prior, which are considered 
missed opportunities to diagnose early neoplasia. Endoscopy sessions with missed 
cancer occurrence had at least one procedure more when compared to sessions where 
cancer was subsequently diagnosed or sessions where benign focal lesions were 
diagnosed.  
 
In the next two studies, we examine the patients experience in a comparative study of 
tolerance and acceptability between magnet controlled capsule endoscopy (MACE) and 
conventional OGD (n=44) and transnasal endoscopy (TNE; n=16). By comparison to 
OGD in Chapter 4 and TNE in Chapter 5, patients were more accepting of and preferred 
MACE. Patients experienced significantly more distress (greater distress with higher 
median score) due to gagging (6 vs 1), choking (5 vs 1), abdominal bloating (2 vs 1), 
instrumentation (4 vs 1), discomfort during (5 vs 1) and after (2 vs 1) OGD when 
compared to MACE (all p<0.0001). Patients undergoing TNE were more distressed by 
gagging (1.5 vs 1, p=0.03), choking (3 vs 1, p=0.001), instrumentation (4.5 vs 1, 
p=0.001), discomfort during (5 vs 1, p=0.001) and after TNE (2 vs 1, p=0.01) by 
comparison to MACE.  
 
A small bowel examination can be performed immediately after an upper GI MACE. It 
is hypothesised that laxative pre-procedure preparation may benefit small bowel 
mucosal visualisation, although likely to impact on tolerability and acceptance. The 
fourth study examines how to optimise an upper GI MACE examination to investigate 
 
iv 
the small bowel. In advance of a small bowel capsule endoscopy, 186 patients were 
randomised to three pre-procedure preparation groups: clear fluids only or a single or 
split dose of polyethylene glycol (PEG) the examine the need for laxative pre-procedure 
medication. Split dose PEG improved distal small bowel mucosal views and overall 
adequacy of examination compared to clear fluids alone, although patients tolerated 
better and were more accepting of the later.  
 
Acceptance of novel technology may be prohibited by cost. In the final study, we 
perform a cost minimisation analysis to examine how the cost of MACE compares to 
TNE and OGD, and examine in scenario analyses the potential effects of the COVID-19 
pandemic and need for endoscopic biopsies on cost. We found that per procedure, 
MACE was most expensive (£329.40), followed by OGD (£121.67) and TNE (£90.10). 
As a result of the COVID-19 pandemic, the costs of OGD and TNE would rise by 
between 27% to 112% depending on changes in endoscopy capacity. In scenario 
analyses, cost parity between MACE and OGD could be reached if the price of single 
use capsule endoscopes fell by two thirds. If endoscopy capacity fell to 40%, cost parity 
could be reached if the price of capsule endoscopes fell by a third.  
 
This thesis supports the use of MACE in the upper GI tract from the perspective of a 
superior patient experience compared to conventional OGD. Further improvements in 
imaging technology and reduction in cost of MACE will advance capsule endoscopy in 
the examination of the upper GI tract.  
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1 INTRODUCTION 
Upper gastrointestinal (GI) endoscopy involves examining the upper gastrointestinal 
tract from the upper oesophagus to the second part of the duodenum. Conventional 
upper GI endoscopy, gastroscopy or oesophagogastroduodenoscopy (OGD) requires 
intubation of the upper oesophagus using a flexible endoscope which is achieved 
conventionally through the mouth, over the tongue and via the oropharynx. This gold-
standard examination however can be uncomfortable and poorly tolerated amongst 
patients who often opt for conscious sedation. An alternative technique for examining 
the upper GI tract, like transnasal endoscopy (TNE) is less intrusive. TNE makes use of 
a thinner flexible endoscope which is passed into the oesophagus through the nasal 
passages and via the nasopharynx.  
 
Capsule endoscopy differs from flexible endoscopy. A light emitting diode (LED) light 
source and image sensors powered by a battery contained within a pill transmits images 
wirelessly. Wireless capsule endoscopy (CE) has now been used to explore the small 
intestine for 20 years 1. This routine examination of the small intestine has led to the 
adaptation of the capsule endoscopy platform towards other parts of the GI tract, such 
as the colon 2 and recently the upper GI tract. This thesis appraises the role of 
conventional flexible upper GI endoscopy and examines the impact of capsule 
endoscopy on the quality of care in upper GI endoscopy.   
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1.1 Conventional upper GI endoscopy  
 
  Conventional Oesophagogastroduodenoscopy (OGD) is the current gold-
standard in endoscopic diagnosis of luminal upper GI disease. In symptomatic patients, 
OGD can help to differentiate between endoluminal disease from symptoms of 
dysmotility, neuroenteric and functional disorders. Common indications for OGD 
include symptoms of dyspepsia, a syndrome including upper abdominal discomfort, 
pain, bloating and heartburn, dysphagia, iron deficiency anaemia or weight loss. In the 
United Kingdom (UK) 0.8% of the population undergo OGD every year and this has 
seen a 40% increase in procedures performed in the last 10 years (Figure 1). One of the 
main roles of OGD is distinguishing benign from malignant disease.  Up to 2% of 
patients are found to have oesophagogastric malignancy 3,4. 
 
 
Figure 1: Number of OGD and colonoscopy procedures performed in the UK 
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Depending on local incidence, OGD has also an evolving role in the surveillance for 
and screening of pre-malignant pathologies, which can give rise to oesophageal and 
gastric adenocarcinoma in the order of 0.2% per patient per annum.5,6 
 
1.1.1 Oesophagogastric malignancy 
 
There is a variation in the incidence of oesophagogastric (OG) malignancy worldwide. 
Oesophageal and gastric cancers overall are the 13th and 17th most common malignancy 
in the UK and are diagnosed in 0.7% of patients who present to primary care with alarm 
features 7,8. Incidence of gastric adenocarcinoma is on the decline in the UK, however 
there is an increase in oesophageal adenocarcinoma due to an increasing prevalence of 
Barrett’s oesophagus 9,10. Both oesophageal and gastric cancers have poor prognoses in 
the UK. They present in the more advanced stages (TNM stage 3 and 4) in 75% 11,12 
with up to a third of patients diagnosed after an emergency admission to secondary 
care. 13 Curative treatment is only suitable in a select 30-40%, with only 20% 
undergoing surgical treatment 14 and an overall 5-year survival rates of 15% and 20% 
respectively. 8 
 
In contrast, the incidence of gastric cancer is over 6 times greater in Japan than the UK 
with estimated age standardised incidence of 29.9 compared to 4.7 per 100,000 
population in the UK 15. In Japan, the high burden of gastric cancer and, in part, vigilant 
population based fluoroscopic and endoscopic screening have meant that over 50% of 
gastric cancers on diagnosis are confined within the mucosa or submucosa (Tumour 
Node Metastasis TNM stage 1a and 1b) 16. Such early neoplasia is amenable to surgery 
or endoscopically organ preserving resection techniques which effectively cure early 
OG neoplasia with 10-year overall survival rates of 95% 17. The success of health 
screening strategies depends on the performance of the screening tool, the incidence of 
disease, but also uptake of the screening test. Tests which are better accepted and 
tolerated by patients are more likely to be associated with greater uptake.18 Less 
invasive methods of screening by comparison to conventional endoscopy are expected 
to be better accepted and therefore may support screening efforts for upper GI 
malignancies. Attempts at screening for Barrett’s oesophagus using novel technologies 
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such as Cytosponge™ a  have been well accepted by patients, 19 while transnasal 
endoscopy and oesophageal capsule endoscopy are preferred by patients than 
conventional OGD, 20,21 therefore may play a role in the prevention of oesophageal 
cancer.  
1.1.2 Post OGD Upper GI Cancer: How gold is the gold standard? 
 
Studies of patients diagnosed with OG malignancy have shown that there is a rate of 
missed cancer with gastroscopy.  Fujita (1978) proposed that early gastric cancers 
(EGCs) have a superficial growth pattern where the majority of cells are on the surface 
of the gastric mucosa and spread laterally 22. He proposed that the cellular doubling 
time of EGCs are estimated at 2-3 years, limited by the mechanical abrasion and 
desquamation of the epithelial wall when spreading laterally at its early stages. This is 
in contrast to the growth pattern of advancing cancers, which penetrate into the tissue, 
limited only by the supply of nutrients and oxygen, and therefore have a cellular 
doubling time amounting to months. It is believed therefore that an early (or advanced) 
gastric cancer seen on endoscopy would have been visible one year prior and 
potentially up to three years prior to endoscopic diagnosis 
 
In Western populations, single centre studies 23-28 and pooled meta-analysis 4 report that 
between 5.3 and 13.9% of patients with OG malignancy have had a seemingly negative 
OGD within three years of OG cancer diagnosis and are termed Post-OGD Upper 
Gastrointestinal Cancers (POUGIC). These diagnoses are therefore considered to be 
potential missed diagnoses if the OGD was performed within one to three years, and 
definitely missed diagnoses when performed within one year of the diagnostic OGD 25. 
 
Recent data from UK wide population based registry studies report oesophageal and 
gastric cancer are missed within the previous three years in 8.3% and 7.8% respectively 
                                                
a The Cytosponge is an ingestible gelatine capsule containing a compressed mesh attached to a string. 
Five minutes after ingestion the capsule dissolves and the spherical mesh is retrieved back up the 
oesophagus collecting cytological samples along the length of the oesophagus for analysis. 
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11,12. Missed cancer occurrence are associated with the presence of alarm features 25,27, 
female gastric cancer patients under the age of 55 years 11 and early disease  (TNM T 
0/1 stage) at diagnosis 11,12. In between 30 to 70% of POUGIC procedures, 
abnormalities have been described at the site of malignancy and therefore endoscopist 
(missing a lesion, not sampling a visible lesion or inadequate sampling) and 
histopathologists error could explain up to 70% of POUGICs 25,27.  The reasons for 
these ‘errors’ however are not entirely clear and subject to substantial discussion on 
how to improve the quality of OGDs and facilitate earlier detection OG cancer. 
1.2 Factors affecting the quality of conventional OGD 
 
What is a high-quality endoscopy? The three dimensions of quality of care are safety, 
clinical effectiveness and patient experience 29 and so a discussion about a high quality 
of endoscopy depends on perspective.  From a clinical perspective a technically high-
quality endoscopy can be considered one where “patients receive an indicated 
procedure, correct and relevant diagnoses are recognized or excluded, any therapy 
provided is appropriate, and all steps that minimize risk have been taken.” 30   
 
On the other hand, a high-quality endoscopy can also be seen from the patients’ 
perspective where a positive patient experience can be defined as one that involves the 
whole team getting to know the patient as an individual, tailoring their care accordingly, 
while building lasting relationships which enable patients to participate in their care 31. 
In this section, we discuss the factors that affect the quality of upper GI endoscopy from 
both a technical and a patient experience perspective.  
1.2.1 Factors which affect a technically high-quality OGD 
 
Advancements in endoscopic imaging technology has led to optical near focus 
magnification and optical chromoendoscopy. With an ever-expanding arsenal of tools at 
our disposal there has been an appropriate interest to review the basics techniques in 
upper GI endoscopy and formalise quality measures around the world with a specific 
focus on improving the sensitivity of gastroscopy in pathology detection. 32-34  
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1.2.1.1 Examination time 
 
Studies have suggested that endoscopist performing procedures quickly increases the 
risk of missed pathology.35,36 One retrospective study of neoplastic findings on OGD 
have suggested that endoscopists who performed procedures lasting over seven minutes 
have a threefold increase in detection of gastric neoplasia (OR 3.4; 95% CI 1.2 – 10.3) 
and were twice as likely to detect high risk lesions (OR 2.5; 95% CI 1.5 – 4.1) 
compared to quicker endoscopists 37. An inspection time of more than 1 minute per 
centimetre (cm) of Barrett’s oesophagus increases detection of high grade dysplasia and 
adenocarcinoma 36. Similarly, colonoscopist who have a mean extubation time of 
greater than six minutes have been shown to detect a greater number of colorectal 
adenomas and cancers than their swifter counterparts 35. Therefore, it is reasonable to 
conclude that longer procedure times can be a surrogate for a more thorough and 
detailed examination.  
 
1.2.1.2 Endoscopist experience 
 
It is logical however that the duration spent examining the upper GI tract is only as 
effective as the experience of the endoscopist in detecting pathology. Case series and 
population based studies have suggested lower rates of POUGIC associate with 
endoscopists with more than 10 years’ endoscopy experience 38, medical (versus 
surgical) endoscopists 39 and procedures performed at specialist centres 40,41. On the 
other hand, Teh et al. amongst others 25,41 have not found that endoscopist experience 
nor professional background (medical or surgical) contributed significantly to rates of 
POUGIC. Endoscopist experience is clearly associated with colonic polyp detection 
rate 42-44 and there is some evidence that it is associated with better diagnostic capability 
in OGD. Two studies have concluded that training and experience in gastroscopy does 
correlate with the ability to detect Helicobacter pylori infection and gastric intestinal 
metaplasia  45,46, both potentially premalignant conditions, requiring recognition of 
subtle endoscopic features. However, it is also likely that even with increasing 
experience or “seniority”, without recognition of the importance of continuous personal 
and professional development and personal reflection, the nuances in detecting subtle 
neoplasia may be lost and result in a less accurate examination.  
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1.2.1.3 Patient co-operation and tolerance to OGD 
 
That time spent inspecting the upper GI tract is one of the most important factors in the 
sensitivity of OGD, it makes sense that a distressed patient will limit ease of endoscopy 
and duration of inspection. Intravenous sedation can be used to augment patient 
tolerance to the procedure and benzodiazepines are the most commonly used non-
dissociative class of sedative for which there are four recognised states of sedation. 
Minimal sedation is a mild anxiolytic and the patient is fully alert. A deeper, moderate 
or conscious, sedation is a state of sleepiness aroused by voice or light touch. Deep 
sedation is defined by a patient requiring painful stimuli to evoke a purposeful response, 
where otherwise spontaneous ventilation may often be inadequate. The use of moderate 
sedation is a satisfactory compromise and is widely considered to improve the quality 
of endoscopy, although most of the evidence relates to improvement in completion and 
adenoma detection rates in colonoscopy 47-49. The use of sedation however does not 
seem to have an effect on the ease of OGD for the endoscopist 50-52, with pharyngeal 
local anaesthetic being most beneficial in improving technical adequacy by reducing 
patient retching. 53 However, there are no studies examining the effect of patient 
tolerance on pathology detection and few studies on the technical success of OGD. One 
study of unsedated patients suggested that after an examination time of 4 minutes a 
technically adequate examination could be achieved in 96%, and although 80% would 
repeat again unsedated, satisfactory tolerance was only reported in 61%. 54 Taken 
together therefore, where best practice suggests that inspection times should be 
increasing, it is likely to be at the cost of an acceptable patient experience. Patient 
acceptance may be improved with re-introduction of historical deeper sedation practices 
55, but at the expense of patient safety, recovery time and costs. Nevertheless, a study of 
colonoscopy has suggested that more experienced endoscopists performed more 
comfortable procedures with less sedation use and a higher completion rate suggesting 
that technique and experience are also fundamentally important 56.  
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1.2.2 A high-quality upper GI endoscopy: a patient experience 
 
Patient experience is the third pillar of quality of care, but less well understood in upper 
GI endoscopy. We consider here, the different measures of patient experience and then 
appraise the tolerance and acceptability of conventional OGD.  
 
1.2.2.1 Measures of patient experience in endoscopy 
 
The aim of understanding patient experience in endoscopy is to direct feedback towards 
promoting positive clinical practices. Measures of patient experience can help identify 
and contextualise factors associated with positive or negative experiences. The most 
common measure of the quality or experience in endoscopy care is patient satisfaction 
of the procedure 57. Patients satisfaction are likely to occur if the healthcare encounter 
meets patients expectations with positive outcomes. 58,59 Meeting these expectations 
have been shown to result in positive health behaviours, improved clinical response and 
adherence to treatment  60,61 and accordingly, an unmet expectation is associated with 
lower satisfaction and weaker intentions to adhere to management.62 In theory 
therefore, a patient with negative expectations but positive outcomes could be expected 
to have greater satisfaction than a patient with positive expectations and similarly 
positive outcomes. However, equally it may be that patients with positive expectations 
are more primed towards being satisfied with a positive outcome than those with 
negative expectations.63  Patient satisfaction and willingness to repeat an endoscopy 
however are not synonymous measures of patient experience.64 If the aim of examining 
patient experiences is to improve on the delivery of quality care, patient’s expectations 
set too low or too high, may mean their satisfaction may be too insensitive to recognise 
deficiencies in their care. Therefore, patient acceptance or willingness to repeat an 
investigation would be a preferred indicator of future behaviour compared to 
satisfaction.  
 
In an attempt to understand what influences patient acceptance, specific constructs 
related to endoscopy such as anxiety prior to endoscopy and adverse symptoms (of 
discomfort or pain) before, during and after the endoscopic procedures are commonly 
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measured. Patients experiences of endoscopy are however more comprehensive than 
just procedural tolerance 65 and endoscopists consistently overestimate the importance 
of adverse physical symptoms. 66,67  
 
Measures of patient acceptance in endoscopy, such as the Endoscopy Concerns Scale 
(ECS) score, were therefore devised to account for distresses peripheral to the tolerance 
of the procedure such as embarrassment, pre-procedure fasting, and intravenous 
cannulation; and to account for all stages of the healthcare encounter including pre-
procedure preparation and post procedure care. 65 The content validity of PREM tools 
such as the ECS may be questioned. That most studies which examine patient 
experience are framed in the context of procedural tolerance is unsurprising. Tools like 
the ECS are often based on clinical, but less often patient opinion, and on self-
perpetuating literature review. 57  Therefore understanding the aspects of a healthcare 
encounter that is valued by and importantly, framed by the patients can therefore more 
accurately reflect their experiences. The Universal Patient Centeredness Questionnaire 
(UPC-Q) is a patient reported experience measure (PREM) where patients determine up 
to three noteworthy aspects of the healthcare experience, rates their experience and 
ranks the aspects by their relative importance. 68 This patient generated index has been 
shown to have construct validity when compared to measures of experience, satisfaction 
and self-perceived health amongst hospital and psychiatric inpatients, and primary care 
outpatients, but has not been validated in hospital outpatient settings.  
1.2.2.2 Patient experience of conventional OGD 
 
The literature on patient experience is dominated by studies examining procedure 
tolerance. When asked, patients in fact prioritise the technical skill and personal manner 
of the endoscopist over control of discomfort. 66,69,70  Furthermore, less priority is given 
to waiting times prior to and on the day of the appointment, privacy and single sex 
environments. These findings are consistent in with both upper and lower GI 
endoscopy, with no difference amongst those undergoing with or without sedation71.  
 
During conventional OGD, discomfort and retching are often experienced due to the 
triggering of the gag-reflex as the endoscope stimulates the oro-pharynx. OGD is 
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feasible for many patients with topical oro-pharyngreal anaesthesia alone, however 
many highly motivated patients find OGD uncomfortable despite their willingness to 
repeat the OGD under the same conditions. 54 Pharyngeal sensitivity (defined as 
pharyngeal constriction with application of topical oropharyngeal anaesthetic), younger 
age and pre-procedural anxiety have been suggested to predict poor tolerance to 
unsedated OGD 54,72. Sedation practices for diagnostic OGD vary considerably 
worldwide. Virtually all procedures are done under sedation in United States and 
Australia, but in less than a quarter of procedures in surveyed European countries. 73,74 
In the United Kingdom, data from the National Endoscopy Database pilot suggest that 
in 2018, around 50% of patients opted for conscious sedation (personal communication: 
Dr Keith Siaw). Sedation may improve patient experience. In a meta-analysis of 
randomised control trials of moderate sedation in endoscopy, only 2 studies were 
identified examining the use of sedation against placebo in OGD. It showed that 
patients were over two-fold more likely to be satisfied with, and 25% more likely to be 
willing to repeat OGD with sedation compared to without. 55 A number of other studies 
have examined the effect of sedation on patient tolerance for OGD and broadly report 
that patient comfort is improved by use of sedation. 50,51,53,75 In the largest of these 
studies (340 patients), Ristikankare et al. (2004) report that midazolam significantly 
reduces the difficulty of intubation and discomfort experienced by the patient compared 
to placebo and control.  
 
1.2.3 The safety of conventional OGD 
 
 Diagnostic OGD is safe and adverse events occur in between 0.01 – 0.5% of 
cases 76. The majority are cardiopulmonary adverse events related to sedation and these 
occur in the order of 0.3% of sedated procedures. 77 Luminal perforation occurs in up to 
0.04% of diagnostic procedures. 78 A recent study has suggested that up to 1% of 
patients undergoing OGD are treated for an infection within 30 days of OGD, five times 
greater than patients undergoing a non-invasive screening mammography. 79 Most of 
these infections were respiratory tract infections and 60% required hospitalisation.   
1.3  Less invasive alternatives in upper GI endoscopy 
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 OGD is uncomfortable and although rare, is associated with significant risks of 
aspiration and infection. Less invasive alternatives in upper GI endoscopy, transnasal 
endoscopy (TNE) and capsule endoscopy are appraised in the following sections, with a 
detailed review on the advancements in capsule endoscopy and the clinical 
effectiveness of capsule endoscopy in the investigation of the upper GI tract.  
 
1.3.1 Transnasal endoscopy 
 
 Transnasal endoscopy use is increasing worldwide. In Japan where enthusiasm 
for TNE originated, a third of outpatient clinics offer TNE outside of a formal 
endoscopy setting 80. The use of an ultrathin diameter endoscope allows upper GI 
endoscopy to be performed through the nasal passages after dilatation and anaesthesia 
of the nasal passages with a topical decongestant and local anaesthetic (Figure 2). The 
benefit of this passage of insertion is that the nasopharynx avoids the gag-reflex 
triggered by afferent stimulation of structures supplied by the 9th cranial nerve within 
the oro-pharynx. 
 
Figure 2: Standard gastroscope and ultra-thin transnasal gastroscope 
A 11mm diameter standard gastroscope (left) compared to a 5.9mm ultra-thin transnasal gastroscope (right)  
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The technical performance of TNE is comparable to conventional OGD. The technical 
success rate of TNE with a less than 5.9mm diameter endoscope is 98% and in 
comparison, no different to OGD 21. The diagnostic yield of Barrett’s oesophagus and 
oesophageal varices are similar between the two modalities 81,82. One study comparing 
high resolution OGD with TNE suggested TNE was inferior in detecting superficial 
gastric neoplasia 83. Earlier generation transnasal endoscopes were challenged by less 
numerous optical fibre bundles and charged coupled device pixels resulting in 
insufficient mucosal illumination and image resolution of capacious areas of the 
stomach, for example at the fundus. However, follow up studies comparing new 
generation transnasal endoscopes with near focus magnification and narrow band 
imaging  have since reported similar performances between ultrathin and conventional 
endoscopes. Transnasal passage however does mean there is additional risk of self-
limiting epistaxis in between 2-5% 84-86 rising to 14% in 28 patients with significant 
bleeding diathesis (platelet count <50 and or INR >1.7) secondary to chronic liver 
disease 82.   
 
Patients undergoing TNE find the experience highly acceptable with 85% willing to 
undergo TNE again the in future and 63% preferring TNE over OGD. 21 Further, the 
use of sedation with OGD does not affect preference between TNE and OGD. 21 Due to 
superior patient tolerance, TNE is usually performed without sedative premedication, 
thereby eliminating sedative related adverse events. The TNE procedure also seems to 
be less physiologically stressful with a smaller rise in pulse rate and systolic blood 
pressure during the procedure compared to OGD 87,88.  
 
1.3.2 Capsule endoscopy 
 
Capsule endoscopy is a non- invasive procedure where the GI tract is examined using a 
wireless pill sized capsule endoscope swallowed by the patient. Its principal 
components are a battery, an array of LEDs, an antennae and transmitter for wireless or 
electric field propagation of images, and an image sensor – most commonly a 
complementary metal oxide semiconductor (CMOS). Originally introduced in 2000 to 
image the small bowel, the first model (M2A capsule, Given Imaging, Yoqneam, Israel) 
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acquired two images per second and sent images wirelessly to a portable data recorder 
1,89,90.  
  
Although non-invasive, complications do occur with capsule endoscopy. Capsule 
retention occurs in about 1% when used for small bowel examinations, 91 more 
commonly when examining patients with suspected or established Crohn’s disease. 92 
Bronchial aspiration of capsules occur much less frequently. A review of case reports 
estimates that it occurred in 0.1% of patients at most, usually in men over 80 years of 
age. 93 However, devices were spontaneously expectorated by half the patients, and the 
remainder needed bronchoscopic removal with no fatalities reported.  
 
1.3.2.1 The challenges of upper GI capsule endoscopy 
 
In the tubular small bowel, video capsules are propelled passively by peristaltic 
movements in a relatively unidimensional plane. The capsules of around 25 x 10mm in 
dimension pass through a 25-30mm diameter small bowel and therefore have minimal 
side to side movement. Even when rotated at an angle away from the lumen, modern 
small bowel capsule endoscopes have a wide 150-170° field of view so the immediate 
mucosal surface is splayed up against peripheries of the optical dome with upcoming 
mucosa in the centre view. 
 
The upper GI tract is made of three distinct areas, the oesophagus, stomach and 
duodenum, and each have their own challenges to visualise with a capsule endoscope. 
The stomach is a capacious hollow viscus with an unusual configuration, is collapsed in 
the fasted state and gravity dictates that a capsule rapidly locates to the dependent part. 
In contrast both the oesophagus and duodenum are tubular structures and while transit 
is relatively stable, the effects of gravity and peristalsis propel capsules quickly. It was 
recognised early that the rapid oesophageal transit of capsules (as fast as 20cm per 
second in the proximal oesophagus) along with a lack of orientation control of single 
sensor capsules meant that complete assessment of the oesophagus was unreliable 94,95. 
The developments in capsule imaging technology have therefore had to simultaneously 
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address the challenges of negotiating the whole surface area of the stomach and 
potential rapid transit through oesophagus and duodenal bulb.  
 
 Advancements in capsule endoscopy imaging technology have resulted in 
measurable improvements. An increase in frame acquisition from two per second and 
an eight hour battery life in the PillCam SB2 (Given Imaging, Yoqneam, Israel) to 2-6 
(variable rate) frames per second and a 12 hour battery in the PillCam SB3 (Given 
Imaging) resulted in an increased small bowel completion rate 96 and diagnostic yield 
for small bowel pathology 97. When two image sensors, one at each end are used, 
improvements in the detection of small bowel lesions 98 and the ampulla of Vater 99 can 
also be demonstrated. 
 
 To date there have been several approaches to achieving a complete upper 
gastrointestinal tract examination with capsule endoscopy. Upper GI capsule endoscopy 
systems in clinical practice are described in Table 1. Key technological developments in 
imaging technology include improvements in battery life, optics and image sensor, 
along with external control of capsule endoscopes have been feasible due to addition of 
real time view and capsule endoscopes with magnetic inclusions. These developments 
are summarised in a timeline (Figure 3). Key clinical studies discussed in the following 
chapters comparing upper GI capsule endoscopy to conventional OGD are summarised 
in Table 2. 
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Figure 3: Key advances leading towards a wireless oesophagogastro duodenoscopy  
† First human studies using wireless capsule endoscopy was reported in Nature in 2000 after collaboration between Paul Swain in UK and Gavriel Iddan, Gavriel Meron and Arkady 




endoscopy introduced by 
Iddan, Meron and Swain✝
Dedicated esophageal capsule 
piloted (Eliakim et al 2004)
• Bidirectional image sensors
• 4 fps 
• 20 minutes imaging
• Mean 189 sec esophageal 
examination swallowed supine
Esophageal capsule endoscopy first 
attempted (Neu et al 2003)
• M2A (small bowel) capsule 
(single camera, 2 fps)
• Mean 2 sec esophageal 
examination swallowed prone
Capsules tethered to string used to 
assess oesophagus (Ramirez et al 
2005)
• M2A capsule
• Mean 8 minutes esophageal 
examination
First generation esophageal 
capsule marketed (PillCam 
ESO) (Koslowsky et al 
2006)
• 14 fps
• 20 minute imaging
2010
Magnetic actuation of 
capsule  endoscopes 
demonstrated in human 
volunteer using an 
external handheld magnet 




• Improved 90 minute 
imaging, 35 fps for 10 




added to Mirocam 
small bowel capsules 
(Mirocam Navi)
Second generation Pillcam ESO2 
(Gralnek et al 2008)
• Improved optics and Field of view 
169º  
• Improved frame rate 19 fps
• Automatic LED light exposure 
control
• 30 minutes imaging
Third generation Pillcam
ESO3
• 35fps in oesophagus
• Improved Field of view 
174º
Real time view achieved using 
attachable laptop introduced to 
Pillcam platform
Real time view integrated 
into Pillcam data 
recorders
Olympus and Siemens collaborate and introduce an robot 
assisted electromagnet system (Rey et al 2011)
Commercial robot-assisted magnetic 
system (NaviCam) released using a 
fixed permanent magnet (Liao et al 
2012)
Bidirectional image sensors 
with magnetic inclusions 
(Mirocam Navi)
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Table 1: Technical specifications for upper GI capsule endoscopes in the literature 
 
 
*35 fps for the first 10 minutes and 18 fps for last 80 minutes. CMOS; complementary metal oxide semiconductor, CCD; charged coupled device, MGCE; Magnetic Guided Capsule 
Endoscope, RF; radiofrequency, EFP; electric field propagation, EM; electromagnet, mT; milliTesla, NR; not reported. 
  
 Image Capsule Control 







Field of view 
(degrees) / depth 
(mm) 




Transmission Type Control Field 
strength 
Pillcam ESO 14 CMOS / 2 NR 140/ 0.1-30 11 x 26 / 2.9 0.33 RF - - - 
Pillcam ESO 2 19 CMOS / 2 256 x 256 169/ 0.1-30 11.4 x 26.4 / 2.9 0.5 RF - - - 
Pillcam ESO 3 35 / 18 * CMOS / 2 256 x 256 172 / 0.1-30 11.6 x 31.5 / 2.9 0.5 RF - - - 




3 CMOS / 1 320 x 320 170/ 0-30 25 x 11 / 3.2 >11 EFP Fixed Handheld 0.2T 
Olympus-Siemens 
MGCE 4 CCD / 2 NR NR 31 x 11 / NR 0.5 RF EM Robot 100mT 
Ankon Technologies  
AKT-1 NaviCam 2 CMOS / 1 480 x 480 >120 / 0-30 28 x 12 / 5 >8 RF Fixed Robot 200mT 
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Table 2: Clinical studies comparing capsule endoscopy against conventional OGD 
  Study Outcomes 
 Reference Type Participant 














al. (2009) 20 
Meta-
analysis 
618 patients, 9 
studies, Screening 




transit time  
1 – 1678s 
NR None 
reported 
2 studies – 
histology 





OGD only   
3 studies; all 
show majority 
preferred CE 
Pooled specificity 86% and 
sensitivity 77% for Barrett’s 
Oesophagus 




446 patients, 7 
studies, Screening 





135 – 251s 
NR NR Blinded 
OGD 
NR Overall pooled specificity 81% 
and sensitivity 86% for OV 
Screening OV patients only (4 
studies; 106 patients) pooled 















Varices, 16 healthy 
controls  







score CE vs 
OGD (1-10 least 
to most)  
9.2 vs 6.7.  
78% preferred 
CE to OGD, 
22% no 
preference  
Oesophageal varices – 
specificity 97%  sensitivity 73% 
Barrett’s Oesophagus - 
specificity 100% sensitivity 
100% 
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50 Recurrent and 
refractory Iron 
deficiency anaemia 
23m (1-60)  Landmark view 
of Oesophagus 


















score CE vs 
OGD (0-10; 
None – extreme)  
 
Pain 0 vs 2. 
Discomfort 0 vs 
3 
Distress 0 vs 3 
n=63 significant findings, 22/63 
CE and OGD (16 Gastritis, 2 
oesophagitis, one duodenal 
atrophy, one duodenitis, one 
angioectasia, one with bleeding 
in duodenum) OGD only 12/63 
(2 Gastritis, 2 oesophagitis, one 
angioectasia, one duodenitis, one 
duodenal ulcer) CE only 33/63 
(2 oesophagitis, 13 gastritis, 4 
gastric ulcers, 6 angioectasia, 2 
atrophy, 3 duodenitis, 2 duodenal 
ulcers, one with altered blood in 
stomach) 






33 Upper GI 
bleeding 
20m (NR) Landmark view 
of Oesophagus 

















score CE vs 
OGD (0-10; 
None – extreme)  
 
Pain 0 vs 2. 
Discomfort 0 vs 
3 
Distress 0 vs 4 
n=51 significant findings, 13/51 
CE and OGD (3 oesophageal 
varices, 3 erosive gastritis 3 
gastric ulcers, 2 gastric varices, 3 
duodenal ulcers and one with 
blood in lumen) 11/51 OGD 
only (2 oesophageal varices, 2 
erosive gastritis, one gastric 
ulcer, 2 angioectasia, 3 duodenal 
ulcers, one erosive duodenitis. 
26/51 CE only (one oesophageal 
varix, one oesophageal ulcer, 8 
erosive gastritis, 2 angioectasia, 
5 erosive duodenitis, 4 duodenal 
ulcers, one duodenal varix, 4 
with blood in lumen.  
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61 patients with 
indication for UGI 
examination  
















n=108 pathological findings, 
63/108 OGD and CE (44 
gastritis/erosions, 8 polyps, 3 
ulcers, 4 atrophy, 2 antral 
metaplasia and one external 
compression) 14/108 OGD only 
(2 polyps, 2 angioectasias, 2 
atrophy, 2 hypertrophic folds, 2 
antral metaplasia, one gastritis, 
one bile reflux). 31/108 CE only 
(11 polyps, 10 gastritis, 5 ulcers, 
2 bleeding lesions, one 
metaplasia, one angioectasia, one 
hiatal hernia) 
 Denzer et 























1.2 CE vs 1.7 
OGD 
(Acceptability 1 
– 10; excellent 




Major lesions (tumours, ulcers, 
angioectasias) specificity 94% 
sensitivity 62% Minor lesions 
(multiple and diffuse) FCGP - 
specificity 87% sensitivity 76% 
Gastritis - specificity 75% 
sensitivity 94% Atrophy - 






Advancing Capsule Endoscopy in the examination of the Upper Gastrointestinal Tract 
20  Foong Way David TAI - September 2020 























NA n=68 pathological findings, 
OGD and CE 53/68 (34 
erosions, 10 polyps, 4 mucosal 
protuberances, 3 atrophy, one 
external compression and one 
bleeding) OGD only 7/68 (3 
erosions, 2 ulcers, one atrophy 
and one mucosal protuberance) 
CE only 8/68 (6 erosions, one 
polyp, one mucosal 
protuberance) 








26m (20-33) Good view 




















Overall gastric focal lesions 
specificity 95% sensitivity 90%, 
Polyps specificity 97% 
sensitivity 91% Ulcer specificity 
100% sensitivity 90%, 
Submucosal tumour specificity 
91% sensitivity 89% Size <5mm 
specificity 92% sensitivity 88%, 
>5mm specificity 88% 
sensitivity 92% 
 
m; minutes, s; seconds, BO; Barretts Oesophagus, OV; oesophageal varices, VAS; Visual Analogue Score, NR; not reported, SAE; Serious adverse events * Examination duration 
reported as range or average (range)
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1.3.2.2 Upper GI capsule endoscopy 
 
A technologically advanced upper gastrointestinal capsule (Pillcam UGI; Medtronic 
Ltd, Dublin, Ireland) has two image sensors capturing as many as 35 images per second 
for 10 minutes and then 18 images per second for 80 minutes (Figure 4). It moves 
passively assisted by gravity and peristalsis within a pool of swallow water. It images 
simultaneously opposing walls in the stomach, as well as proximal and distal lumens in 
the oesophagus and duodenum. It is licensed to identify blood in patients with suspected 
upper gastrointestinal bleeding. In suspected upper GI bleeding, the live capsule view is 
superior to nasogastric aspiration in identifying blood in the upper GI tract, predicts 
high-risk endoscopic stigmata better than the Blatchford or pre-endoscopic Rockall 
scores and may be a cost-effective method of triaging upper GI bleeding in the 
emergency department 108-111. 
 
 
Figure 4: Pillcam Upper GI (UGI; Medtronic Ltd, Dublin, Ireland) 
 
To achieve more complete views of the stomach, patients can adopt 9 different position 
changes in 90-degree intervals along lateral decubitus and recumbent (supine and 
prone) positions with and without a 30 degree tilt along the cranial-caudal axis. 112 This 
might be a relatively inexpensive approach: although a clinician would need to view 
and interpret the findings, no trained endoscopist or support staff are needed, no 
monitoring is necessary as sedation is not required and the equipment is disposable, 
therefore decontamination facilities are not needed. However, although excellent views 
were demonstrated throughout the distal oesophagus and stomach, entry into the 
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duodenum occurred in only 64% of cases and viewing of the video took a lengthy 48 
minutes. No trials have yet compared the diagnostic yield or cost-effectiveness of this 
approach against conventional gastroscopy.  
 
1.3.2.3 Magnet controlled capsule endoscopy 
 
Control of the capsule endoscope is desirable. In particular, to stop capsule transit and 
image areas at risk of pathology such as the distal oesophagus, cardia and duodenal 
bulb, but also to translocate the capsule towards an area of interest. Active manipulation 
of the capsule endoscope can be achieved by external and internal actuation. Prototypes 
of capsules with internal actuation mechanisms (like motorised legs, fins and 
propellers) have been invented, but only external actuation devices, specifically those 
using magnetic fields have been subject to clinical trials. Experimental and pre-clinical 
approaches have been summarised elsewhere 113.  
 
The addition of magnetic inclusions in capsule endoscopes allow manipulation of the 
capsule by an external magnet of varying sizes and types (Table 1). Swain and Keller 
first described the feasibility of magnet controlled capsule endoscopy (MACE) in the 
stomach and oesophagus using a handheld magnet and a real-time view platform 114,115. 
Since then, the Mirocam Navi (Figure 5) has been shown to be equivalent to 
conventional gastroscopy in the detection of beads sewn into an ex-vivo porcine 
stomach in a blinded trial 116 and identified gastric landmarks in 94-100% of 26 human 
volunteers 117. In the oesophagus the Mirocam Navi handheld magnet cannot translocate 
against gravity and peristalsis but can be held stationary for a 3 to 10 minute 
examination of the oesophagus in one study, 101 but less successfully in another. 102 In 
the stomach, while gastric landmarks can be identified in 95%, only relatively distant 
views of the proximal stomach can be visualised and gastric transit times was no 
different when controlled and when not. 102,117,118  It is believed this is due to a handheld 
magnets inherent lack of sensitive control and inability to overcome peristalsis.  
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Figure 5: Handheld Magnet controlled capsule endoscope 
The Mirocam Navi (Intromedic, Seoul, Korea) system consists of a 1005g handheld magnetic ‘hammer’, a 
data recorder and a tablet computer  
 
Sensitive but durable control of a magnetically assisted capsule endoscope relies on 
subtle alterations of the distance of the magnet from the capsule and rotation of the 
magnet head (which alters magnetic pole direction), which is difficult to achieve when 
suspending a handheld magnet of 1005 grams by hand above the abdominal wall for 
extended periods of time. Robot controlled MACE offers a more consistent and precise 
means of directing magnetic fields compared to handheld control, 119 with the key 
difference being the ability to control the direction and distance of the magnetic poles 
independently. 
 
Two iterations of robot controlled MACE have been trialled using electromagnets 105 
and fixed magnets 120. The NaviCam by AnX Robotica Corp (Texas, USA) is a robot 
controlled MACE platform. Two joysticks are used by the endoscopist to control the 
polarity and distance of a fixed magnet attached from a ‘C’ arm hovering above a 
patient lying on a bed (Figure 6a). By altering polarity and position of the external 
magnet simultaneously, a combination of rotational (Figure 6d and e) and translational 
movements (Figure 6f) can be achieved while viewing the live video on the console 
(Figure 6b). 
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Figure 6: Robot controlled Magnet controlled capsule endoscopy 
The Ankon Technologies NaviCam system consists of a) robot magnet platform with b) computer console 
for live view and c) wireless sensor belt and data recorder. The rotation of the capsule endoscope d) pitch 
and e) yaw, is controlled by moving the left joystick and capsule translocation achieved by movements of 
the magnet in the f) cranio caudal (Y axis), antero posterior (Z axis) and medio lateral (X axis) directions by 
controlling the right joystick. 
 
This system has shown promise with widespread adoption in China. Using a 
combination of patient positions to more efficiently align magnetic fields with 
anatomical sites of interest and robot control of the external magnet, a comprehensive 
view of the stomach can be achieved in 93%. 121 After examination of the stomach, 
magnet assisted transpyloric transit can be achieved consistently with a significant 
reduction in capsule pyloric transit time (4.4 minutes) compared to unassisted by 
magnet with iv. domperidone only after 30 minutes (56.7 minutes, p<0.001). 122 Liao 
and collaborators report in a 350-patient multicentre study that capsule endoscopy had a 
90.4% sensitivity compared to gastroscopy in the detection of gastric focal lesions 
irrespective of site or size of the lesion. 107 This large study supports the use of MACE 
in the stomach, however further studies should confirm these findings, which including 
studies of pathology detection in the oesophagus. No conclusions can therefore be made 
regarding the accuracy of MACE compared to OGD presently.  
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Recent reports however demonstrate the potential of this system in gastric cancer 
surveillance. In an uncontrolled operator blinded case series of superficial EGCs 
undergoing MACE prior to endoscopic resection, the size, site and morphology of 11 of 
12 lesion  were correctly identified 123. Zhao and colleagues report in a multicentre 
study of 3,182 asymptomatic Chinese patients, seven (0.22%) patients diagnosed with 
gastric cancer. Mean procedure times were 14 minutes where 7 patients (0.74%) of 
patients above 50 were found to have gastric cancer 124. These examination times are 
similar to the 15-20 minutes afforded to patients and endoscopist in the UK for 
conventional OGD which include, on average, up to 23 minutes to turn over the room 
between patients and administer conscious sedation where required. 125,126 Therefore, it 
is postulated that with training and experience, it is possible that such robot controlled 
MACE can examine similar volumes of patients to traditional OGD.  
 
Finally, although a 1% capsule retention rate for small bowel capsule endoscopy is 
significant 91, no major adverse events have been reported following MACE, although 
experience of this technology is still limited.  The study by Zhao et al (2018) is the 
largest series of upper GI MACE at present and no capsules were retained beyond four 
weeks. 93   
 
1.4 Improving clinical effectiveness of upper GI capsule 
endoscopy  
 
 Every capsule endoscope passes throughout the length of the GI tract and so 
the opportunity exists to image the entire GI tract in a single examination. Capsule 
endoscopes with two image sensors and adaptive frame rates can now image both the 
small and large bowel in its entirety in a single non-invasive examination in patients 
with suspected or established Crohn’s disease. 127 In capsule endoscopy, meticulous 
bowel cleansing is important in ensuring adequate mucosal visualisation, more so than 
conventional endoscopy where suction and water irrigation can be used to clear debris 
and staining of the mucosa. With upper GI MACE, the opportunity now exists to 
examine the upper GI tract and the small bowel together. The potential benefit of such 
an examination and the anticipated pre-procedure preparation are discussed.    
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1.4.1 Anaemia and the role of panenteric capsule endoscopy 
 
 Iron deficiency anaemia (IDA) affects 2-5% of the adult population and 
accounts for between 4-13% of gastroenterology referrals as GI blood loss is considered 
the commonest cause in men and non-menstruating women. A single visit upper and 
lower endoscopic investigation is recommended because synchronous pathologies 
causing anaemia may occur in as many as 26% of cases. 128,129 The cause of anaemia is 
not identified by upper and lower GI tract investigation in 30% of cases and uncertainty 
exists as to whether minor pathologies which do not exhibit overt bleeding (such as 
oesophagitis, gastritis and colonic polyps) are the cause of anaemia. 130,131 Historically, 
pathology in the small bowel is considered to account for only 5% of all gastrointestinal 
causes of anaemia 132, however these were based on fluoroscopic examinations prior to 
the advent of capsule endoscopy. Capsule endoscopy can now detect flat vascular 
lesions such as angioectasias which were previously undetected by small bowel 
radiology and meta-analyses show significantly better diagnostic yields of capsule 
endoscopy compared to small bowel radiology (42% and 6%, respectively) in patients 
with IDA. 133 In patients with recurrent or refractory (as opposed to first presentation 
of) anaemia, capsule endoscopy studies show a diagnostic yield of small bowel 
pathology in 44% and 23% are due to angioectasias. 134 
 
Upper GI capsule endoscopy and in particular one with magnet control would allow for 
both an upper GI and small bowel investigation. In a study of 49 patients with recurrent 
or refractory anaemia undergoing both handheld upper GI MACE and conventional 
gastroscopy, 17 (34%) patients were deemed have a cause for their anaemia distal to D2 
and out of reach of a conventional gastroscope 102. However, 15 of these 17 patients 
also had a synchronous upper GI lesion (proximal to D2) known to be a cause of 
anaemia and so without a small bowel investigation 30% (15/49) may have been given 
an incorrect diagnosis for their anaemia. Whilst this high prevalence is specific to a 
cohort of patients who likely to be pathology enriched, it highlights a proof of concept 
that upper GI MACE can more effectively identify causes of anaemia because it 
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examines both the upper GI tract and small bowel. The most apparent cost of examining 
the small bowel after an upper GI MACE would be the inconvenience of fasting an 
additional 2 hours (until the capsule passes more distally into the small bowel) and 
continuing to wear the data recorder for 8 hours. The effectiveness of such an approach 
is dependent on the cleanliness of the upper GI tract where an overnight fast is usually 
sufficient, but also the small bowel, where there is evidence that bowel purgatives may 
help cleansing. 
1.4.2 Bowel purgatives in small bowel capsule endoscopy 
 
Bowel purgatives are used routinely in advance of colonic examinations and have been 
shown to improve examination completion and pathology detection. 135 Purgatives can 
also be used prior to small bowel capsule endoscopy as some studies suggest it can 
improve small bowel mucosal views. However, pre-procedure preparation with fasting 
and drinking of clear fluids the day before a small bowel capsule endoscopy or an upper 
GI capsule endoscopy is already well accepted by patients. After an upper GI MACE 
procedure, the small bowel can be examined as the capsule endoscope passes, therefore 
the effect of purgatives on small bowel cleansing and acceptability to patients prior to 
an upper GI MACE with small bowel examination is relevant.  
 
Controlled studies which support the use of bowel purgatives report that polyethylene 
glycol (PEG) improves views 136-139 and even diagnostic yield in one study, 136 but 
larger studies dispute these findings. 140-142 The distal small bowel is most affected and 
mucosal views can be poor with no purgative preparation. 143 In most trials of small 
bowel cleansing, purgatives are consumed the evening before the procedure, however in 
ileocolonoscopy, it is well established that the terminal ileum and caecal views are 
improved with purgatives taken a few hours before the examination and studies splitting 
doses of purgatives have shown more superior cleansing and pathology detection. 135,144 
The potential benefits of this approach may be better patient tolerance to the preparation 
and improvements in distal small bowel views. 
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2 HYPOTHESIS AND AIMS 
NULL HYPOTHESIS: Capsule endoscopy does not advance the quality of the 
endoscopic examination of the upper gastrointestinal tract. 
 
 This body of work aims examine the role of capsule endoscopy in the 
endoscopic examination of the upper gastrointestinal tract, in particular, in advancing 
the quality of an upper gastrointestinal endoscopy. In Chapter 3, the clinical 
effectiveness of conventional OGD is examined by evaluating the rate of missed OG 
cancer occurring during conventional OGD and examining the factors which affect 
these occurrences. Capsule endoscopy is a less invasive examination than conventional 
OGD. In Chapter 4, the differences in patient experience of Magnet controlled capsule 
endoscopy (MACE) and conventional OGD are examined in a clinical trial of patients 
with dyspepsia. Yet, transnasal endoscopy is already better tolerated and accepted than 
conventional OGD. In Chapter 5, differences in patient experience of MACE and 
transnasal endoscopy are examined. Could the introduction of capsule endoscopy in 
upper GI endoscopy result in additional clinical benefit to the patient over flexible 
endoscopy? In Chapter 6, a randomised control trial of bowel purgatives in small bowel 
capsule endoscopy examines whether preparation with fasting and a clear liquid diet is 
an optimal method of examining the small bowel, or whether bowel purgatives are 
required. Finally, widespread adoption of capsule endoscopy in the upper GI tract will 
only be feasible where costs are controlled. In Chapter 7, a study of the economic 
impact of three upper GI endoscopic modalities: conventional OGD, TNE and MACE 
are examined.  
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3 FACTORS ASSOCIATED WITH 
UPPER GASTROINTESTINAL 
CANCERS MISSED BY 
GASTROSCOPY: A CASE 
CONTROL STUDY   
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3.1 Abstract 
 
Introduction: Gastroscopy or Oesophagogastroduodenoscopy (OGD) is presumed to 
have missed oesophagogastric (OG) cancer if performed in the three years prior to 
diagnosis. Meta-analyses suggest that this occurs in 11% of OG cancer patients. We 
examine patient, endoscopist and service level factors that may affect rates of missed 
OG cancers in a case control study. 
 
Methods: Cases of missed OG cancer were identified between January 2013 and 
December 2017 in Sheffield, UK. We examine the factors which affect missed cancer 
occurring during OGD procedures. Differences in use of sedative premedication, 
endoscopist experience and endoscopy service pressures were examined between 
procedures with missed cancer occurrence and two procedure controls: those on the 
same patients at which cancers were subsequently diagnosed and a group of procedures 
matched for endoscopist and location of lesion during which small benign focal lesions 
were identified. 
 
Results: We identified 627 patients diagnosed with OG cancer and of these 48 (7.7%) 
had undergone gastroscopy in the preceding three years.  Endoscopy lists where missed 
cancer procedures occurred contained a greater number of procedures compared to lists 
on which cancer diagnoses were subsequently made (OR 2.16, 95% CI 1.19 – 3.91) and 
when compared to lists during which benign small focal lesions were diagnosed (OR 
1.25, 95% CI 1.02 – 1.52). The use of sedation, endoscopist profession and experience, 
or time of day of procedure were not associated with missed cancer occurrence during a 
procedure. Missed gastric cancer was more common in female patients (OR 3.0, 95% 
CI 1.32– 6.91). There were fewer cases of missed oesophageal cancer amongst those 
who were examined for dysphagia (OR 0.16, 95% CI 0.05 – 0.50), but more cases 
amongst those examined for anaemia (OR 5.36, 95% CI 1.87 – 15.41). 
 
Conclusion:  7.7% of patients diagnosed with OG cancer could have been diagnosed 
and treated earlier. Our study suggests that endoscopy lists on which there are greater 
numbers of procedures may be associated with missed OG cancers. 
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3.2 Introduction 
 
Oesophagogastroduodenoscopy (OGD) is the most common procedure performed in GI 
endoscopy units 145. These OGDs are normal or yield benign pathology in the majority 
146, however oesophagogastric (OG) cancers are diagnosed in between 1-2% and 
diagnostic yield has remained relatively static despite an over 40% increase in OGDs 
performed in the United Kingdom (UK) in the last 10 years (Figure 1). 
 
It is well recognised that colorectal cancers may be diagnosed shortly after reportedly 
normal colonoscopy and a similar situation exists in OG cancer: between 5.3 and 13.9% 
of patients with OG malignancy in the Western population have had normal 
gastroscopies reported within the previous three years. 4,23-28  Reasons for missed 
cancers are unclear and the subject of much interest. In most cases pathology has been 
noted and these lesions might not have been sampled or inadequately sampled 4,27. 
However up to 30% of procedures presumed to have missed cancers are reported as 
normal. 25,27 It is hypothesised therefore that this may be due to endoscopist experience 
and or poor patient tolerance. 
 
 Studies have suggested that performing procedures quickly increases the risk 
of missed pathology 35,36.  Endoscopist experience is clearly associated with colonic 
polyp detection rate 42-44 and there is some evidence that experience is associated with 
better diagnostic capability in OGD. 45,46 Service level factors such as endoscopy list 
composition and workload are often out of control of the endoscopist and may 
conceivably influence missed procedures owing to pressures of service provision and 
endoscopist fatigue. 147 Finally, while the use of sedation has been shown to improve 
completion rate in colonoscopy and potentially pathology detection, 48,148 it has only 
been shown to improve overall patient satisfaction and willingness to have a repeat 
OGDs 55. Whether diagnostic quality of endoscopy improves with sedation is unknown.  
 
In this case control study, we investigate whether endoscopist factors (procedural 
experience and professional background) or service level factors (number and types of 
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endoscopic procedures on endoscopy lists) and the use of sedative premedication 




Patients diagnosed with OG cancer between January 2013 and December 2017 were 
retrospectively identified from a local cancer database (Infoflex version 5, Chameleon 
Information Management Systems) for the population of Sheffield, UK using 
International Classification of Diseases (ICD) 15 and 16 codes. OGDs performed on 
these OG cancer patients between January 2010 and December 2017 at Sheffield 
Teaching Hospitals (Northern General Hospital and Royal Hallamshire Hospital) were 
reviewed to identify patients who have had procedures which are presumed to have 
missed cancer up to three years prior to diagnosis. Symptomatic patients investigated 
out with a surveillance procedure were included. Diagnoses made on asymptomatic 
patients in surveillance programmes and planned follow up endoscopies were excluded. 
Patient factors (gender, age, indication for procedure and anatomical location of cancer) 
was performed on the whole cohort of OG cancer patients. 
 
A case control study of endoscopy procedures was then performed. The cases were the 
procedures where missed cancer was presumed to have occurred and they are compared 
to two control procedure groups. The first control comprised the procedures done on the 
same patients at their subsequent OGD which diagnosed cancer. However, endoscopists 
performing procedures presumed to have missed early cancer by definition would have 
missed small subtle lesions. Therefore, a second control group comprised select 
procedures at which small (<10mm) benign focal lesions were detected. These 
procedures were performed by the same endoscopist which performed the missed 
cancer procedure, on patients of the same age, gender and location of pathology (i.e. 
matched for endoscopist, patient and location of pathology). 
 
Potential factors resulting in missed cancer occurrence examined were: use of sedation, 
professional background, training status and volume of OGD procedures of the 
examining endoscopist, endoscopy list size, procedure mix, time of day and position on 
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endoscopy list. Endoscopy session sizes are also examined by number of points, or 
procedure equivalents per session, as defined by the UK Joint Advisory Group (JAG) 
for GI endoscopy as 15 – 20 minute intervals per point. Trainee endoscopists were 
defined as those who were supervised during the procedure by UK Joint Advisory 
Group (JAG) certified independent endoscopists. The number of OGDs performed by 
an endoscopist between January 2008 and the procedure in question were divided by 
the months elapsed to measure endoscopists average monthly procedural volume.  
 
This study was approved by the Clinical Effectiveness Unit at Sheffield Teaching 
Hospitals (CEU reference number 8301) and the University of Sheffield ethics review 
board (Reference number 018420). Data were analysed using SPSS (version 23.0, IBM, 
Armonk, USA). Continuous data are presented as mean (± standard deviation; SD) or 
median (interquartile range; IQR) and categorical variables and their difference are 
presented as a frequency (%) and Chi-Square (or exact) tests. Logistic regression was 
used to examine potential factors contributing to missed cancer procedures when 
compared to procedural controls.  Significant values (p<0.05) are reported as odds 
ratios (OR) with 95% confidence intervals (CI). 
3.4 Results 
 
A total of 60214 OGDs were performed between January 2012 and December 2017 
(Figure 1). We identified 627 patients diagnosed with oesophageal (50.9%) and gastric 
(48.8%) cancer during this period having excluded 45 cancers diagnosed on 
surveillance or follow up OGDs. Forty-eight patients with OG cancer (7.7%) had OGDs 
performed in the preceding three years and considered to have a missed cancer 
occurrence. These procedures were performed within one year in 2.9% and between one 
and three years in 4.8% prior to diagnosis (1.9% and 5.2% for oesophageal cancer and 
3.9% and 4.6% for gastric cancer respectively). Oesophagogastric cancer and 
procedures at which missed cancer occurred represent 1.0% (627/60214) and 0.08% 
(48/60214) of all OGDs performed during the study period respectively. 
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Characteristics of patients with missed cancer occurrence were compared to the cohort 
of patients without missed cancer (n=578) in Table 3. There were more cases of missed 
gastric cancer in female patients (OR 3.0, 95% CI 1.32– 6.91) and potentially fewer 
cases amongst those who were examined for anaemia (OR 0.23, 95% CI 0.05 – 1.00). 
There were fewer cases of missed oesophageal cancer occurrence amongst those who 
were examined for dysphagia (OR 0.16, 95% CI 0.05 – 0.50), but more cases amongst 
those examined for anaemia (OR 5.36, 95% CI 1.87 – 15.41). 
 
In a case control study, procedures with missed cancer occurrence were subsequently 
compared to two groups of control procedures (Figure 7). Three patients with missed 
cancer presented as upper GI bleeds requiring emergency endoscopy in theatres and 
were excluded from analysis. There was a median of 558 (IQR 635) days between the 
missed cancer occurrence (case) and OGDs diagnostic of cancer (control 1) with no 
difference in median times between those diagnosed with gastric and oesophageal 
cancers (p=0.09). Total number of procedures and procedure equivalents, number of 
OGDs on endoscopy lists and lists with OGDs only were associated with missed cancer 
occurrences when compared to procedures diagnostic of cancer (Table 4). The use of 
sedation, endoscopist experience or background, and time of day of procedure did not 
affect the outcome. 
 
Procedures diagnostic of benign focal lesions (control 2) matched to the endoscopist 
performing the missed cancer procedure were identified in 44 of 45 patients. In one 
case, no suitable procedure was found within 3 months of missed cancer procedure and 
therefore excluded.  In the oesophagus, these lesions were ulcers (n=4), submucosal 
lesions (n=2), polyps (n=5), nodules (n=5), a raised lesion (n=1), an erosion (n=1), an 
oesophageal varix with red spot (n=1) and an endoscopic mucosal resection (EMR) scar 
(n=1). In the stomach, these lesions were polyps (n=8), ulcers (n=4), erosions (n=5), 
nodules (n=2), angioectasias (n=2), a gastric varix with red sign (n=1), a healed gastric 
ulcer scar (n=1) and an EMR scar (n=1). These procedures were performed a median of 
22 (IQR 125) days after the missed cancer procedure. Only total number of procedures 
(OR 1.25, 95% CI 1.02 – 1.52) and procedure equivalent points (OR 1.37 95% CI 1.04 
– 1.79) on endoscopy lists were associated with a risk of missing cancer (Table 4). 
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Figure 7: A study of missed OG cancer occurrence: selection of cases and control 
OGD procedures  
OG oesophagogastric, GA general anaesthetic 
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Table 3: Comparison of oesophagogastric cancer patients with and without missed cancer procedures 
 
 Overall Oesophageal Cancer 
 
Gastric Cancer 
  Not missed Missed p Not missed Missed p 
        
n (%) 627 319 (94.1) 20 (5.9)  305 (91.6) 28 (8.4)  
Age, mean (s.d) 72.1 (12.0) 70.9 (11.9) 74.3 (8.5) 0.22 73.7 (12.2) 71.8 (11.5) 0.45 
Female gender, n (%) 446 (66.4) 92 (30.8) 6 (30.0) 0.94 97 (34.6) 16 (61.5) 0.01 
        
Indication for gastroscopy, n (%)        
Dysphagia 236 (40.4) 172 (60.6) 4 (20.0) 0.001 55 (21.7) 5 (19.2) 0.77 
Anaemia 96 (16.4) 21 (7.4) 6 (30.0) 0.005 67 (26.4) 2 (7.7) 0.03 
Loss of weight 75 (12.8) 33 (11.6) 3 (15.0) 0.65 38 (15.0) 1 (3.8) 0.12 
Dyspepsia 126 (21.6) 41 (14.4) 5 (25.0) 0.20 70 (27.6) 10 (38.5) 0.24 
Vomiting 5 (0.9) 2 (0.7) 0 (0.0) 0.70 2 (0.8) 1 (3.8) 0.15 
GI bleed 53 (9.1) 15 (5.3) 1 (5.0) 0.96 33 (13.0) 4 (15.4) 0.73 
Imaging abnormality 51 (8.2) 19 (6.4) 1 (5.0) - 28 (10.0) 3 (11.5) - 
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(continued) Overall Oesophageal Cancer 
 
Gastric Cancer 
  Not missed Missed p Not missed Missed p 
Location of cancer, n (%)        
        
Oesophagus (C15.x)    0.45    
Upper 11 (3.4) 10 (3.1) 1 (5.0)     
Middle 61 (19.1) 55 (18.4) 6 (30.0)     
Lower 204 (63.9) 192 (64.2) 12 (60.0)     
Unspecified 43 (13.5) 42 (14.0) 1 (5.0)     
        
Gastric (C16.x)       0.76 
Cardia  87 (28.4)    77 (27.5) 10 (38.5)  
Fundus 17 (5.6)    15 (5.4) 2 (7.7)  
Body 75 (24.5)    69 (24.6) 6 (23.1)  
Antrum 48 (15.7)    45 (16.1) 3 (11.5)  
Pylorus 18 (5.9)    18 (6.4) 0 (0.0)  
Unspecified 41 (13.4)    38 (13.6) 3 (11.5)  
        
Comparison of age, gender and indication and location of cancer between oesophagogastric cancer patients with missed cancer occurrence and without.
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Table 4: Factors affecting missed cancer occurrence: a study of cases and two controls  
 Case: Procedures with 
missed cancer occurrence 
 Control 1: Procedures which diagnosed 
cancer 
 Control 2: Benign focal lesions 
 
    OR (95% CI)   OR (95% CI) 
 
 
n 45  45   44  
        
Xylocaine 45 (100)  44 (97.8) -  44 (100.0) - 
Sedation n, (%) 11 (24.4)  19 (42.2) 2.26 (0.92 - 5.56)  10 (22.7) 1.1 (0.43 – 3.02) 
        
Endoscopist, n (%)         
Gastroenterologist 27 (62.8)  27 (62.8) Reference    
Surgeon 10 (23.3)  14 (32.6) 0.71 (0.27 - 1.89)    
Other (Nurse / Radiologist / GP) 6 (14.0)  2 (4.7) 3.00 (0.56 - 16.21)    
        
Performed by trainee 7 (16.3)  7 (16.3) 1.00 (0.32 - 3.14)    
Mean OGDs performed per month, (s.d) 26 (20.5)  25 (15.7) 1.00 (0.98 - 1.03)    
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(continued) 
 
Case: Procedures with 
missed cancer occurrence 
 Control 1: Procedures which diagnosed 
cancer 
 Control 2: Benign focal lesions 
 
    OR (95% CI)   OR (95% CI) 
 Endoscopy List        
        
Procedures per list, mean (s.d) 8.5 (2.0)  7.1 (2.0) 1.42 (1.13 - 1.78)*  7.4 (2.5) 1.25 (1.02 - 1.52)* 
Procedure equivalents or points per list, mean 
(s.d) 
9.4 (1.4)  8.2 (1.7) 1.64 (1.2 - 2.22)*  8.5 (2.0) 1.37 (1.04 – 1.79)* 
Gastroscopies per list n, (%) 7.6 (3.2)  5.9 (3.0) 1.19 (1.03 - 1.36)*  6.5 (3.2) 1.11 (0.97 - 1.26) 
Gastroscopy only lists n, (%) 29 (64.4)  19 (42.8) 2.48 (1.06 - 5.80)*  27 (61.4) 1.27 (0.51 - 2.91) 
Sigmoidoscopies per list, median (range) 0 (0 - 4)  0 (0-3) 0.84 (0.50 - 1.42)  0 (0 - 2) 1.45 (0.72 - 2.92) 
Colonoscopies per list, median, (range) 0 (0 - 4)  0 (0-3) 0.90 (0.63 - 1.27)  0 (0 - 4) 0.95 (0.68 - 1.31) 
Therapeutic procedures per list, median (range) 0 (0 - 3)  0 (0-6) 0.66 (0.36 - 1.21)  0 (0 - 2) 0.85 (0.38 - 1.88) 
List with therapies n, (%) 5 (11.1)  10 (22.2) 0.44 (0.14 - 1.40)  10 (22.7) 0.34 (0.10 - 1.18) 
Time of day (PM or evening) n, (%) 25 (55.6)  26 (57.8) 0.91 (0.39 - 2.10)  17 (38.6) 1.91 (0.82 - 4.45) 
Last procedure on list n,(%) 5 (11.1)  1 (2.2) 5.50 (0.62 – 49.11)  4 (9.1) 1.28 (0.32 – 5.13) 
Latter half of list n,(%) 34 (75.6)  34 (75.6) 1.00 (0.38 – 2.61)  37 (84.1) 0.64 (0.22 – 1.88) 
Procedures with missed cancer occurrence (cases) compared to procedures diagnostic of cancer (control 1) and matched procedures at which benign focal lesions were identified (control 
2). Odd ratios (OR) and 95% confidence intervals (CI) case procedures compared to two control groups. * p<0.05 
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3.5 Discussion 
 
Of 627 patients diagnosed with OG cancer, 48 (7.7%) had undergone OGDs in the 
previous three years at which 5.9% of oesophageal and 8.4% of gastric cancers were 
presumed to have been missed. UK population cohort studies from the National 
Oesophagogastric Cancer audit (NOGCA) report 7.8% and 8.3% of oesophageal and 
gastric cancers are missed respectively 11,12. That we excluded cancers diagnosed on 
asymptomatic patients in surveillance programs, may explain our lower rate of missed 
oesophageal cancer occurrence. Gastric cancers were missed more commonly in female 
patients. Oesophageal and gastric cancers were missed less commonly when OGDs 
were performed for dysphagia and anaemia respectively. NOGCA data in the UK report 
similar gender differences in missed gastric cancer occurrence 11. Further, they reported 
that lower proportions of advanced cancers (T3/4 stage) were associated with missed 
oesophageal 12 and gastric 11 cancers at diagnosis. This is consistent with our finding 
that missed oesophageal and gastric cancer occurrence was less commonly associated 
with OGDs performed for alarm symptoms, as if OG cancers manifests 
symptomatically, they are more likely to be advanced in nature. 149,150. We found that 
amongst patients with oesophageal cancer, a missed procedure was more likely if 
indicated for anaemia. An explanation may be that endoscopists may not exercise the 
same index of suspicion to oesophageal lesions in OGDs indicated for anaemia in 
comparison to dysphagia. However, whether or not the cause of the anaemia at the time 
of missed cancer OGD was related to occult oesophageal malignancy is uncertain.  
 
In this case control study, OGDs with missed cancer occurrence were compared to two 
control groups of procedures. Increasing numbers of procedures on endoscopy lists 
were associated with missed cancers when compared to both control groups where 
cancer, and benign focal lesions were detected respectively. Endoscopy lists with 
procedures where missed cancer had occurred had on average an additional procedure 
compared to lists where cancer or focal lesions were diagnosed. Use of sedation, 
endoscopist professional background or procedural experience, time of day or when the 
procedure was performed and types of procedures on list did not affect the outcome.  
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By using the latter procedures at which cancer was diagnosed, we controlled for patient 
factors (age, gender and anatomical location of cancer) and examined endoscopist and 
service factors which could be contributing to cases of missed OG cancer. However, it 
could be argued that the size of the lesion could be the primary determinant of whether 
or not cancer was detected. Therefore, to control for the size of the lesion and 
endoscopist ability, a second control group of procedures performed by the same 
endoscopist who missed cancer and furthermore diagnostic of benign (<10mm) focal 
lesions were compared with procedures with missed cancer occurrence. The actual size 
of the missed lesions cannot be known but reasonable to assume they were 10mm or 
less in size 22. 
 
The reasons for the suggested relationship between missed cancer occurrence and 
greater numbers of procedures on endoscopy lists can be considered a few ways. The 
sensitivity of endoscopic procedures relates to inspection time. 35-37 Teh and 
collaborators (2015) have shown that endoscopists with procedure times of more than 
seven minutes had an over two-fold (OR 2.50; 95% CI 1.52 – 4.12) diagnostic yield of 
high risk lesions and an over threefold yield of gastric neoplasia (OR 3.42; 95% CI 1.25 
–10.38) than those performing shorter examinations. 37 Increasing workload may also 
be due to fatigue. In a survey of colonoscopy practice in the USA, 7% of respondents 
reported that increasingly populated endoscopy sessions have resulted in conscious 
reductions in examination times 147. Colorectal adenoma detection and examination 
times have also been shown to fall by 7% and 20% respectively by the end of the day in 
another study 151. It is therefore conceivable that increasing workload and fatigue have a 
negative impact on endoscopists examination times or thoroughness of examination in 
the upper GI tract. 
 
Although 35% of missed cancer occurrences were on lists with lower GI procedures, 
there is no association between presence of lower GI or therapeutic procedures and 
missed OG cancer occurrences on endoscopy lists. Diagnostic OGDs are quicker 
examinations to perform than colonoscopies and so endoscopy sessions with only 
OGDs would have more procedures. That over 60% of cases of missed cancer occurred 
on lists with only OGDs, and that the number of procedure equivalent points per session 
also associated with missed cancer occurrence may suggest that it is the number of 
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procedures performed per list, rather than the overall workload from longer or more 
complex procedures that negatively affect outcome. In fact, it is the activity between 
procedures which takes most of the time during an endoscopy list: the turnaround time, 
defined as time between the extubation of one patient and intubation of the next 152,153. 
In the UK, Bryce et al. (2018) reported that in a single centre across 43 endoscopy lists 
and 169 patients, mean turnaround time per patient was 20.8 minutes 152. In Ontario, 
Canada where conscious sedation is used routinely, the patients spend on average a total 
of 23 minutes in the endoscopy room before and after the procedure 125. A further 
increase in endoscopy activity might be achieved by improving workflow efficiencies, 
thereby reducing turnaround time, without having a negative impact on examination 
time. However, Edmondson et al. (2016) reported a similar turnaround time of 20 
minutes even after implementing a nurse-led consent and intravenous cannulation, and 
with the peak effect of the sedative midazolam being between 3-4 minutes after 
administration 154, it may be that patient and physician preference for intravenous 
sedation may limit peri-procedural time efficiencies. In that using sedative medication 
takes additional time, our data did not find a beneficial effect of using intravenous 
sedation on outcome. However, there is likely a lack of power in this study to 
demonstrate an association between miss cancer occurrence and use of sedation. Studies 
of less invasive upper GI endoscopic modalities such as transnasal endoscopy (TNE) 
and magnet controlled capsule endoscopy (MACE) have been suggested to be better 
tolerated than conventional OGD and importantly, mean examination times reported to 
be longer 87,107. It would therefore be important to further examine the association 
between use of sedation, its impact on patient tolerance, adequacy of views (which may 
be affected by patient intolerance), examination times and ultimately pathology 
detection.  
 
Our data failed to demonstrate any association between professional background and 
training grade with missed cancer occurrences. This would be consistent with studies 
which report that endoscopist experience, when measured by number of years’ 
experience, did not affect sensitivity of OGD to detect early gastric cancer 41 and 
further, inconclusive differences in missed cancer occurrence between medical and non-
medical endoscopists.39. We were unable to show that trainee status or experience were 
associated with missed OG cancer occurrence. This is in contrast to the study of Teh et 
al. who found that trainee grade endoscopists (with procedural independence) were 
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more likely to miss high-risk lesions at gastroscopies than staff grade endoscopists. The 
difference may be explained by the fact that trainees in our study performed all 
gastroscopies under the direct supervision of an accredited endoscopist which may 
augment the diagnostic yield of the trainee. Two further studies concluded that training 
and experience correlated with the ability to detect endoscopic evidence of 
Helicobacter pylori infection and gastric intestinal metaplasia 45,46. It seems more 
likely, that expertise, based on training and experience, is the main determinant of high 
quality gastroscopies, rather than professional background or procedural volume per se. 
Structured training programs such as the interactive web-based Barrett’s Oesophagus 
Related Neoplasia project have shown that web-based modules can improve 
endoscopists ability to detect and delineate dysplastic areas within videos of Barrett’s 
oesophagus segments over the course of four sets of 20 training videos with tailored 
mandatory feedback. These improvements were independent of whether the participant 
was a gastroenterology trainee, a junior or senior gastroenterologist (with less than or 
more than 5 years board certified experience respectively) 155. Finally, our study did not 
demonstrate an association between time of day of procedure and missed cancer. 
Colorectal adenoma detection rates have been shown to decline as time passes in the 
day suggesting that endoscopist fatigue and attention span may affect performance 
156,157. However, our study is likely not large enough to adequately address this 
question.  
 
There are limitations to the study. The number of cases were small and it cannot be 
certain that all had visible lesions at the time of the initial non-diagnostic procedure. 
Procedures presumed to have missed cancer were rare with one occurring every 1250 
procedures during our 5-year study period. A case control design was therefore selected 
to examine factors which were more peripheral to the case of missed cancer occurrence, 
for example, endoscopy list size and case mix during which the miss cancer procedure 
occurred. This means however, we cannot be certain of the differences in endoscopy list 
size in procedures which did not have an OG cancer diagnosis. Endoscopy examination 
times were not available and further research is needed to determine if this is affected 
by number of procedures on a list. Consecutive cases of OG cancer were included, 
however some have been missed if procedures were performed out of area, in the 
private sector on in cases where radiological imaging in patients was sufficient for 
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pragmatic patient management. Nevertheless, these cases are likely to be low given a 
similar rate of missed cancers found in this and other studies. 4,11,12  
 
The implications of this study on service delivery are important. They suggest that 
endoscopy lists with more procedures are associated with a risk of missing OG cancer. 
British and European guidance recommend documenting examination times 32,33 and 
this study supports this measure to ensure that pressures of service delivery does not 
result in shorter examination times. On the other hand, the turnaround time between 
conventional endoscopic procedures are relatively constant and likely vary insofar as 
the additional time required when offering sedation 125,152,153. A non-invasive 
examination such as MACE therefore may allow for longer examination times if better 
tolerated by patients, and within the same timeframe if turnaround time is reduced in 
the absence of a need for sedation, monitoring and endoscope reprocessing. 
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4 A COMPARATIVE STUDY OF 
PATIENT TOLERANCE AND 




GASTROSCOPY IN DYSPEPSIA  
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4.1 Abstract 
 
Introduction: Gastroscopy or Oesophagogastroduodenoscopy (OGD) is commonly 
performed to investigate dyspepsia, but oropharyngeal intubation can cause patient 
distress. These reactions may be attenuated following the administration of intravenous 
sedatives or by the use of non-invasive alternatives. In this study, patient tolerance and 
acceptability of OGD have been compared with magnet-controlled capsule endoscopy 
(MACE).  
 
Methods: A self-controlled blinded comparison of OGD and MACE in the 
investigation of dyspepsia was performed. Factors affecting patient tolerance and 
acceptability were examined using the Endoscopy concerns scale (ECS) and a patient 
generated index, the Universal Patient Centredness Questionnaire (UPC-Q).  
 
Results: Forty-four patients undertook MACE followed by OGD. Pre-procedure ECS 
scores were higher before OGD (39 vs 26, p<0.0001) than MACE suggesting OGD 
results in more distress to patients than MACE in anticipation of endoscopy. Patients 
experienced significantly more distress (median score) due to gagging (6 vs 1, 
p<0.0001), choking (5 vs 1, p<0.0001), abdominal bloating (2 vs 1, p<0.0001), 
instrumentation (4 vs 1, p<0.0001), discomfort during (5 vs 1, p<0.0001) and after (2 vs 
1, p<0.0001) OGD when compared to MACE. All of patients found MACE acceptable 
compared to 64% with OGD. ECS scores were significantly higher after OGD (34 vs 
11, p<0.0001) and UPC-Q score was lower for OGD (50 vs 98, p<0.0001) compared to 
MACE, both supporting superior acceptance of MACE over OGD. If given a choice, all 
patients preferred MACE to OGD. If there was a 50% chance of requiring an OGD after 
MACE for tissue samples, 83% patients would still choose MACE as the first 
procedure. Two-thirds of endoscopic findings are detected by both MACE and OGD.  
 
Conclusion: MACE is better tolerated, accepted and preferred by patients than OGD 
and most patients would prefer MACE first even if OGD was required to obtain 
biopsies.  
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4.2 Introduction 
 
Gastroscopy or Oesophagogastroduodenoscopy (OGD) is an uncomfortable procedure 
and many patients require intravenous sedation or general anaesthesia which may, 
therefore, require planning and reorganisation of routines at work and home. Adverse 
events occur in up to 1 in 200 OGDs and 60% are cardiopulmonary events and often 
related to sedation. 76,158 It is, therefore, understandable that patients may delay seeking 
medical advice for symptoms due to fear of investigation. 159 The recent COVID-19 
pandemic has prompted consideration of the risks of transmission of microbial agents to 
endoscopy staff by aerosol-generating procedures such as OGD. 160 These concerns 
underlie a continuing search for less invasive upper GI investigative tools which are 
effective, safe, simple to perform and acceptable to patients. 
 
Capsule endoscopy does not involve intubation by the endoscopist but rather patient 
directed swallowing of the imaging device. Developments include magnetic control of 
the capsule which can be moved and rotated in a stream of swallowed water to achieve 
gastric visualisation. Studies suggest that patients find magnet-controlled capsule 
endoscopy (MACE) more comfortable than, 102,103 and preferable to OGD. 105,107 
 
Other than studies of procedural tolerance or satisfaction, understanding of patients’ 
OGD experience is limited 57. In this study, we have performed a detailed comparison 
of tolerance of OGD and MACE. It is well recognised that procedural tolerance is only 
one of several factors which affect acceptability of a test and the overall patient 
experience. Therefore, we have also compared acceptability and assessed the broader 
experience of each investigative pathway using the Endoscopy Concerns Scale (ECS) 65 
and the Universal Patient Centredness Questionnaire (UPC-Q), 68 a patient-reported 
experience measure. 
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Patients between the ages of 18 and 80 years of age referred to Sheffield Teaching 
Hospitals (Sheffield, UK) for the endoscopic investigation of dyspepsia as per National 
Institute of Clinical Excellence guidance (CG184) were invited to join the study 161. 
Patients with implanted metallic devices or prostheses were excluded. Contraindications 
to capsule endoscopy included a history of dysphagia, Crohn’s disease, small bowel 
resection or previous abdominopelvic irradiation and long term (over six months) daily 
consumption of a non-steroidal anti-inflammatory drug (NSAID). 
4.3.2 Interventions 
 
Patients were offered the choice of OGD (with or without sedation) or transnasal 
endoscopy (TNE). Procedures were described to the patients verbally and in 
standardised hospital information leaflets provided as part of routine clinical practice. 
Those who agreed to participate in the study of OGD were also asked to have MACE in 
the two weeks preceding their OGD and included in this study. 
 
MACE was performed using the NaviCam (AnX Robotica Corp, Texas, USA). The 
system comprises two joysticks which control the polarity and proximity of an external 
magnet suspended on a robot arm above the patient recumbent on an examination 
couch. Examinations were performed by two endoscopist trained in the technique in 
Shanghai, China. Prior to the examination, patients swallowed 80mg simethicone 
(Infacol, Teva, Castleford, UK) in 100mls of water and followed a series of position 
changes to wash the stomach. Immediately before swallowing the capsule, patients 
drank between 500 to 1000mls of water to distend the stomach. 162 The capsule 
endoscope (AKEM-11SW; AnX Robotica Corp, Texas, USA) was ingested in the left 
lateral decubitus position. The operation of the MACE and examination of the stomach 
is described elsewhere 163. MACE was considered incomplete and patients excluded 
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from the study if there was undigested food in the stomach, the procedure time was less 
than 10 minutes or there were prolonged periods of signal loss. 
 
OGD (GIF-H260 or GIF-H290, Olympus Corp, Tokyo, Japan or EC34-i10F, Pentax 
Corp, Tokyo, Japan) was performed within two weeks of MACE by a JAG accredited 
endoscopist blinded to the findings of MACE. Patients were given 6 sprays of 
oropharyngeal topical anaesthesia (10% Xylocaine, 10mg per spray; Aspen Pharma 
Trading Ltd, London, UK) with or without conscious sedation according to normal 
practice.  
 
4.3.3 Data collection and analysis 
 
Tolerance, acceptability and preference questionnaire 
 
Pre-procedure 
Knowledge of what patients anticipate in advance of their investigative experience is 
necessary to understand their health seeking behaviour and compliance. Prior to each 
examination patients are asked to score on a visual analogue scale (1-10: not at all to 
extremely) their anxiety, as well as 13 aspects causing concern related to telling friends 
about, fasting and discomfort prior to, the test; intravenous cannulation, instrumentation 
(defined as insertion of flexible endoscope or swallowing the capsule), expressions of 
emotions, the endoscopist seeing food in the stomach during the test and feelings of 
gagging, choking, vomiting, bloating, discomfort during the test. 65 Summation of each 
of these 13 aspects scores was used as a measure of how acceptable the patient regarded 
the test in advance of the procedure (pre-procedure Endoscopy concerns scale (ECS) 
scores between 13-130: most to least acceptable). 
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Post-procedure 
Four measures of patient acceptance and preference were collected after the procedure:  
 
1)  An ECS questionnaire scoring 10 of the 13 items described earlier quantified 
their actual experience. The three pre-procedural items (concerns related to telling 
friends about, fasting and discomfort prior to, the test) were not repeated. Items are 
summated to provide a measure of acceptability in light of their actual experience (post 
procedure ECS: 10-100). 
 
2) Patients were asked to consider three scenarios: whether or not they would 
undergo the test again or advise a friend to do the same in similar medical 
circumstances or have the test as a screen for cancer in five years’ time. A patient was 
regarded as finding the test acceptable if they answered in the affirmative to all three 
questions. 
 
3) The UPC-Q assesses and compares patients’ individual experience of each 
form of endoscopy. 68  Each patient was asked to identify three aspects of the overall 
pathway which was most important to them and rank the level of importance of the 
three aspects relative to each other by dividing a total of six points between the aspects.  
They were then asked to rate their experience of each aspect (1-5: poor to excellent). 
The overall UPC-Q score (0-100: least to most acceptable) was obtained using the 
following equation (where A1, A2 and A3 are the three aspects of the pathway chosen by 
each patient): 
 
UPC-Q score = (Grade A1 x Rate A1/6) + (Grade A2 x Rate A2/6) + (Grade A3 x Rate 
A3/6) x 25 
 
Aspects of the care pathway listed as important to patients were categorised according 
to whether their subject matter related to communication, procedural tolerance or 
aftercare, test accuracy or results.   
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4) Patients are asked to express a preference between tests. Where histological 
assessment is warranted after MACE, a second conventional endoscopy is required and 
therefore may affect patients’ initial preference. Patients are asked a series of questions 
designed to examine preference for the primary diagnostic test based on an increasing 
probability of requiring a second procedure to obtain biopsies. 
 
Baseline characteristics and endoscopic findings 
 
Patient age, gender, previous experience with endoscopy, and Hospital Anxiety and 
Depression scale (HADS) scores were collected prior to examination. HADS was used 
to diagnose anxiety (trait) and depression if patients scored over eight on a 21-point 
scale as previously described. 164,165 During OGD the use of sedation, video recordings 
of the procedure and examination findings are collected. During MACE examination 
findings are documented with images. MACE and OGD findings are compared against 
an unblinded review of OGD and MACE videos in parallel to identify each finding. 
Time spent examining overall, in the oesophagus and stomach were compared 
(excluding biopsies, and including both phases of intubation and extubation for 
conventional OGD).  
4.3.4 Outcome measures 
 
The primary outcomes of the study were to determine aspects of endoscopy which 
cause distress to patients and to compare these individual aspects, overall acceptability 
and global experience of OGD and MACE. A secondary outcome was an analysis of 
how the need for a second procedure to obtain biopsies after MACE affected patients’ 
choice of their primary investigation and to compare endoscopic findings between 
modalities.  
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4.3.5 Statistical methods 
 
Advice was sought from the Statistical Services Unit at the University of Sheffield. A 
sample of 44 patients would have 90% power to detect a difference in mean distress 
scores of 1 between MACE and OGD, assuming a standard deviation of the differences 
of 2, using a paired t-test with a 0.05 two-sided significant level. 
 
SPSS Statistics for Macintosh, Version 24.0.0 (IBM Corp, New York, USA) was used 
for statistical analysis. Parametric and non-parametric continuous data is presented as 
mean and standard deviation (SD) or median and interquartile range (IQR) respectively. 
Normality of data is determined by an insignificant Shapiro-Wilk test. Non-parametric 
paired differences in central tendencies were examined using Wilcoxon signed rank 
tests. Unpaired differences were examined using Mann Whitney U or Kruskal-Wallis H 
test. Categorical data is presented as number and percentages: n (%), and McNemar test 
was used to compare paired dichotomous variables. Construct validity of the UPC-Q 
was examined by correlation of convergent and discriminant factors. Statistical 
significance is defined as p<0.05. 
4.3.6 Ethics 
 
This study was approved and conducted in accordance with the ethical standards of the 
South Central – Berkshire B Research Ethics Committee (16/SC/0606. 
ClinicalTrials.gov NCT03420729), and the 1964 declaration of Helsinki and its later 
amendments. 
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Recruitment towards this study comparing OGD and MACE is part of a larger study 
involving, in addition, a cohort of patient who opted for TNE (reported in Chapter 5). A 
total of 111 patients were approached and 108 were confirmed eligible. A patient with 
dysphagia, a metallic heart valve and long-term NSAID use were ineligible. Of 108 
patients invited to participate, 69 completed the study (36 patients declined and three 
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agreed to do so but failed to attend their appointments) of which 47 opted for OGD 
 
Figure 8). The majority of patients who declined to participate did not want to undergo 
clinically unnecessary examinations.  
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MACE was successful in 44 patients (91.7%) and OGD in all patients. MACE was 
unsuccessful in three patients due to undigested food in the stomach (n=1), a procedure 
time of less than 10 minutes (n=1) and prolonged periods of signal loss (n=1). The 
median age of included patients was 53 (IQR 31), were female in 66% (n=27), had 
previous experience of OGD in 41% (n=18) and opted for conscious sedation in 41% 
(n=18) with a median dose of midazolam and fentanyl of 2mg (range 1.5 - 4) and 
50mcg (range 25 - 75). Median (IQR) HADS anxiety score was 5 (8) with 29% (n=12) 
having an anxiety trait (score >8).   
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Figure 8: Patients who opted for OGD in a comparison of patient experience of 
OGD and MACE 
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4.4.2 Patient anxiety and anticipatory concerns of OGD and MACE  
 
Prior to their procedure, patients were more anxious about having OGD than MACE, 
with median state anxiety scores of 5 and 2 (p<0.0001; Table 5a). Trait anxiety scores 
(HADS) correlated with state anxiety scores prior to OGD (r=0.42 p=0.004) and MACE 
(r=0.55, p<0.0001). Median pre-procedure ECS scores were higher before OGD (39 vs 
26, p<0.0001) than MACE. What caused most distress (median score) prior to OGD 
were concerns about procedure related factors: the process of intubation (5 vs 3, 
p<0.0001), gagging (5 vs 2, p<0.0001), choking (5 vs. 2, p<0.0001), vomiting (4 vs 1, 
p=0.001) and discomfort (5 vs 2, p<0.0001); by comparison, discussing the procedure 
with friends and relatives, fasting pre-procedure, the anticipation of the need for 
intravenous cannulation, displays of emotions and the endoscopist seeing food in the 
stomach caused negligible distress (Table 5a). No differences were seen in the pre-
procedure ECS (p=0.28) and state anxiety (p=0.95) scores between those who have and 
those who have not experienced OGD before.  
4.4.3 Patient tolerance and factors causing distress during OGD and 
MACE 
 
After their procedure, patients reported experiencing significantly more distress 
(median score) due to gagging (6 vs 1, p<0.0001), choking (5 vs 1, p<0.0001), 
abdominal bloating (2 vs 1, p<0.0001), instrumentation (4 vs 1, p<0.0001), discomfort 
during (5 vs 1, p<0.0001) and after (2 vs 1, p<0.0001) OGD when compared to MACE 
(Table 5b). Amongst the patients undergoing OGD with sedation, MACE was still 
significantly better tolerated than sedated OGD (Table 6). Patients correctly anticipated 
which factors related to OGD caused them distress. No differences were found in 
distress caused in anticipation of OGD and actual experience of OGD (Table 7). All 
factors related to MACE caused significantly less distress than anticipated.  
 
4.4.4 Acceptability and patient related experience of OGD and MACE 
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Median post procedure ECS scores were significantly higher after OGD (34 vs 11, 
p<0.0001) compared to MACE. UPC-Q score was lower for OGD (50 vs 98, p<0.0001) 
than MACE. Amongst the patients undergoing OGD with sedation, MACE was 
significantly better accepted than sedated OGD (Table 6). As defined by affirmative 
answers to all three questions regarding preparedness to undergo the same test again to 
investigate symptoms or screen for cancer or recommend the test to a friend, 64% and 
100% of patients found OGD and MACE acceptable.  
 
The UPC-Q was completed appropriately by 95% (n=42). Aspects of care deemed 
important by patients can broadly be divided into the following categories: procedural 
tolerance (including drinking the water, swallowing the capsule, test discomfort and 
duration), staff communication (including information about, and progress of, the test), 
procedural aftercare and recovery (including a comfortable environment and adverse 
effects), test results, test accuracy and other matters. The importance of each aspects of 




Figure 9: Aspects of care important to patients undergoing OGD and MACE 
generated by the UPC Questionnaire.  
Six points were allocated by 42 patients each to aspects of care pathway deemed important after each 
procedure. There was a greater percentage of a total 252 allocated points towards procedure tolerance after 
OGD than MACE (67.1% and 54.0%, p=0.003) suggesting that procedure tolerance was significantly more 
important after OGD than MACE. No differences were found in staff communication (4.4% and 4.1%, 
p=0.68), procedure aftercare and recovery (6.7% and 4.1%, p=0.71), test results (12.7% and 14.4%, 
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4.4.5 Patient preference between OGD and MACE 
 
When asked to express a preference for one or other test, all patients preferred MACE 
to OGD. If tissue biopsies were necessary (therefore requiring flexible endoscopy as a 
second test) after MACE and the chance of requiring biopsies was 1 in 20, 1 in 10, 1 in 
5, 1 in 4 or 1 in 2, 100%, 100%, 94%, 94% and 83% would prefer MACE followed by 
OGD (rather than a single OGD test). 
4.4.6 Performance characteristics of UPC-Q and ECS 
 
The UPC-Q correlated with post procedure ECS after both MACE (r = -0.32 p=0.01) 
and gastroscopy (r = -0.40 p=0.002) demonstrating convergent validity, but not with 
pre-procedure ECS (p=0.49 and p=0.29) nor state anxiety scores (p= 0.25 and p=0.26) 
providing some evidence of discriminant validity as well. 
4.4.7 Endoscopic findings 
 
Twenty-three patients were included in the analysis of endoscopic findings b. Magnetic 
transpyloric steering of the capsule into the duodendum occurred in 47.8% (11/23). The 
mean (SD) examination time of MACE and OGD are 40.1 (2.9) and 4.9 (0.5) minutes 
(p<0.0001) with significantly more time spent examining the stomach with MACE 
(38.7 (2.9) vs. 3.0 (0.3) minutes, p<0.0001) but similar time examining the oesophagus 
(1.3 (0.5) vs. 0.9 (0.1) minutes, p=0.43). No serious adverse events occurred after 
MACE nor OGD.  
 
There was agreement in findings between MACE and OGD in 65% (15/23) of patients 
(Table 8). Eight patients (35%) had normal examinations on both MACE and OGD. 
                                                
b The first initial 18 patients did not have OGD video recordings as amendments for ethics proposals and 
recording equipment were pending. Three patients had incomplete video recordings owing to technical 
problems.   
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Thirty endoscopic findings were found in total: 66% of findings (20/30) were seen by 
both MACE and OGD, 16.7% (5/30) by MACE alone and 16.7% (5/30) by OGD alone. 
Endoscopic images of findings on MACE and OGD for each finding is detailed in 
Figure 10 (Cases 2, 4, 5 and 8), Figure 11 (Cases 9-12), Figure 5 (Cases 16-18), Figure 
13 (Cases 20 and 21) and Figure 14 (Cases 22 and 23). 
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Table 5: Distress caused in anticipation of and by actual experience of OGD compared to MACE   
	 a)	Pre-procedure	anticipation	 	 b)	Patient	experience	
	 OGD	 MACE	 p	 	 OGD	 MACE	 p	
Telling	friends/colleagues	about	test	 1	(0)	 1	(3)	 0.01	 	 	 	 	
Fasting	 1	(1)	 1	(2)	 0.15	 	 	 	 	
Discomfort	prior	to	procedure	 1	(1)	 1	(2)	 <0.0001	 	 	 	 	
Gagging	 5	(4)	 2	(5)	 <0.0001	 	 6	(6)	 1	(0)	 <0.0001	
Choking	 5	(2)	 2	(5)	 0.05	 	 5	(6)	 1	(0)	 <0.0001	
Bloating	 2	(2)	 2	(4)	 0.001	 	 2	(4)	 1	(0)	 0.08	
Vomiting	 4	(2)	 1	(6)	 0.19	 	 1	(3)	 1	(0)	 <0.0001	
Doctor	seeing	food	in	stomach	 1	(0)	 1	(0)	 0.002	 	 1	(0)	 1	(0)	 0.79	
Displaying	emotions	during	the	test	 1	(1)	 1	(3)	 <0.0001	 	 1	(4)	 1	(0)	 <0.0001	
Instrumentation	 5	(4)	 3	(5)	 0.03	 	 4	(7)	 1	(1)	 <0.0001	
Intravenous	catheter	 1	(1)	 1	(3)	 0.12	 	 1	(1)	 1	(0)	 0.001	
Discomfort	during	procedure	 5	(3)	 2	(6)	 <0.0001	 	 5	(5)	 1	(0)	 <0.0001	
Discomfort	after	procedure	 2	(2)	 2	(4)	 0.04	 	 2	(4)	 1	(0)	 <0.0001	
	 	 	 	 	 	 	 	Pre	procedure	anxiety	 5	(5)	 2	(2)	 <0.0001	 	 	 	 	
Pre	procedure	ECS	 39	(41)	 26	(7)	
	
<0.0001	 	 	 	 	
Post	procedure	ECS	 	 	 	 	 34	(32)	 11	(1)	 <0.0001	
UPC-Q	 	 	 	 	 50	(50)	 98	(25)	 <0.0001	
	Pairwise comparison of pre-procedure anxiety and pre- and post- procedure distress (1 – 10: Least to most) scores; pre- (13-130: Most to least acceptable) and post- (10-100) procedure 
endoscopic concern scale (ECS) score and universal patient centredness questionnaire (UPC-Q) scores (least to most acceptable: 0-100) between OGD and MACE reported as a median 
(IQR).
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Table 6: Patient experience in those undergoing OGD with sedation compared to MACE 
  
	 Patient	experience	
	 OGD	(with	sedation)	 MACE	 p	
	 	 	 	
Gagging	 6	(6)	 1	(0)	 0.001	
Choking	 4	(5)	 1	(0)	 0.001	
Bloating	 1	(2)	 1	(0)	 0.17	
Vomiting	 1	(2)	 1	(0)	 0.04	
Doctor	seeing	food	in	stomach	 1	(0)	 1	(0)	 1.00	
Displaying	emotions	during	the	test	 1	(4)	 1	(0)	 0.04	
Instrumentation	 3	(5)	 1	(1)	 0.008	
Intravenous	catheter	 2	(3)	 1	(0)	 0.005	
Discomfort	during	procedure	 4	(6)	 1	(0)	 0.001	
Discomfort	after	procedure	 2	(3)	 1	(0)	 0.005	
	 	 	 	
Post	procedure	ECS	 25	(26)	 10.5	(2)	 <0.0001	




Pairwise comparison of distress scores (1 – 10: Least to most distressing), post- procedure endoscopic concern scale (ECS) score (10-100: Most to least acceptable) and universal patient 
centredness questionnaire (UPC-Q) score (Least to most acceptable: 0-100) between OGD with sedation and MACE reported as median (IQR). 
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Table 7: Comparison of patient expectation and experience during OGD and MACE  
 















Paired comparison of distress scores (1 – 10: Least to most) cause in anticipation of and actual experience of OGD and MACE reported as median (IQR)
	 OGD	 	 MACE	
	 Expectation	 Experience	 p	 	 Expectation	 Experience	 p	
	 	 	 	 	 	 	 	
Gagging	 5	(5)	 6	(6)	 0.22	 	 2	(4)	 1	(0)	 <0.0001	
Choking	 5	(5)	 5	(6)	 0.85	 	 2	(2)	 1	(0)	 <0.0001	
Bloating	 2	(4)	 2	(4)	 0.79	 	 2	(2)	 1	(0)	 0.002	
Vomiting	 4	(6)	 1	(3)	 0.08	 	 1	(2)	 1	(0)	 <0.0001	
Doctor	seeing	food	in	stomach	 1	(0)	 1(0)	 0.34	 	 1	(0)	 1	(0)	 0.04	
Displaying	emotions	during	the	test	 1	(3)	 1	(4)	 0.49	 	 1	(1)	 1	(0)	 0.002	
Instrumentation	 5	(5)	 4	(7)	 0.16	 	 3	(4)	 1	(1)	 <0.0001	
Intravenous	catheter	 1	(3)	 1	(1)	 0.04	 	 1	(1)	 1	(0)	 <0.0001	
Discomfort	during	procedure	 5	(6)	 5	(5)	 0.92	 	 2	(3)	 1	(0)	 <0.0001	
Discomfort	after	procedure	 2	(4)	 2	(4)	 0.72	 	 2	(2)	 1	(0)	 <0.0001	
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Table 8: Comparison of findings in 23 patients with dyspepsia investigated with 
MACE and OGD.  
 
Case	 MACE	and	OGD	 MACE	only	 OGD	only	
1	 Normal	 	 	
2	 	 Fundal	polyp	 	
3	 Normal	 	 	
4	 Antral	angioectasia	 Antral	erosion	 	
5	 	 (antral	bulge)§	 Oesophagitis	
6	 Normal	 	 	
7	 Normal	 	 	
8	 Prepyloric	erosion	x2	 	 	
9	 D2	Angioectasia		 	 	
10	 Antral	gastritis*		 Prepyloric	erosion	 	
11	 Antral	erosion	and	fundal	polyp†	 	 	
12	 	 	 Pyloric	erosion	
13	 Normal	 	 	
14	 Normal	 	 	
15	 Normal	 	 	
16	 Oesophagitis*	and	Fundal	polyp†	 	 	
17	 Duodenditis	 	 	
18	 Antral	erosions	 	 Duodenitis	
19	 Normal	 	 	
20	 Oesophagitis*	 Fundal	polyp	 Hiatus	hernia,	
duodenitis	









*Not seen on live MACE examination, but seen on retrospective review of capsule video. †not seen on 
initial blinded review of OGD videos, but seen in retrospect after unblinding. §Antral bulge not seen on 
OGD 
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Case 4: Antral angioectasia and antral erosion.  a) Angioectasia seen on MACE and b) on 
OGD; c) Antral erosion seen on MACE but not on OGD. d) Best view of antrum on OGD 
Case 5:  Oesophagitis Grade A. a) Oesophagitis seen on OGD but not seen on MACE. b) 
submucosal bulge seen in pylorus on MACE, but not on OGD. c) Antrum view on OGD 
shows the mucosa is flat suggesting the finding on MACE is a false positive 
Case 2:  Fundal polyp.  a) Polyp seen on MACE but not OGD. b) Best view of the fundus 
seen during OGD with a much retching.  
Case 8:  Two pyloric erosions.  a) Erosions seen on MACE and b) OGD  
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Case 11: Antral nodular erosion and small polyp. a) Antral nodular erosion seen on 
MACE and b) OGD; c) Subtle fundal polyp seen on MACE and on d) OGD in retrospect 
after unblinding. 
Case 9: Second part of duodenum angioectasia. a) Angioectasia seen on MACE and b) OGD.  
Case 8:  Solitary pre-pyloric erosion. a) Pre-pyloric erosion seen on OGD but not on MACE. 
b) MACE view of pylorus. 
Case 10: Antral erosive gastritis. a) Solitary erosion seen on MACE but not on OGD. b) 
Antral linear erythema seen on OGD but more subtly seen on c) MACE in retrospect after 
unblinding. 
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Case 18: Two pre-pyloric erosions and duodenitis. a) Pre-pyloric erosions seen on MACE 
and b) OGD; c) Duodenitis seen on OGD. The capsule did not record into the small bowel – 
guided transpyloric passage was attempted but failed and patient did not want to keep data 
recorder on. 
Case 16: Fundal polyp and Oesophagitis grade D. a) Fundal polyp seen on MACE and on b) 
OGD in retrospect after unblinding. c) Oesophagitis seen on OGD but not on MACE initially. d) 
On retrospective review of MACE, one image has the tips of the ulcerated oesophagus (blue 
arrows).   
Case 17: Duodenitis. a) Patches of red tipped and oedematous villi seen on MACE and b) on 
OGD 
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Figure 13: Endoscopic images of cases 20 and 21 
21




Case 20: Oesophagitis grade B, hiatus hernia, fundal polyp and duodenitis. a) Oesophagitis 
seen on OGD but not live MACE. b) On retrospective review of MACE video, tips of 
oesophagitis can be seen (blue arrows). c) Fundal polyp seen on MACE but not OGD. d) Best 
view of fundus on OGD shows significant hiatal hernia but poor distension of fundus. Hiatal 
hernia not seen on MACE. e) Duodenitis seen on OGD. The capsule did not record into the 
small bowel – guided transpyloric passage was attempted but failed and patient did not want to 
keep data recorder on. 
Case 21: Two fundal polyps and antral erosive gastritis. a) Bigger and b) smaller fundal 
polyp seen on MACE. c) Both polyp seen on OGD in the distance after unblinding. d) A single 
erosion and e) linear erythema seen on MACE. f) OGD shows erosion (blue arrow) and linear 
erythema. 
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Case 22: Oesophagitis grade A and a cluster of gastric polyps.  a) Oesophagitis seen on 
MACE and on b) OGD. c) A cluster of polyps on the lower posterior body of stomach seen on 
c) MACE and d) OGD 
Case 23: Multiple flat polyps, large hiatus hernia, Cameron ulcer and antral gastritis. a) 
multiple pale flat polyps scattered along body of stomach seen on MACE and b) OGD. c) 
Converging gastric folds seen on MACE and d) OGD suggesting a hiatus hernia. e) A linear 
ulcer that tracks down a single fold along the length of the lesser curve to the f) antrum seen on 
MACE. This ulcer was not seen on OGD. This is likely a Cameron ulcer associated with the 
large hiatus hernia.  g)  Linear erythema seen on MACE and h) on OGD. 
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4.5 Discussion 
 
The anticipation of an OGD causes significantly more distress in comparison to MACE 
as evidenced by higher pre-procedure ECS scores. In advance of OGD, concerns 
causing most distress were related to procedural tolerance (intubation, feelings of 
gagging, choking and discomfort during OGD) and these matched by patients’ actual 
experience. This may explain in part why OGD causes considerable patient anxiety but 
significantly less so prior to MACE. Patients’ actual experience favours MACE over  
OGD by some margin and by all measures, including specific aspects of procedural 
tolerance, acceptability (including both patient-related experience measures: UPC-Q 
and post procedure ECS score) and preference. The majority of patients would prefer 
two procedures, MACE followed by OGD rather than a single OGD, even if there was a 
50% chance of requiring flexible endoscopy as a second test to obtain biopsies for 
histological assessment. 
 
OGD is the accepted gold standard in upper GI investigation, however, about 10% of 
early cancers are missed at initial OGD. 4 Upper GI lesions  have been identified during 
push enteroscopy 166 and capsule endoscopy 167 and are presumed to have been missed 
by prior OGD. Furthermore, recent studies of MACE using a handheld or robot 
controlled magnet suggest at least diagnostic equivalence with OGD. 102,103,107  In these 
studies, both MACE and OGD missed pathologies. This is consistent with the finding 
of this study where a third of endoscopic findings were only seen with one modality. 
Although both MACE and OGD detected 25 of 30 endoscopic findings each, 
suggesting similar performance, this study is not powered to examine differences in 
diagnostic yield in a general population of dyspeptic patients where a low yield of 
pathology is expected.  
 
Pathologies in this study were graded independently at the MACE examination and at 
the conventional OGD procedure. Each finding was then confirmed on an unblinded 
review of the MACE and OGD videos read in parallel. Interestingly, in four cases of 
fundal polyps detected on MACE but not OGD, the polyps could be seen in the fundus 
from a distance on OGD videos in retrospect (Case 11, 16 and 21: Table 8). That the 
mean examination time of OGDs was 4.9 minutes, and falls short of the 7 minutes now 
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expected by endoscopists, may explain why pathology may have been missed on OGD 
32,33. However, small gastric polyps are mostly inconsequential in patients with 
dyspepsia and therefore this discrepancy may reflect a reporting bias of the 
conventional endoscopist. On the other hand, a longer examination time with MACE 
may have contributed to an increased detection in gastric pathology. There were cases 
of a missed polyp in the fundus (case 2) and a Cameron’s ulcer along the lesser curve 
(case 23) which were clearly identified by MACE, but not identified on OGD due to 
imperfect distension and mucosal inspection. It could be further hypothesised that when 
the upper GI tract is distended with water some pathologies are more apparent than 
when inflated with air which is seemingly less physiological. For example one study 
found that gastric antral vascular ectasia were commonly detected amongst anaemic 
patients during small bowel capsule endoscopy, but missed on initial OGD. 168. 
 
Early studies of handheld MACE have suggested that while distant views were 
achieved in the majority 117, detailed views were difficult to achieve in the upper 
stomach. In a large 350-patient multicentre study of patients undergoing both robot 
MACE and conventional OGD, MACE was equally capable in detecting focal gastric 
lesions irrespective of size or location with an overall 90% sensitivity and 94% 
specificity compared to OGD. The manoeuvrability of capsule endoscopes using a robot 
MACE system in the stomach is therefore felt therefore to be an improvement over the 
handheld device, although comparative studies between MACE systems are lacking.  
 
In contrast to Asian countries, where gastric cancer is more prevalent, in the west there 
is an increasing incidence of Barrett’s oesophagus and oesophageal adenocarcinoma 
and therefore the adoption of upper GI capsule endoscopy in Western populations is 
likely to be limited by its ability to detect oesophageal pathology 9. Our initial 
experience of oesophageal examination using the robot MACE system has been 
disappointing. Although the amount of time spent examining the oesophagus was no 
different between MACE and OGD, three cases of oesophagitis were missed by MACE 
and in two seen on one or two frames briefly when unblinded. This is possibly because 
the capsule endoscope has only a unidirectional image sensor and if by chance held 
facing away from the gastrooesophageal junction, it would miss pathology. Handheld 
MACE systems such as the Mirocam Navi seem more capable in holding the capsule in 
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the lower oesophagus with a mean oesophageal examination time of 3.1 minutes 169, 
likely due to closer apposition of the magnet to the chest wall. Other techniques such as 
tethering the capsule endoscope to a detachable string are being re-examined and have 
the additional advantage of a controlled examination of the upper and middle 
oesophagus, 170 although more technologically advanced capsules with higher image 
capture rates and bidirectional image sensors are likely to be more tolerable and 
acceptable to patients. 112 Finally, a controlled transpyloric transit rate in less than half 
of cases is disappointing and would explain why duodenal pathology was occasionally 
missed. With the benefit of more experience and practice, it is possible to achieve 
transpyloric passage in all cases within 4.4 minutes in a series of 107 patients 122.  
 
Along with clinical effectiveness, patient experience is a further pillar in quality of care 
and the primary focus of this study. 171 Studies of patient experience of endoscopy have 
focused on procedural tolerance and satisfaction. 57,171  This study has shown that over a 
third of patients volunteered concerns were unrelated to their procedural tolerance. That 
test results are important to patients is unsurprising, but many also expressed an interest 
in the overall investigative pathway, the detail (like sensations experienced) and 
duration of the test. Patients valued a comfortable environment during recovery and 
information about potential adverse effects.  
 
A measure of satisfaction is unidimensional and conveys patients’ overall contentedness 
with their experience, but in contrast to patient-related experience measures (PREMs), 
does not encompass all aspects of care nor discriminate which aspects are important. 172 
Patient experience may affect compliance with investigation and participation in 
screening programmes and therefore services responsive to feedback can improve 
patient outcomes.71,172  Therefore we chose to use two PREMs, the ECS and UPC-Q. 
The ECS comprised aspects of patient concerns before, during and after endoscopy, and 
the score derived was shown to demonstrate good internal consistency and construct 
validity and to correlate with patients’ acceptance of OGD.65 The UPC-Q is a patient-
generated index based on each individual’s concerns, priorities and experiences and 
serves to examine patient acceptability of a healthcare experience beyond the 
constraints set by an endoscopy paradigm. It performs reliably and correlates well 
against known measures of patient satisfaction in other in- and out-patient settings.68 
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That it correlates with the ECS in this study, an experience score designed for 
endoscopic practice, suggests that the UPC-Q could be used as a patient-related 
experience measure in this setting. However, one of the main limitations of this study is 
that the ECS has not been validated in MACE, and some question have been adapted 
without evidence of validity.  No PREM has yet been developed specifically for capsule 
endoscopy. The ECS was developed based on patient reports and literature review of 
conventional endoscopy, but not by more systematic qualitative interviews of patients 
experiences of endoscopies. Therefore, the content validity of the ECS tool even with 
conventional endoscopy could also be questioned. At present no better tool exists, and 
therefore it is possible that the measures may bias towards better tolerance and 
acceptance of MACE. This is because the conventional distresses to intubational 
endoscopy, such as gagging and feelings of choking may not apply to such a degree that 
is important to patients.  
 
Our results are consistent with previous studies of tolerance and preference for capsule 
endoscopy over OGD. 101-105,107 Patients are thought to formulate a notion of 
satisfaction by comparing their expectation with actual experience. 173 Our patients 
accurately anticipated the unpleasant aspects of OGD, yet only 64% of patients 
regarded it as acceptable and it performed comparatively poorly in the UPC-Q. Patients 
MACE experience was universally better than anticipated compared to 76% of patients 
who reported feeling more distressed than anticipated in at least one domain after 
OGD.c  This would explain why patients place a greater ranking of importance to 
procedural tolerance after OGD than MACE. 
 
Our study contrasts with the 95% acceptability rate of OGD identified in the study of 
Condon et al. 65 where all patients were sedated. The use of conscious sedation for 
OGD had a disappointing impact in this study. However, systematic review and meta-
analysis showed that compared to no sedation, use of midazolam alone only improves 
                                                
c Patients who reported a worse experience than anticipated distress in at least one of 10 post-procedure 
measures of distress: 0/44 for MACE and 32/44 for OGD   
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patient satisfaction and willingness to repeat the procedure (not any aspect of tolerance 
nor overall experience) 55, and at mean doses of 4.8-10.3 mg, far greater than would be 
used in current practice. That patients may not always feel ‘conscious’ sedation is 
adequate may explain the move towards anaesthetist-directed sedation using propofol in 
the USA. 77  
 
Studies which examine the diagnostic yield of upper GI capsule endoscopy technology 
and OGD perform MACE prior to OGD to ensure biopsy defects are not mistaken as 
false positives on MACE 104. As in our study, when patients act as their own controls, 
exposing patients to MACE prior to OGD might cause bias in their responses to 
tolerance and acceptability. It is likely that acceptability is defined by the context in 
which it is assessed, and the experience of a non-invasive alternative in this study prior 
to OGD may have adversely affected the acceptability of OGD. Future prospective 
trials of patient experience should consider this exposure bias and randomisation of 
order of procedure could be considered.  
 
This study demonstrates patient’s preference for MACE over OGD even where biopsies 
and subsequent OGD are required. However, the present study does not consider 
patients preferences informed with information regarding the accuracy of the 
investigations. We show in Chapter 3 that the miss cancer occurrence rate is 1 in 1250 
OGD procedures.  Liao et al. (2015) show that the sensitivity of MACE to detect focal 
gastric lesions is 90.4% by comparison to OGD. 107 Our anecdotal experience suggests 
the current iteration of MACE performs poorly in the oesophagus, however no 
adequately powered studies yet examine the accuracy of MACE in the oesophagus. 
When patients are not informed about the accuracy of the procedures, our UPC-Q data 
suggests that test accuracy is ranked as a priority by 1.6% and 2.7% of those 
undergoing OGD and MACE respectively (p=0.17). It is expected however that 
informing patients that MACE likely performs poorer than OGD, the gold standard, 
would negatively influence their acceptance of MACE and ultimately preference 
between OGD and MACE.  
 
The ability to obtain biopsies remains an important advantage of OGD. It has been 
previously found that whilst 84% of 500 patients having OGD to investigate dyspepsia 
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had biopsies taken, they contributed to management in only 16% beyond empirical 
treatment with proton pump inhibitors or Helicobacter pylori ‘test and treat’ strategies. 
174 If however, lesions are seen requiring biopsies, this study suggest that patients are 
willing to return for a gastroscopy and prefer to have a MACE examinations initially.  
The utility and cost effectiveness of this approach in upper GI endoscopy should be 
further examined. Finally, in recent times, it is increasingly recognised that aerosols 
generated by retching increase the risk of transmitting COVD-19 to endoscopy staff and 
patients. 160 This could be mitigated by the use of MACE where oro-pharyngeal 
reactions are typically absent when swallowing the capsule endoscope.
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5 A COMPARATIVE STUDY OF 
PATIENT TOLERANCE AND 
ACCEPTABILITY OF MAGNET 
CONTROLLED CAPSULE 
ENDOSCOPY AND 
TRANSNASAL ENDOSCOPY IN 
DYSPEPSIA 
  
Chapter 5: A Comparative study of patient tolerance and acceptability of magnet controlled capsule 
endoscopy and transnasal endoscopy in dyspepsia 




Introduction: Transnasal endoscopy (TNE) is a less invasive and better tolerated upper 
GI examination than conventional per oral Oesophagogastroduodenoscopy (OGD). 
Where an already less invasive alternative exists, the benefits of capsule endoscopy in 
the upper GI tract should be examined. In this study, patient tolerance and acceptability 
of OGD and transnasal endoscopy (TNE) have been compared with magnet-controlled 
capsule endoscopy (MACE).  
 
Methods: A self-controlled unblinded comparison of MACE and TNE in the 
investigation of patients with dyspepsia was performed. Factors affecting patient 
tolerance and acceptability were examined using two patient reported experience 
measures, the Endoscopy concerns scale (ECS) and Universal Patient Centredness 
Questionnaire (UPC-Q).  
 
Results: Pre-procedure ECS scores were higher before TNE (42 and 32, p=0.04) than 
MACE. Patients were more distressed (median scores) by gagging (1.5 vs 1, p=0.03), 
choking (3 vs 1, p=0.001), instrumentation (4.5 vs 1, p=0.001), discomfort during (5 vs 
1, p=0.001) and after (2 vs 1, p=0.01) TNE compared to MACE. All and 94% of 
patients found MACE and TNE acceptable respectively. However, UPC-Q score was 
lower (75 vs 88, p=0.007) and post procedure ECS higher (25 vs 10.5; p=0.001) for 
TNE than MACE suggesting MACE is better accepted than TNE. MACE would be 
preferred by 64% of patients even if TNE was subsequently recommended to obtain 
biopsies. 
 
Conclusion: Overall discomfort and instrumentation are the main causes of patient 
distress during TNE and tolerance and patient experience favoured MACE. Patients 
prefer MACE to TNE, even if a further TNE is required after MACE for biopsies in 
50% of cases.  
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Transnasal endoscopy (TNE) involves the intubation of an ultrathin endoscope through 
the nasal passages to examine the upper GI tract. It is less invasive, better tolerated and 
accepted by patients than conventional oesophagogastroduodenoscopy (OGD). 21,80 
Studies suggest that in the diagnoses of oesophageal disease, TNE is equivalent to 
conventional OGD. 81,82 There is a self-limiting risk of epistaxis in up to 5%. However 
because of superior patient tolerance most cases are performed without conscious 
sedation and therefore its cardiovascular risks. 76  
 
Capsule endoscopy may be less invasive still. A single study has described that 
oesophageal capsule endoscopy is more comfortable and preferred by patients 
compared to transnasal oesophagoscopy in the examination of Barrett’s oesophagus. 175 
Capsule endoscopy however is unable to take mucosal biopsies which is the main 
advantage of flexible endoscopes, ones including TNE. Where a less invasive and better 
tolerated upper GI investigation already exists, the relative benefits of capsule 
endoscopy should be explored.  A more detailed understanding of patients’ experience 
with TNE and studies comparing patient tolerance and acceptability of MACE and TNE 
are lacking. 57 
 
We compare the broader experience of MACE and TNE using two patient-related 
experience measures (PREMs), the Endoscopy Concerns Scale (ECS) and the Universal 
Patient Centredness Questionnaire (UPCQ), as well as examine patient preference 
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The recruitment for this study is part of a larger study of previously described in 
Chapter 4. The subjects included in this study are similar to that described in section 
4.3.1 (on page 48) with the exception that patients with contraindications to TNE were 
not eligible for participation in this study. This included patients with a bleeding 
diathesis (such as those on Warfarin or have chronic liver disease), a history of nasal 




Patients were offered the choice of OGD (with or without sedation) or transnasal 
endoscopy (TNE). Procedures were described to the patients verbally and in 
standardised hospital information leaflets provided as part of routine clinical practice. 
Those who agreed to participate in the study of TNE were also asked to have MACE in 
the two weeks preceding their TNE and included in this study. The MACE procedure 
was performed as described previously in section 4.3.2 (on page 48). TNE was 
performed after MACE on the same day by FWDT who was unblinded to the findings 
of MACE. Patients were prepared with 5 sprays (1 ml) of 5% lidocaine/ 0.5% 
phenyephrine nasal spray (Alliance Healthcare Ltd, Surrey, UK) per nostril 15 minutes 
prior to procedure followed by 6 sprays of topical local anaesthetic spray (10% 
Xylocaine, 10mg per spray; Aspen Pharma Trading Ltd, London, UK) immediately 
prior to TNE (GIF-XP290N, Olympus Corp, Tokyo, Japan).  
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5.3.3 Data collection and analysis 
 
Data collection and analysis of pre-procedure and post-procedure measures of 
acceptability and procedural tolerance measures were performed in this study as 
described in Chapter 4 (section 4.3.3, on page 49). Briefly, measures of acceptability 
include pre-procedure anxiety, the 13 anticipated aspects causing distress (and 
summated pre- and post-procedure ECS scores), the UPC-Q patient generated index, 
the assessment of acceptability based on three scenarios (undergoing the test again, 
advising a friend to undergo the test or having the test as a screen for cancer) and 
preference between MACE and TNE. Patient tolerance was measured using aspects 
causing distress experienced by patient during the examination. Aspects important to 
patients which were generated and ranked in the UPC-Q were categorised and degree of 
importance quantified. 
 
5.3.4 Outcome measures 
 
The primary outcomes were to determine aspects of endoscopy which caused distress to 
patients and to compare these individual aspects, overall acceptability and experience of 
MACE compared to TNE 
 
5.3.5 Statistical methods 
 
Advice was sought from the Statistical Services Unit at the University of Sheffield. A 
sample of 44 per group would have a 90% power to detect a difference in distress 
scores of 1 between MACE and flexible endoscopy assuming a standard deviation of 2 
using a paired t-test with a 0.05 two-sided significance level. A sample of 48 patients 
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would allow for an a priori interim analysis to be performed after 16 transnasal 
gastroscopies which would have a 90% power to detect a difference in mean distress 
score of 2 and satisfy the requirements of full power. d 
 
SPSS Statistics for Macintosh, Version 24.0.0 (IBM Corp, New York, USA) was used 
for statistical analysis. Parametric and non-parametric continuous data is presented as 
mean and standard deviation (SD) or median and interquartile range (IQR) respectively. 
Non-parametric paired differences in central tendencies were examined using Wilcoxon 
signed rank tests. Unpaired differences were examined using Mann Whitney U or 
Kruskal-Wallis H test. Categorical data is presented as number and percentages: n (%), 
and McNemar test was used to compare paired dichotomous variables. Statistical 




This study was approved and conducted in accordance with the ethical standards of the 
South Central – Berkshire B Research Ethics Committee (16/SC/0606. 
ClinicalTrials.gov NCT03420729), and the 1964 declaration of Helsinki and its later 
amendments. 
  
                                                
d This study design was considered due to a limited supply of capsule endoscopes supplied for research 
purposes. It was decided that should the primary outcome not be reached that a further supply of capsules 
could be considered, therefore necessary to design a study which allowed for an interim analysis.  
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Recruitment towards this study comparing TNE and MACE is part of a larger study 
involving, in addition, a larger cohort of patients who opted for OGD (reported in 
Chapter 4). A total of 111 patients were approached and 108 were confirmed eligible. A 
patient with dysphagia, a metallic heart valve and long-term NSAID use were 
ineligible. Of 108 patients invited to participate, 69 completed the study (36 patients 
declined and three agreed to do so but failed to attend their appointments) of which 22 
opted for TNE (Figure 15).   
 
MACE was successful in 16 (72%) and TNE in 21 (96%) of patients. MACE was 
unsuccessful in 5 due to undigested food in the stomach (n=1), a procedure time of less 
than 10 minutes (n=3) and prolonged periods of signal loss (n=1) and TNE unsuccessful 
in one due to failure to intubate either nostril. The median age of included patients was 
52.5 (IQR 27), were female in 56% (n=9), had previous experience of conventional 
OGD in 13% (n=2) but none had previous experience of TNE. Median (IQR) HADS 
anxiety score was 2 (6) with 27% (n=3) having an anxious trait (HADS anxiety score 
>8).   
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Figure 15: Patients who opted for TNE in a comparison of patient tolerance and 
acceptability of TNE and MACE 
5.4.2 Patient anxiety, anticipatory concerns and views on acceptability of 
MACE and TNE 
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Before the procedure, patients were no more anxious about having TNE than MACE 
with median (IQR) state anxiety scores of 4.5 (5) and 4 (4) respectively (p=0.57). 
Median pre-procedure ECS scores were higher before TNE (42 vs 32, p=0.04; Table 
9a) than MACE. Median distress scores were significantly more in anticipation of TNE 
than MACE when patients anticipated instrumentation (7.5 vs. 2.5, p=0.008) and 
procedural discomfort (6.5 vs. 3, p=0.005; Table 9a). 
5.4.3 Patient tolerance and factors causing distress during TNE and MACE 
 
After their procedure, patients reported experiencing significantly more distress 
(median score) due to gagging (1.5 vs 1, p=0.03), choking (3 vs 1, p=0.001), 
instrumentation (4.5 vs 1, p=0.001), discomfort during (5 vs 1, p=0.001) and after (2 vs 
1, p=0.01) TNE compared to MACE (Table 9b). Patients experienced significantly less 
distress from instrumentation and feelings of choking during TNE than anticipated 
(Table 10). With the exception of abdominal bloating, patients experienced less distress 
related to all factors affecting procedural tolerance (gagging, choking, discomfort, 
instrumentation) during MACE than anticipated.  
5.4.4 Acceptability and patient related experience of TNE and MACE 
 
Median post procedure ECS scores were significantly higher after TNE (25 vs 10.5, 
p=0.001) compared to MACE. UPC-Q score was lower after TNE (75 vs 88, p=0.007) 
than MACE (Table 9b). As defined by affirmative answers to all three questions 
regarding preparedness to undergo the same test again or recommend the test or 
undergo as screening procedure, 100% and 94% (15/16) of patients found MACE and 
TNE acceptable. When given a choice 94% (15/16) preferred MACE to TNE.  
 
The UPC-Q was completed appropriately by 94% (n=15). Aspects of care deemed 
important by patients can broadly be divided into the following categories: procedural 
tolerance (including drinking the water, swallowing the capsule, test discomfort and 
duration), staff communication (including information about, and progress of, the test), 
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procedural aftercare and recovery (including a comfortable environment and adverse 
effects), test results, test accuracy and other matters. The importance of each aspects of 




Figure 16: Aspects of care important to patients undergoing TNE and MACE 
generated by the UPC Questionnaire.  
Six points were allocated by 15 patients each (totalling to 90 points) to aspects of care pathway deemed 
important after each procedure. Patients apportioned points for procedure tolerance (TNE 54.4% and 
MACE 53.3%, p=0.89), staff communication (17.8% and 15.6%, p=0.69), procedure aftercare and recovery 
(8.9% and 3.3%, p=0.12), test results (14.4% and 16.7%, p=0.17), test accuracy (4.4% and 7.8%, p=0.87) 
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5.4.5 Effect of the need to obtain mucosal biopsies on patient test 
preference 
 
If tissue biopsies were necessary, therefore requiring TNE as a second test after MACE 
and the chance of requiring biopsies was 1 in 20, 1 in 10, 1 in 5, 1 in 4 or 1 in 2, 94%, 
94%, 81%, 75% and 63% would prefer MACE followed by TNE respectively.
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Table 9: Distress caused in anticipation of and by actual experience of TNE compared to MACE 
	 a)	Pre-procedure	anticipation	 	 b)	Patient	experience	
	 TNE	 MACE	 p	 	 TNE	 MACE	 p	
Telling	friends/colleagues	about	test	 1	(1)	 1	(2)	 0.89	 	 	 	 	
Fasting	 1.5	(3)	 1.5	(3)	 0.16	 	 	 	 	
Discomfort	prior	to	procedure	 1	(1)	 1	(2)	 0.88	 	 	 	 	
Gagging	 3	(5)	 3.5	(6)	 0.94	 	 1.5	(2)	 1(0)	 0.03	
Choking	 3	(5)	 3.5	(6)	 0.14	 	 1.5	(2)	 1(0)	 0.02	
Bloating	 1	(1)	 2	(2)	 0.13	 	 1	(3)	 1(1)	 0.86	
Vomiting	 1.5	(1)	 1	(3)	 1.00	 	 1	(0)	 1(0)	 0.66	
Doctor	seeing	food	in	stomach	 1	(0)	 1	(0)	 0.34	 	 1	(0)	 1(0)	 0.16	
Displaying	emotions	during	the	test	 1	(1)	 1	(3)	 0.08	 	 1	(1)	 1(0)	 0.24	
Instrumentation	 7.5	(4)	 2.5	(3)	 0.008	 	 4.5	(4)	 1(0)	 0.001	
Intravenous	catheter	 1	(1)	 1	(2)	 0.93	 	 1	(0)	 1(0)	 0.29	
Discomfort	during	procedure	 6.5	(3)	 3	(4)	 0.005	 	 5	(5)	 1(0)	 0.001	
Discomfort	after	procedure	 4	(3)	 3	(5)	 0.40	 	 2	(3)	 1(0)	 0.01	
Pre	procedure	anxiety	 4.5	(5)	 4	(4)	 0.57	 	 	 	 	
Pre	procedure	ECS	 45	(25)	 32	(19)	 0.04	 	 	 	 	
Post	procedure	ECS	 	 	 	 	 25	(15)	 10.5	(5)	 0.001	
UPC-Q	 	 	 	 	 75	(67)	 88	(37)	 0.007	
Pairwise comparison of pre-procedure anxiety and pre- and post- procedure distress (1 – 10: Least to most) scores; pre- (13-130: Most to least acceptable) and post- (10-100) procedure 
endoscopic concern scale (ECS) score and universal patient centredness questionnaire (UPC-Q) scores (least to most acceptable: 0-100) between TNE and MACE reported as a median 
(IQR).
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Paired comparison of distress scores (1 – 10: Least to most) cause in anticipation of and actual experience of OGD and MACE reported as median (IQR) 
	 TNE	 	 MACE	
	 Expectation	 Experience	 p	 	 Expectation	 Experience	 p	
	 	 	 	 	 	 	 	
Gagging	 3	(6)	 1.5	(2)	 0.10	 	 3.5	(5)	 1	(0)	 0.003	
Choking	 3	(6)	 1.5	(2)	 0.05	 	 3.5	(5)	 1	(0)	 0.004	
Bloating	 1	(2)	 1	(3)	 0.10	 	 2	(2)	 1	(1)	 0.08	
Vomiting	 1.5	(3)	 1	(0)	 0.08	 	 1	(1)	 1	(0)	 0.04	
Doctor	seeing	food	in	stomach	 1	(0)	 1	(0)	 0.31	 	 1	(0)	 1	(0)	 0.32	
Displaying	emotions	during	the	test	 1	(3)	 1	(1)	 0.23	 	 1	(1)	 1	(0)	 0.06	
Instrumentation	 7.5	(3)	 4.5	(4)	 0.04	 	 2.5	(4)	 1	(0)	 0.008	
Intravenous	catheter	 1	(2)	 1	(0)	 0.40	 	 1	(1)	 1	(0)	 0.06	
Discomfort	during	procedure	 6.5	(4)	 5	(5)	 0.14	 	 3	(3)	 1	(0)	 0.002	
Discomfort	after	procedure	 4	(4)	 2	(3)	 0.09	 	 3	(3)	 1	(0)	 0.002	
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Transnasal endoscopy and MACE are both well accepted by patients. Prior to 
procedures, there were no differences in anxiety levels and participants were marginally 
more accepting of MACE than TNE as evidence by higher pre-procedure ECS scores. 
Prior to endoscopies, patients were more distressed in anticipation of instrumentation of 
the nostril and discomfort of the TNE procedure than swallowing a capsule endoscope 
and the discomfort of MACE. Their actual experience mirrored this with significantly 
more distress during instrumentation and discomfort of TNE, but also, minimal but 
significantly greater distress caused by gagging and choking with TNE compared to 
MACE. Patients were marginally more accepting of MACE than TNE by both patient-
reported experience measures (PREMs), the ECS and UPC-Q but furthermore 94% 
preferred MACE over TNE and 64% of patients would prefer MACE followed by TNE 
rather than a single TNE test if biopsies were required in 50% of the cases.  
 
Patients experienced less distress than anticipated during both procedures: due to 
choking and instrumentation with TNE, and by most measures of tolerance with MACE 
and this would explain the high acceptability of both procedures. Procedural tolerance, 
although not the only aspect important to patients experience, was the most important 
aspect with over 50% of volunteered concerns. This study reports significantly more 
discomfort during TNE than MACE. In particular, this interim analysis after 16 
transnasal endoscopy patients revealed a mean difference in the primary endpoint, the 
discomfort score of 4.1 (95% CI 2.5 – 5.6, p<0.0001) favouring MACE and satisfying 
an a priori condition for full power in detecting at least a difference of 2 points between 
modalities. Therefore, the trial was concluded at this point.  
 
The concept of discomfort is broad and in endoscopy encompasses more specifically 
unpleasant sensations. Studies which compare patient experience of TNE to 
conventional OGD report overall better acceptance of TNE 21 and less desire for 
sedation during future procedures 176,177. Nevertheless, consistent with the findings of 
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this study, they all report minimal but discernible degrees of discomfort 177, with 
gagging 87, choking 178,179 and retching 176 in patients undergoing TNE. In one study 
23% of patients undergoing TNE experienced minimal gagging 87. Nasal intubation was 
distressing amongst the participants of this study. This may be because the endoscopists 
experience of TNE was limited to 30 procedures at the end of the trial and further 
experience would have been desirable prior to starting the trial. On the other hand, nasal 
intubation, despite the appropriate pre-procedure medication, can be painful and cause 
distress. In a study by Preiss and collaborators, nasal intubation was significantly more 
painful and cause more choking than oral intubation, both when using the same 5.9mm 
ultrathin scope. 180 Broadly the literature suggests that TNE can be distressing during 
nasal intubation due to nasal pain and in contrast, whilst conventional oral intubation is 
not painful per se, causes discomfort due to gagging. It may be expected therefore that a 
less invasive investigation (than per oral OGD), but still ultimately requiring the 
passage and manipulation of a flexible endoscope through a lumen, to cause more 
distress on instrumentation and during the procedure than one that is non-invasive and 
does not involve endoscope manipulation in the traditional way. 
 
The focus of this study was on patient tolerance and acceptability and with this in mind 
methodology should be discussed. This was a non-blinded study, both interventions 
performed by the same endoscopist, and therefore not designed to examine differences 
in pathology detection. However, even in comparing patient experience the study 
suffers from performance bias due to the interventions being performed by the same 
unblinded endoscopist. Furthermore, as previously suggest in Chapter 4 (section 4.5 on 
page 70), because patient act as their own controls, always performing MACE prior to 
TNE may affect patient’s expectations and negatively impact acceptability of TNE, 
especially amongst the majority (88%) of patients in the study who have not 
experienced upper GI endoscopy before. Therefore, randomisation of which 
intervention occurred first would have been more ideal. The impact of these effects 
however is thought to be small. Acceptability favours MACE, although the differences 
in the ECS and UPC-Q scores between MACE and TNE are minimal in this small study 
of 16 patients, so it is possible that a more experienced endoscopist, randomisation and 
blinding may result in no differences in acceptability between MACE and TNE, but 
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unlikely to make TNE more acceptable or preferable than MACE. It may, however 
result in more patients opting for TNE directly rather than MACE followed by TNE 
with increasing probabilities of requiring biopsies. Nevertheless, 15 of 16 patients 
would repeat the TNE again, recommend to a friend under the same conditions and 
undergo as a screening test, in spite of the distresses of intubation and procedural 
discomfort.  
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6 THE EFFECT OF 
POLYETHYLENE GLYCOL 
PURGATIVES IN SMALL 
BOWEL CAPSULE 
ENDOSCOPY  
Chapter 6: The effect of Polyethylene Glycol purgatives in small bowel capsule endoscopy 




Introduction: Capsule endoscopy can examine both the upper GI tract and small bowel 
with the same device. The role of bowel purgatives in advance of a small bowel capsule 
endoscopy is contentious and therefore the pre-procedure preparation for a MACE 
examination for an examination of both the upper GI tract and small bowel is yet to be 
defined. We examine the benefit of polyethylene glycol (PEG) prior to a small bowel 
examination and further the role of different timing interventions of the PEG laxative.  
 
Methods: A randomised control trial of a single 2 litre dose, a split dose  
(1 litre the evening before and 1 litre the morning of the procedure) of PEG and a clear 
liquid diet only was performed. We examined a computed assessment of cleansing 
(CAC), a reviewer assessment of cleansing and further the tolerability and acceptability 
of pre-procedure interventions 
 
Results: A total of 186 (85%) of recruited patients were analysed. There were no 
differences in the CAC scores between the intervention groups. However, there was a 
significantly greater reviewer assessed quantitative index in the fourth quartile of the 
small bowel between PEG and clear fluids (8.4 vs 7.7 p=0.006), in particular when PEG 
was administered as a split dose (8.5; p=0.01). Furthermore, overall adequacy of 
assessment was significantly greater with PEG interventions than clear liquid diet only 
(single 91.4%, split 91.5% vs clear liquid diet 72.9%, p=0.005). However, patients 
better tolerated (0-4: completely intolerable to completely tolerable) a clear liquid diet 
(3.7) compared to a single dose (3.0) and split dose (2.8) of PEG (both p<0.0001 vs. 
clear liquid diet) and were more accepting of a clear liquid diet (95.9%) than single 
(87.5%) and split (77.6%) dose of PEG (p=0.03). 
 
Conclusion: Pre-procedure PEG laxatives given on the morning of the procedure 
improve distal small bowel mucosal views. However, patients better tolerate and are 
more accepting of a clear liquid diet only compared to pre-procedure PEG laxatives. 
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Turbid fluid and digestive residue overlying the small bowel mucosal surface result in 
inadequate examinations and repeat investigations due to the potential for missed 
diagnoses during capsule endoscopy. Historically, a clear liquid diet and a 12 hour fast 
was the recommended pre-procedure preparation for small bowel capsule endoscopy 
181. This is similar to and adequate preparation for upper GI capsule endoscopy. 162 
Bowel purgatives are used routinely in advance of colonic examinations and have been 
shown to improve examination completion and pathology detection. 135 It is well 
established that terminal ileum and right colon views are improved with purgatives 
taken a few hours before the examination and splitting doses of purgatives have shown 
more superior cleansing and pathology detection. 135,144 It is not clear however, whether 
purgatives prior to capsule endoscopy augment small bowel mucosal views. 182,183. 
Controlled studies which support the use of purgatives report that Polyethylene glycol 
(PEG) improves views 136-139 and even diagnostic yield in one study 136, but larger 
studies dispute these findings.140-142  
 
Robot controlled MACE has the advantage of investigating the small bowel beyond the 
reach of a conventional endoscope in the same examination as the upper GI 
examination. To achieve this, pre-procedure bowel preparation suitable for both the 
upper GI tract and small bowel would need to be defined. We examine the additional 
benefit of using PEG laxative in the small bowel over a clear liquid diet and 12 hour 
fast. Furthermore, we examine the effect of two different dose timings, a single and a 
split dose of PEG laxative.  
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6.3.1 Patient selection and randomisation 
 
Patients undergoing a small bowel capsule endoscopy were invited to join the trial from 
the outpatient department of Sheffield Teaching Hospitals NHS Foundation Trust. 
Written consent was obtained by the requesting physician and confirmed by a member 
of the small bowel capsule endoscopy team over the phone prior to randomisation. 
Participants were randomised to one of three treatment groups: Split dose polyethylene 
glycol (PEG), Single dose PEG and clear liquid only. A central online randomizer 
application (Randomizer for Clinical Trial, Medsharing, France) using variable size 
permuted blocks of 6 and 9 were used. After randomisation, the patient was sent 
detailed written instructions by a team of capsule endoscopy specialist nurses.   
6.3.2 Interventions and procedure 
 
Common to all participants, patients were advised to stop iron supplements for 5 days 
prior, and to fast after a light breakfast and lunch the day before the examination. They 
were encouraged to drink at least 2 litres of only clear fluid during the course of the day 
before the examination. Patients randomised to the clear liquid arm were given no 
further instructions. Patients randomised to an intervention arm were provided with 
PEG (Klean-prep 69 grams per litre, Norgine, Middlesex, UK) and if randomised to the 
split dose PEG arm, were instructed to consume 1 litre of PEG solution at 7 pm the day 
before, and again at 6am on the day of the procedure. If randomised to the single dose 
PEG arm, patients were instructed to consume 2 litres of PEG solution at 6 am on the 
day of the examination.  
 
Patients on the day of the examination completed a post preparation questionnaire 
(Appendix 5). This contained questions regarding the amount of laxative consumed 
(where appropriate: none, some, most or all of it), overall tolerance of the pre-procedure 
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preparation (completely intolerable to completely tolerable: score 0-4), tolerance of 7 
factors (bloating, dizziness, nausea, vomiting, abdominal pain, poor sleep and bad taste, 
completely intolerable to completely tolerable: score 0-4) and willingness to repeat the 
examination with the same pre-procedure preparation.  
 
Patients ingested 80mg simethicone (Infacol, Teva, Castleford, UK) in 100mls of water 
10 minutes before swallowing the capsule endoscope as per standard protocol. The 
capsule is swallowed at 9 am and after transpyloric passage is confirmed on the real-
time monitor, the patient is instructed to abstain from fluids for 2 hours and food for 4 
hours. As per standard protocol, intramuscular metoclopramide 10mg is given after 1 
hour if the capsule endoscope is still within the stomach. Upon completion, video data 
is downloaded on the Pillcam Reader (Medtronic, Minneapolis, USA), read and 
reported in a standard fashion. At trial completion, the cases were pseudoanonymised 




The primary outcome of this study was cleanliness of the small bowel preparation 
assessed by the computed assessment of cleanliness (CAC) score. Secondary outcomes 
include the effect of the intervention on a reviewer assessment of cleansing, gastric and 
small bowel capsule transit time, the examination findings and patient tolerance and 




Tissue colour bars were extracted by taking a screenshot (Snipping Tool, Microsoft, 
Redmond, USA). A computed assessment of cleanliness (CAC) score is generated by 
measuring ratios of red and green channel intensities on the tissue colour bar produced 
by Pillcam Reader software with each examination. This CAC method, previously 
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described by Van Weyenberg et al. (2011), produces a score between 0 and 10 with a 
higher score representing better visualisation.184 Analyses were examined overall and 
individually by small bowel quartiles (divided by time) to assess the effect of the 
intervention on different segments of the small bowel. Red and green channel 
intensities (0-255: least to most intense) were measured (Photoshop CC 2017 v1.1, 
Adobe Inc, California, USA) and CAC calculated using the following formula: 
 
CAC score = (Red channel intensity / Green channel intensity) -1 x 10 
 
Figure 17a and b show a worked example and representative images of bowel 
cleanliness and their corresponding CAC values respectively. The CAC score 
calculations were performed by one blinded examiner (FWDT). 
 
Each case was further reviewed by an expert (MM) blinded to the findings specifically 
to assess bowel cleansing (Table 11). The five elements which impair mucosal views 
were assessed in each of the four quartiles. The percentage mucosa visualised, fluid and 
debris, bubbles, bile/chyme staining and brightness were scored out of two (severe, 
moderate and minimal/mild impairment: 0-2) and summated to derive a quantitative 
index (QI; scored 0-10, higher score represents superior cleansing). A qualitative 
evaluation (QE; Poor, Fair, Good and Excellent) and overall assessment adequacy 
(OAA; adequate or inadequate) were also scored. This methodology for quantitative 
and qualitative assessment of cleansing in the small bowel was conceived and validated 
by Brotz et al (2009) and has been used in the conception and validation of the CAC 
score by Van Weyenberg et al (2011).  
 
Owing to the Coronavirus 2019 pandemic, a pragmatic decision was made to perform 
an interim analysis of this study for the purposes of this doctoral thesis as the trial was 
temporarily suspended in March 2020. 
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Figure 17: Computed assessment of cleansing adopted from van Weyenberg et al. 
(2011).  
a) Worked example of a single quartile. Histograms of red and green channel intensities of the highlighted 
portion of the colour bar as measured in Adobe Photoshop CC. The ratio of mean intensities of red (218.5) 
and green (132.7) are used calculate the CAC score (6.5). b) Representative small bowel cleanliness and the 
segment (blue bar) of tissue colour bar used to calculate the CAC score for the corresponding segments. i) 
Shows excellent small bowel cleanliness, ii) and iii) deteriorating bowel cleanliness. 
  
CAC 6.5  
A. 
i)     02:09:04  
CAC 7.7 CAC 3.9 CAC 1.6 
ii)     03:14:36  iii)     04:28:32  
B. 
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Table 11: Blinded reviewer assessment of bowel cleansing using the Quantitative 






































* Severe <80% = 0, moderate 80-89% = 1, minimal/mild ≥90% =2 
Advancing Capsule Endoscopy in the examination of the Upper Gastrointestinal Tract 
 




Sample size calculation 
 
Advice was sought from the University of Sheffield Mathematics and Statistics 
resource centre. A sample of 101 patients per arm will have a 90% power to detect a 
mean difference of 0.5 points at a 0.025 two tailed significance level between either 
interventions and the control arm. A randomized study of bowel purgatives showed a 
within group standard deviation of around one point 140, therefore with this assumption 
a mean difference of 0.5 points is a moderate effect. Assuming at 15% withdrawal rate 
115 patients will be recruited to each group and it is estimated that 230 patients will be 




Continuous variables are presented as mean (SD) and compared using unpaired T-test 
or one-way analysis of variance (ANOVA) to compare differences between arms. 
Where differences between arms exist, Bonferroni’s post hoc correction is used to 
examine differences within groups. Categorical variables are presented as n, % and 
examined between groups using Chi Square (and Fisher’s exact test where appropriate). 
Statistical significance is set at the 0.05 level.     
6.3.6 Ethics 
 
This study sponsored by Sheffield Teaching Hospitals and approved and conducted in 
accordance with the ethical standards of the Yorkshire & The Humber - South 
                                                
e This study is part of a larger multicentre study with a centre in Ontario, Canada. 
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Yorkshire Research Ethics Committee (17/YH/0359, ClinicalTrials.gov 





 Between the 13th of December 2017 and 27th of February 2020, 220 patients 
were enrolled and randomised into this study. Patient flow through the study is 
illustrated in Figure 18. Thirty-four patients (10.9%) were withdrawn from the study for 
withdrawal of consent for trial (n=6), refusing investigation (n=6), referrer cancelling 
the investigation (n=2), being unable to swallow patency device (n=3), failure of 
passage of patency device (n=3), not attending the capsule endoscopy appointment 
(n=7), using a non-Pillcam SB capsule endoscope (n=5) and at the discretion of the PI 
(n=2; detailed in Figure 18). There was no difference in proportion of patients who did 
not receive the interventions (p=0.07). 
 
 There were 186 patients who successfully completed the small bowel capsule 
endoscopy (Table 12). There were 5 incomplete examinations (n=1 capsule remained in 
the stomach, n=4 capsules did not reach the caecum), 4 examinations with significant 
loss of signal and one study with data corruption, resulting in a complete small bowel 
examination in 177 (95.1%) and a complete CAC analysis in 176 patients (94.6%). 
Indications for capsule endoscopy include suspected small bowel bleeding (n=39), 
abdominal symptoms (n=83), assessment of established Crohn’s disease (n=27), 
assessment of coeliac disease (n=31) and other (n=6).  
6.4.2 Assessment of cleansing 
 
 The mean overall CAC score for clear fluids (5.5) was no different to PEG 
overall (5.6, p=0.52), nor single (5.6) or split dose (5.7, group p=0.73) PEG 
interventions (Table 13). The mean overall reviewer assessed quantitative index (QI) 
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for PEG overall was marginally higher than clear fluids only (mean difference 0.3, 
p=0.05), but no differences found between clear fluids and different timing 
interventions of PEG (clear fluids: vs. split p=0.04, vs. single p=0.65; Table 13). In the 
fourth (distal) quartile, there was however a significantly higher QI with PEG laxatives 
overall (mean difference 0.7, p=0.006), favouring a split dose prep (vs. clear fluid only 
mean difference 0.8 p=0.01), and a significantly better QE (good or excellent 
visualisation) with PEG overall (77.8% vs. 59.3% p=0.01). There were no differences 
in the mean QI and the proportion of QE marked as good or excellent between clear 
fluids and PEG overall nor amongst single or split doses interventions within the first 
three small bowel quartiles. No differences were found with respect to cleanliness 
scores between single and split doses by all measures of cleanliness and across all 
quartiles. Overall proportion of adequately cleansed examinations was significantly 
greater with PEG overall (OR 4.0 95% CI 1.7 – 9.5) compared to clear fluids (Table 
13). All but one inadequate examination had inadequacies in the fourth quartile. 
6.4.3 Transit time and diagnostic yield 
 
Mean gastric and small bowel transit time were no different between clear fluid (35 and 
243 mins respectively) and PEG overall (41 and 215 mins, p=0.31 and 0.06 
respectively) nor between clear fluids and individual timing interventions (group 
p=0.50 and 0.14 respectively; Table 13). No differences in proportion of patients with 
abnormal findings were found between clear fluids and PEG overall (p=0.88), nor 
between clear fluids and individual timing interventions (group p=0.28; Table 13) 
6.4.4 Patient tolerance and acceptability  
 
 Tolerance questionnaire data was complete in 157 patients (84.4%; Clear 
fluids n=56, Split n=53, Single n=48) and summarised in Table 14. There were no 
differences in questionnaire completion rates between interventions. Of 101 patients 
who were allocated to PEG laxatives, 82 (81.2%), 14 (13.9%) and 5 (5.0%) patients 
consumed all, most and some of the PEG solution. There was no difference in the 
reported consumption of the PEG solution between the split and single dose arms 
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(p=0.71). Clear fluid only was significantly more tolerable (mean score 3.7) than PEG 
overall (mean difference -0.8, p<0.0001) and when compared to both PEG timing 
interventions (mean difference vs. split dose -1.0, p<0.0001 and single dose -0.7, 
p<0.0001). Abdominal bloating and bad taste cause by PEG laxatives were significantly 
less tolerable than clear fluids only (Table 14). No differences were seen in overall 
tolerance between split and single dose PEG interventions (p=0.86).  More patients 
were willing to repeat a small bowel capsule endoscopy with clear fluids alone (96.3%) 
than split dose PEG (77.6%; p=0.02). 
6.4.5 Performance of quantitative and qualitative scores  
 
There was a moderate positive correlation (Spearmans rho) between the CAC and QI 
scores overall (r=0.56), in the first (r=0.42), second (r=0.53), third (r=0.46) and fourth 
quartile (r=0.52; all p<0.0001).  Adequate small bowel examinations (n=150) had a 
significantly greater overall mean CAC (mean difference 1.0, 95% CI 0.5 – 1.5) and QI 
(mean difference 1.7 95% CI 1.4 – 2.0) than inadequate examinations (n=26) 
(p<0.0001). 
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Figure 18: CONSORT diagram outlining patient flow through the trial 
PEG Polyethylene glycol, PI Principal investigator    
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Table 12: Baseline characteristics of patients completing trial 
 
	 All	patients	 	 Clear	liquid	
only	
	 PEG	overall	 	 PEG	by	dose	timing	 	 p	value	
Clear	liquid	vs.	
Age, gender, indication of small bowel capsule endoscopy (SBCE), need for patency assessment and SBCE completion rates. †group differences one way-ANOVA or Z-test of column 
proportions. *one patient corrupt data file excluded. 
  
	 	 	 	 	 	 	 Single	 Split	 	 PEG	overall	 by	PEG	timing†	
n	 186	 	 65	 	 121	 	 60	 61	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	
Age,	years	(sd)	 47.1	(17.1)	 	 49.3	(17.8)	 	 46.0	(16.6)	 	 44.6	(15.7)	 47.4	(17.5)	 	 0.23	 0.31	
Female	gender,	n	(%)	 117	(62.9)	 	 38	(58.5)	 	 79	(65.3)	 	 40	(67.8)	 38	(62.3)	 	 0.43	 0.58	
Indication,	n	(%)	 	 	 	 	 	 	 	 	 	 0.97	 0.89	
Suspected	small	bowel	bleeding	 39	(21.0)	 	 13	(20.0)	 	 26	(21.5)	 	 10	(16.7)	 16	(26.2)	 	 	 	
Abdominal	pain	or	diarrhoea	 83	(44.6)	 	 28	(43.1)	 	 55	(45.5)	 	 30	(50.0)	 25	(41.0)	 	 	 	
Assessment	of	established	
Crohn’s	disease	
27	(14.5)	 	 11	(16.9)	 	 16	(13.2)	 	 8	(13.3)	 8	(13.1)	 	 	 	
Assessment	of	Coeliac	disease	 31	(16.7)	 	 11	(16.9)	 	 20	(16.5)	 	 9	(15.0)	 11	(18.0)	 	 	 	
Other	 6	(3.2)	 	 2	(3.1)	 	 4	(3.3)	 	 3	(5.0)	 1	(1.6)	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	
Patency	assessment,	n	(%)	 74	(39.8)	 	 28	(43.1)	 	 46	(38.0)	 	 19	(31.7)	 27	(44.3)	 	 0.53	 0.29	
SBCE	completion,	n	(%)	 177	(95.1)*	 	 60	(92.3)	 	 118	(98.3)	 	 58	(98.3)	 60	(98.4)	 	 0.34	 0.49	
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Table 13: Computed and reviewer assessment of cleansing, capsule transit times and diagnostic yield using PEG and dose timing interventions 
 
	 All	patients	 	 Clear	liquid	
only	
	 PEG	overall	 	 PEG	by	dose	timing	 	 p	value	
Clear	liquid	vs.	
	 	 	 	 	 	 	 Single	 Split	 	 PEG	overall	 by	PEG	timing†	
	 	 	 	 	 	 	 	 	 	 	 	
n	 176	 	 59	 	 117	 	 58	 59	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	
CAC	overall,	mean	(sd)	 5.6	(0.9)	 	 5.5	(1.0)	 	 5.6	(0.8)	 	 5.6	(0.7)	 5.7	(0.9)	 	 0.52	 0.73	
First	Quartile	 6.0	(0.9)	 	 6.1	(0.9)	 	 6.0	(1.0)	 	 6.0	(0.9)	 6.0	(1.0)	 	 0.50	 0.80	
Second	Quartile	 5.7	(0.9)	 	 5.8	(0.9)	 	 5.7	(0.9)	 	 5.6	(0.8)	 5.7	(1.0)	 	 0.60	 0.71	
Third	Quartile	 5.6	(1.0)	 	 5.5	(1.3)	 	 5.6	(0.9)	 	 5.5	(0.9)	 5.7	(0.9)	 	 0.60	 0.54	
Fourth	Quartile	 5.2	(1.2)	 	 5.0	(1.6)	 	 5.3	(1.0)	 	 5.4	(1.0)	 5.3	(1.0)	 	 0.10	 0.14	
	 	 	 	 	 	 	 	 	 	 	 	
Quantitative	Index,	mean	(sd)	 8.9	(0.9)	 	 8.7	(1.0)	 	 9.0	(0.8)	 	 8.9	(0.8)	 9.1	(0.8)	 	 0.05	 0.04	
First	Quartile	 9.2	(1.0)	 	 9.1	(1.1)	 	 9.3	(1.0)	 	 9.2	(1.0)	 9.4	(1.0)	 	 0.26	 0.30	
Second	Quartile	 9.2	(1.1)	 	 9.1	(1.2)	 	 9.3	(1.1)	 	 9.2	(1.1)	 9.4	(1.0)	 	 0.19	 0.22	
Third	Quartile	 8.9	(1.4)	 	 8.8	(1.5)	 	 9.0	(1.4)	 	 8.9	(1.5)	 9.2	(1.2)	 	 0.44	 0.39	
Fourth	Quartile	 8.2	(1.4)	 	 7.7	(1.6)*	 	 8.4	(1.3)	 	 8.4	(1.3)	 8.5	(1.4)*	 	 0.006	 0.01	
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Continued	 All	patients	 	 Clear	liquid	
only	
	 PEG	overall	 	 PEG	by	dose	timing	 	 p	value	
Clear	liquid	vs.	
	 	 	 	 	 	 	 Single	 Split	 	 PEG	overall	 by	PEG	timing†	
Qualitative	Evaluation,	n	
Good/Excellent	(%)	
	 	 	 	 	 	 	 	 	 	 	
First	Quartile	 165	(93.8)	 	 55	(93.2)	 	 110	(94.0)	 	 54	(93.1)	 56	(94.9)	 	 1.0	 0.90	
Second	Quartile	 166	(94.3)	 	 54	(91.5)	 	 112	(95.7)	 	 54	(93.1)	 58	(98.3)	 	 0.31	 0.25	
Third	Quartile	 146	(83.0)	 	 45	(76.3)	 	 101	(86.3)	 	 49	(84.5)	 52	(88.1)	 	 0.14	 0.21	
Fourth	Quartile	 126	(71.6)	 	 35	(59.3)	 	 91	(77.8)	 	 58	(79.3)	 45	(76.3)	 	 0.01	 0.04	
	 	 	 	 	 	 	 	 	 	 	 	
Overall	adequacy	of	
assessment,	n(%)	
150	(85.2)	 	 43	(72.9)^*	 	 107	(91.5)	 	 53	(91.4)^	 54	(91.5)*	 	 0.003	 0.005	
First	Quartile	 175	(99.4)	 	 59	(100)	 	 116	(99.1)	 	 58	(100)	 58	(98.3)	 	 1.0	 0.37	
Second	Quartile	 174	(98.9)	 	 58	(98.3)	 	 116	(99.1)	 	 58	(100)	 58	(98.3)	 	 1.0	 0.60	
Third	Quartile	 168	(95.5)	 	 57	(96.6)	 	 111	(94.9)	 	 54	(93.1)	 57	(96.6)	 	 0.72	 0.58	
Fourth	Quartile	 151	(85.8)	 	 43	(72.9)^*	 	 108	(92.3)	 	 54	(93.1)^	 54	(91.5)*	 	 0.001	 0.002	
	 	 	 	 	 	 	 	 	 	 	 	
GTT,	min	(sd)	 39	(37)	 	 35	(32)	 	 41	(39)	 	 43	(37)	 39	(41)	 	 0.31	 0.50	
SBTT,	min	(sd)	 225	(95)	 	 243	(85)	 	 215	(99)	 	 209	(92)	 221	(105)	 	 0.06	 0.14	
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Small bowel computed assessment of cleansing (CAC, score 0-10: higher representing better cleansing), reviewer assessed Quantitative Index (QI; 0-10: higher representing better 
cleansing), Qualitative evaluation and Overall adequacy of assessment of bowel cleansing, gastric transit time (GTT), small bowel transit time (SBTT) and examination findings of PEG 
overall and by timing intervention vs. clear fluid only. †group differences one way-ANOVA or Z-test of column proportions: * / ^ significant between group differences after 
Bonferroni’s correction p<0.016 a One angioectasia and one arteriovenous malformation seen as significant in contrast to 9/27 insignificant small non-bleeding angioectasia listed as 
benign. SMT Submucosal tumour, GTT Gastric transit time, SBTT small bowel transit time, PEG polyethylene glycol, sd standard deviation 
Continued	 All	patients	 	 Clear	liquid	
only	
	 PEG	overall	 	 PEG	by	dose	timing	 	 p	value	
Clear	liquid	vs.	
	 	 	 	 	 	 	 Single	 Split	 	 PEG	overall	 by	PEG	timing†	
	 	 	 	 	 	 	 	 	 	 	 	
Findings,	n	abnormal	(%)	 79	(44.9)	 	 25	(42.4)	 	 54	(46.2)	 	 32	(55.9)	 22	(36.2)	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	
Significant	findings		 42	(23.9)	 	 13	(22.0)	 	 29	(24.8)	 	 17	(28.8)	 12	(20.7)	 	 0.91	 0.45	
Coeliac	disease	 25	(14.2)	 	 8	(13.6)	 	 17	(14.5)	 	 8	(13.6)	 9	(15.5)	 	 	 	
Crohns	disease	 10	(5.7)	 	 3	(5.1)	 	 7	(6.0)	 	 4	(6.8)	 3	(5.2)	 	 	 	
Blood	 2	(1.1)	 	 1	(1.7)	 	 1	(0.9)	 	 1	(1.7)	 0	(0.0)	 	 	 	
Polyp	/	SMT	 4	(2.3)	 	 1	(1.7)	 	 3	(2.6)	 	 3	(5.1)	 0	(0.0)	 	 	 	
Significant	angioectasiaa	 2	(1.1)	 	 0	(0.0)	 	 2	(1.7)	 	 0	(0.0)	 2	(3.4)	 	 	 	
Insignificant	findings	 37	(21.0)	 	 12	(20.3)	 	 25	(21.4)	 	 16	(27.1)	 9	(15.5)	 	 	 	
Benign		 26	(14.8)	 	 10	(16.9)	 	 16	(13.7)	 	 12	(20.3)	 5	(8.6)	 	 	 	
Non-specific	inflammation	 10	(5.7)	 	 2	(3.4)	 	 8	(6.8)	 	 4	(6.8)	 4	(6.9)	 	 	 	
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Table 14: Patient tolerance and acceptance of PEG laxative compared to a clear liquid diet only 
 
Overall and seven different factors affecting tolerance to pre-procedure preparation. Tolerance scores ranged from completely intolerable to completely tolerable (0 – 4: higher 
representing better tolerance) †group differences one way-ANOVA or Z-test of column proportions: * / ^ significant between group differences after Bonferroni’s correction p<0.016. §3 
patients with missing responses. PEG polyethylene glycol, sd standard deviation  
	 All	patients 	 Clear	liquid	
only 
	 PEG	overall 	 PEG	by	dose	timing 	 p	value	
Clear	liquid	vs. 
	 	 	 	 	 	 	 Single	 Split	 	 PEG	overall	 PEG	by	timing†	
n	 149	 	 50	 	 99	 	 48	 51	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	
Overall	tolerance	 3.2	(1.0)	 	 3.7	(0.5)*^	 	 2.9	(1.1)	 	 3.0	(1.0)*	 2.8	(1.2)^	 	 <0.0001	 <0.0001	
Abdominal	bloating	 3.5	(0.9)	 	 3.7	(0.7)*^	 	 3.3	(1.0)	 	 3.4	(0.9)*	 3.2	(1.0)^	 	 0.004	 0.017	
Dizziness	 3.8	(0.5)	 	 3.8	(0.6)	 	 3.8	(0.5)	 	 3.8	(0.5)	 3.8	(0.5)	 	 0.86	 0.97	
Nausea	 3.4	(0.8)	 	 3.7	(0.6)*	 	 3.3	(0.8)	 	 3.3	(0.8)*	 3.3	(0.9)	 	 0.001	 0.006	
Vomiting	 3.9	(0.5)	 	 4.0	(0.3)	 	 3.8	(0.5)	 	 3.8	(0.6)	 3.8	(0.5)	 	 0.07	 0.32	
Pain	 3.6	(0.8)	 	 3.8	(0.5)^	 	 3.4	(0.8)	 	 3.5	(0.8)	 3.4	(0.9)^	 	 <0.0001	 0.004	
Poor	sleep	 3.4	(1.0)	 	 3.5	(0.8)	 	 3.3	(1.0)	 	 3.5	(1.0)	 3.2	(1.0)	 	 0.35	 0.23	
Bad	taste	 3.1	(1.2)	 	 3.9	(0.4)*^	 	 2.7	(1.2)	 	 2.7	(1.1)*	 2.7	(1.3)^	 	 <0.0001	 <0.0001	




127	(87.0)§	 	 47	(95.9)*	 	 80	(82.5)	 	 42	(87.5)	 38	(77.6)*	 	 0.03	 0.03	
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In this preliminary reporting of a randomised control trial of the use of PEG laxatives 
administered as a split dose or as a single dose on the day of the procedure, we show no 
difference in the computed assessment of cleansing (CAC) scores between patients who 
have had clear liquids only pre-procedure preparation and PEG laxative. However, on 
blinded reviewer assessment, the overall adequacy of bowel cleansing was significantly 
greater with both single and split dose PEG compared to clear liquids only, mostly due 
to the adequacy of the fourth (distal) quartile cleansing. This corroborates a better 
cleansing score with PEG laxatives, using both the quantitative index (QI) and 
qualitative assessment (QA) scores, in particular with a split dose dosing regime in the 
distal small bowel. We show that patients tolerate better, and are more accepting of 
clear liquids than PEG laxative pre-procedure with no difference in patient tolerance 
between a split and single dose preparation.  
 
 Views of the distal small bowel are most affected during small bowel capsule 
endoscopy 143 and this study would support this view with worse bowel cleansing in the 
distal compared to proximal quartiles in all intervention groups and by all measures of 
bowel cleanliness. A systematic review and meta-analysis in 2016 on the whole extent 
of the literature on laxatives in small bowel cleansing supported the use of laxatives in 
improving small bowel views 183. Controlled studies which support the use of PEG 
report that 2 litres (compared to 1 or 4 litres) is optimal in improving views 136,137,185, 
however recent larger studies show no clear benefit of PEG laxatives over clear liquids 
only. 140-142 In fact, by using a reviewer assessed five-point ordinal scale (0-5: 
inadequate to excellent cleanliness), Hookey et al (2017) report clear fluids only 
resulted in cleaner small bowel overall compared to PEG taken the evening before the 
procedure. Our preliminary analysis supports the view that PEG laxatives do improve 
small bowel cleansing, particularly in the distal small bowel. We believe the 
discrepancy in bowel cleansing between ours and others can be explained by a 
difference in the timing of the preparations. In our study, all patients randomised to a 
Chapter 6: The effect of Polyethylene Glycol purgatives in small bowel capsule endoscopy 
Foong Way David TAI - September 2020   111 
 
PEG group had at least 1 litre of PEG (as split dose or 2 litres at 6am as a single dose) 
on the morning of the procedure.  
 
In advance of ileocolonoscopy, there is a precedent in using a split dose of PEG laxative 
and it is accepted that such timing results in superior cleansing and pathology detection 
compared to a single dose the evening before the procedure, particularly in the proximal 
segments (right colon and terminal ileum). 144,186 In most trials of small bowel cleansing 
however, purgatives are consumed in the day before the procedure, including the larger 
negative studies 140-142. In two small studies, administration of PEG as a split dose (the 
evening before the procedure and on the day of the procedure) offered some benefit 
over a single dose of PEG the evening before the procedure 187 and clear fluids 143. It is 
therefore hypothesised that the cleansing, particularly in the distal small bowel, is due 
to the dose of PEG taken on the morning, hours before the procedure.  
 
Of interest, although this analysis is underpowered by a third, our preliminary results 
might suggest that for cleansing of the distal most quartile, split dose PEG is more 
effective than clear fluids only. No differences in cleanliness as measured by QI or QE, 
were seen between a split and single dose, and single dose and clear fluids. This would 
be consistent with one previous study which compared a single 2 litre PEG dose in the 
evening before versus on the morning of the capsule endoscopy which showed no 
difference in mucosal views, however this study was small (n=34) and uncontrolled 188. 
The differences between the efficacy of a split or single dose therefore remain 
inconclusive until trial completion, but the current results support taking a dose of PEG 
in the morning of the procedure.  
 
The results of this study have implications on patient experience of a combined upper 
GI and small bowel capsule endoscopy. A morning dose of PEG laxative improves 
distal small bowel views. However, the requirement for PEG laxative for a small bowel 
investigation in addition to upper GI MACE would be expected to negatively impact 
patient experience as patients better tolerated, and more were accepting of clear fluid 
only pre-procedure preparation. The majority (95%) of those randomised to a PEG 
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laxative group however were able to drink all or most of the preparation and there were 
no differences in tolerance between the single and split dose PEG preparations. 
Numerically more patients found the single dose acceptable than split dose, possibly 
because of its simplicity, but further power is required to conclude this on this finding.  
 
It was not practical to control the volume of fluid consumed by those randomised to 
clear liquid (or additional liquid consumed by laxative groups) and so the differences in 
effects of equal volumes of liquid and active preparation cannot be determined. One 
previous study has suggested that preparation with 4 litres of clear liquids is not inferior 
to 2 or 4 litres of PEG suggesting that volume of water ingested before the procedure, 
and in transit with the capsule endoscope during examination, may therefore be more 
important than use of an active purgative 142. The superior cleansing effect of PEG seen 
in the reviewer assessment may therefore be in fact due to a lack of clear fluids 
consumed by patients allocated to clear fluids only. If this is the case, it is likely that the 
additional litre of water consumed to distend the stomach prior to the upper GI MACE 
would augment small bowel mucosal views proximally, but its effect on distal portions 
is yet to be determined.  
  
Although at the expense of patient tolerance, it would also be possible to use the 
solution of klean-prep as the fluid to distend the stomach as the opaque PEG precipitate 
sediments to a clear solution with time. One small study examined the effect of dosing 4 
litres of klean-prep split three ways: the evening before, the morning of the procedure, 
and after swallowing the capsule 189. They found that this preparation significantly 
improved distal segment views compared to clear fluids only. Further optimisation of 
the volume and the timing of PEG on the day of the procedure could help improve both 
distal segment views and patient experience by reducing the overall volume of liquid 
consumed prior to the examination.  
 
The discrepancies in assessment of cleansing using computed and reviewer assessments 
remain a curiosity. There is a heterogeneity within the literature regarding bowel 
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cleansing trial endpoints. The most relevant endpoint is a difference in diagnostic yield, 
however this study is not powered to examine such differences in examination findings. 
Mucosal visibility is therefore an important surrogate for diagnostic yield, but this is 
difficult to measure consistently. The simplest measure of mucosal visibility is a 
dichotomised assessment of adequacy, but it is also the least objective. Individual 
elements which contribute to adequacy of examination, such as the degrees of fluid 
opacity (with bile and turbid fluid) and degrees of mucosal obscuration (with bubbles 
and chyme) have been previously scored and summated to quantify cleansing 190,191. 
Brotz et al. (2009) have validated such a score which have been used in this and 
previous trials 141,142,187. However, these assessments are still somewhat subjective with 
the original validation reporting moderate interobserver variation with a kappa of 0.47 
190, and in another study an even fairer concordance (k=0.38). 141 A reproducible 
objective measure of mucosal clarity, independent of the reviewers, is therefore highly 
desirable. The CAC score, originally described by van Weyenberg et al (2011) was 
validated against the QI reference described by Brotz and colleagues (2009) and van 
Weyenberg et al. have reported a strong correlation between the CAC and QI by two 
independent reviewers (r= 0.68 and 0.75 respectively). The present study reports a 
weaker, but moderate correlation (r= 0.56). 
 
Hookey et al. (2017) found no difference in overall and CAC score by quartiles 
between PEG and clear fluids only, despite suggesting that by reviewer assessment (0-
5: inadequate to excellent cleanliness) clear fluids resulted in better cleansing than PEG 
(mean difference 0.4 p=0.03). No assessment of individual quartiles by reviewers were 
performed in their study. In our study, we show a trend towards better QI overall (mean 
difference 0.3, p=0.05) and a significantly better QI in the fourth quartile (mean 
difference 0.7, p=0.006) with PEG laxative compared to clear fluids only, and in fact 
we also demonstrate a trend towards better CAC in the fourth quartile (mean difference 
0.3, p=0.10) with PEG compared to clear fluids only. Taken together, both our and 
Hookey’s (2017) studies might suggest that the CAC is insensitive compared to 
reviewer assessment in the determination of bowel cleanliness and if so, with the 
completion of trial the differences in CAC between clear fluids and PEG in the fourth 
quartile might become more obvious, although potentially not statistically significant. 
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7 THE ECONOMIC IMPACT OF 
MAGNET CONTROLLED 
CAPSULE ENDOSCOPY IN 
THE INVESTIGATION OF THE 
UPPER GI TRACT IN THE 
POST COVID-19 ERA  
Chapter 7: The economic impact of Magnet controlled capsule endoscopy in the investigation of the 
upper GI tract in the post COVID-19 era 




Introduction: Since the outbreak of the Coronavirus disease 2019 (COVID-19) 
pandemic, restarting endoscopy services worldwide has been challenged by decreased 
capacity due to mounting infection prevention and control procedures. Advancements 
in endoscopy have led to the use of increasingly less invasive endoscopes, an ultrathin 
transnasal endoscope (TNE) and a magnet controlled capsule endoscope (MACE). We 
examine the economic viability of TNE and MACE in the post-COVID-19 period.  
 
Methods: The cost of OGD, TNE and MACE were estimated using a combination of 
activity based ‘bottom up’ costing and a top down averaging of fixed costs. Baseline 
endoscopy capacity pre-pandemic was extrapolated from local endoscopy and 
decontamination datasets. Costs of TNE and MACE were compared against 
conventional OGD in scenarios where capsule endoscopes were priced differently, 
tissue biopsies were required and assuming post COVID-19 capacity is between 30 and 
75% of pre-pandemic values. 
 
Results: The baseline pre-pandemic capacity for OGDs was 8.5 procedures (95% CI 
6.5 – 10.5) per endoscopy session. The baseline cost of OGD, TNE and MACE prior to 
the COVID-19 pandemic was £121.67, £90.10 and £329.40 per procedure. Post 
pandemic we estimate that costs for OGD and TNE will increase by between 0.30 to 
1.12 and 0.27 to 1.03 times for respectively. At current prices of capsule endoscopes 
cost parity with OGD is unattainable, but if prices are discounted to £200, cost parity 
would be achieved at 38% capacity and at £100 per capsule (£117 per procedure 
overall), the costs of MACE would on par with OGD at baseline. If capsule endoscopes 
are discounted to £100, cost parity between MACE and OGD can be achieved at 
baseline capacity, 70% capacity and 30% capacity, if 16%, 28% and 56% of MACE 
cases proceeded to OGD for biopsies.  
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Conclusion: A reduction in endoscopy capacity results in an increase in the cost of 
conventional OGDs and TNE. At current prices of capsule endoscopes, MACE is too 
expensive for widespread adoption in diagnostic upper GI endoscopy, however 
reductions in prices may make it more competitive, especially where capacity for 




The demand for upper GI endoscopy has increased over the last decade and up to 2% of 
the population of the United Kingdom (UK) and 3% of Medicare beneficiaries in the 
United states (US) undergo oesophagogastroduodenoscopy (OGD) per annum. 192,193 
On the 11th of March 2020 Coronavirus disease 2019 (COVID-19) was declared a 
global pandemic and in response to the local contagion peaks, all non-essential 
endoscopy services, including most OGDs around the world, have at some point been 
rapidly put on hold. In the deceleration phase of the pandemic, how best to mitigate the 
detrimental effects of the pandemic on the outcomes of GI diseases, while safely 
restarting endoscopy services is being considered. 160,194-196 The main risk in performing 
upper GI endoscopy with flexible endoscopes is that they are aerosol generating 
procedures (AGPs). 195,197 Infection prevention and control (IPC) procedures including 
screening, separation and isolation of patients and personal protective equipment (PPE) 
for staff are effective in reducing the risk of cross-contamination. 160 However, 
endoscopy services are now continually challenged by both decreased capacity due to 
these mounting IPC procedures on routine practice, which is estimated to limit capacity 
to between 30 to 75%, 196 as well as increased demand due to accrued patients on peri-
pandemic waiting lists. There may therefore be a role for alternative less invasive 
diagnostic tests to supplement conventional endoscopy capacity.  
 
Advancements in endoscopy technologies have led to the use of increasingly less 
invasive endoscopes. Transnasal endoscopy (TNE) with a much slimmer profile 
endoscopes are better tolerated than conventional OGD and routinely performed 
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unsedated. 21 Although still aerosol generating, 197 TNE produces less of an 
oropharyngeal reaction than conventional OGD and would be expected to be less 
aerosol generating. Less invasive than this, capsule endoscopes fitted with magnetic 
inclusions (Magnet controlled capsule endoscopy; MACE) can now be controlled with 
a handheld device or with robot computer assistance in a pool of swallowed water. 
They have shown potential in detecting gastric and oesophageal pathologies. 107,169 
Patient tolerance of and acceptance of capsule endoscopy is excellent and with no 
intubation required MACE is considered an alternative non-aerosol generating upper GI 
endoscopic investigation. Nevertheless, no studies have yet compared the economic 
viability of upper GI capsule endoscopy with flexible endoscopy. 
 
The aim of this study is to examine the costs involved in performing conventional 
OGD, TNE and robot controlled MACE and perform cost modelling to examine the 





Process maps of diagnostic upper GI endoscopy pathways using flexible endoscopy and 
Magnet controlled capsule endoscopy (MACE; NaviCam, AnX Technologies Robotica 
Corp., Texas, USA) were developed in consultation of two research fellows, two 
consultant gastroenterologists and two endoscopy nurse specialists. Total costs of the 
three upper GI modalities were estimated using a combination of a) bottom up 
aggregation of costs associated with each procedure and b) top down averaging of fixed 
costs. The reason for this combination of approaches is because fixed costs for running 
an endoscopy session (such as equipment, maintenance and staff costs) are incurred 
irrespective of the number of procedures performed and therefore the unit cost of a 
procedure will depend on the volume of procedures performed per endoscopy session. 
In contrast costs including endoscopy consumables and costs of endoscope reprocessing 
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are incurred with each individual procedure. The costs described in the following 
sections are itemised in Appendix 6. 
 
7.3.1 Fixed costs 
 
The fixed costs for running an endoscopy session include endoscopy equipment, 
maintenance and staff costs. The equipment costs for setting up a new endoscopy room 
to perform 10 upper GI endoscopies per session was amortised over 10 years. For 
flexible endoscopy, we assume 10 endoscopes were required to perform two sessions 
per day. Similarly, 10 data recording belts were assumed to be required for MACE 
sessions. Wages for healthcare professional staff were calculated on a pro rata basis for 
each four-hour session based on published pay scales for UK NHS healthcare 
professionals. 198 In addition to the endoscopist, OGD sessions require a staff nurse and 
healthcare support worker in both the endoscopy room and endoscopy recovery. 
Sedation is not required for both TNE and MACE so in addition to the endoscopist, 
TNE sessions only require one staff nurse in the endoscopy room, and MACE sessions 
only one support worker in addition to the endoscopist.  
 
7.3.2 Costs per procedure 
 
The costs of individual procedures include endoscopy consumables, endoscope 
reprocessing and potential adverse events. Facilities for endoscope reprocessing were 
shared across different speciality groups and its costs were therefore calculated per 
single endoscope wash cycle. Equipment costs for reprocessing endoscopes were 
amortised over 10 years and divided over a total number of wash cycles. Two support 
workers are required for endoscope reprocessing and local audit data has shown each 
cycle requires 54 minutes of staff time. Data from the UK National endoscopy database 
(NED) suggest that 50% of OGDs are performed with conscious sedation (Personal 
communication; K. Siaw). Finally, we consider costs related to adverse events requiring 
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hospital admission based on the 2018/19 NHS schedule of reference costs. 199 Wang et 
al. (2018) have reported that the rate of outpatient OGD related infections is 1.08% and 
64% require admission into hospital. 79 Therefore we assume that 0.69% of all OGDs 
have admissions into hospital for OGD related infections.  
 
7.3.3 Scenario analyses: pre- and post COVID-19 and need for biopsies 
 
Endoscopy capacity and costs were based on demand for OGD and endoscope 
reprocessing extrapolated from 10 years of local data (Royal Hallamshire Hospital, 
Sheffield, UK) between 2010 and 2020. At baseline, the most optimal pre COVID-19 
pandemic capacity (100% capacity) was defined as the number of OGDs per session 
assuming all diagnostic OGDs over the 10-year period were performed in a single 
endoscopy room over two endoscopy sessions every five-day working weekday.  
 
In scenario analyses, the cost of different endoscope technologies post-pandemic is 
estimated where capacity is assumed to be between 30 and 75% pre-pandemic, and 
where capsule endoscopes are priced differently. 196,200 Costs of alternative technologies 
(TNE and MACE) are examined against conventional OGD assuming that all three 
technologies have equivalent clinical effectiveness. One exception is that should 
patients undergoing MACE require tissue biopsies, they will require a subsequent 
flexible endoscopy. Therefore, further scenario analyses examining the cost of MACE 
with increasing probabilities of requiring biopsies and a second flexible endoscopy was 
compared against a straight to OGD or TNE strategy. 
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Process maps of patient pathways during flexible endoscopy and MACE are illustrated 
in Figure 19.  
7.4.1 Fixed costs per session 
 
Endoscopy equipment amortised over 10 years’ costs £47,991 for OGD, £50,119 for 
TNE or £10,680 for MACE per annum. Maintenance of flexible endoscope and MACE 
systems cost £19,812 and £2,500 per annum respectively. Therefore, the cost of 
endoscopy equipment and maintenance is more expensive for flexible endoscopy (OGD 
£130.40 and TNE £134.48) than MACE (£25.34) per endoscopy session (Table 15). An 
OGD session is supported by a registered nurse and a support worker in both the 
endoscopy room and endoscopy recovery area each and amounts to £196.97 per 
session. In contrast a TNE list is supported by a single nurse in the endoscopy room and 
a MACE list is supported by a single support worker preparing patients for MACE, 
amounting to £52.64 and £45.85 respectively. The endoscopist are either consultants 
(£173.61 per 4-hour session), non-consultant middle grade doctors (£104.51 per 
session), advanced nurse practitioners (£81.67 per session) or in the case of MACE, a 
trained support worker (£45.85 per session) which averages to £119.93 for flexible 
endoscopy and £101.41 for MACE for an endoscopist per session. Overall staffing of 
an OGD, TNE and MACE session amounts to £316.90, £172.54 and £147.25 per 4-hour 
session respectively. 
 
7.4.2 Costs per procedure 
 
An average of 18,000 endoscope reprocessing cycles occurred each year. Each 
endoscope takes 54 minutes of staff time on average to process which amounts to £9.20 
per cycle and reprocessing consumables for each endoscope amounts to £20.70. With 
the cost of equipment amortised over 10 years and maintenance amounting to £154,344 
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and £135,436 per year respectively, each endoscope reprocessing cycle costs £46.00 per 
cycle (Table 15). 
 
The consumable costs of endoscopy are significantly greater with MACE as the price of 
capsule endoscopes are £309.00 in comparison to the consumable costs of a sedated 
OGD at £10.48, unsedated OGD or TNE at £8.00 and tissue biopsies which costs an 
additional £6.12. The costs of airborne respiratory precautions (level 2 PPE) are £4.50 
per individual which amounts to £13.50 for an OGD (three sets) and £9.00 (two sets) 
for a TNE. The rate of OGD related infections requiring admission into hospital are 
estimated to be 0.69% of all OGDs, costing £1,996 per admission, and an average of 
£13.84 per OGD. 79,199 
 
7.4.3 Scenario analyses 
 
A total of 44,288 diagnostic outpatient OGD procedures were performed in the 10 years 
between 01/01/2010 and 31/12/2019. The baseline pre-pandemic capacity for OGDs 
was 8.5 procedures (95% CI 6.5 – 10.5) per endoscopy session. The baseline cost of a 
OGD, TNE and MACE prior to the COVID-19 pandemic was therefore £121.67, 
£90.10 and £329.40.  
 
In the time during and after the COVID-19 pandemic, the cost of each OGD and TNE 
will depend on the number of procedures performed per endoscopy session (Figure 20). 
Assuming capacity of GI endoscopy services ranges between 30 to 70% of pre-
pandemic values, 196 the cost of OGD and TNE will be between £257.89 to £157.71 and 
£183.31 to £114.56 respectively (Figure 20). MACE is non-invasive with no aerosol 
generation and therefore baseline capacity is assumed to be feasible. At the current 
price (£309) of capsule endoscopes, cost parity of MACE procedures with OGD and 
TNE occurs only when between one to two flexible endoscopies are performed per 
session or between 13-21% of baseline capacity is achieved. If the prices of capsule 
endoscopes are discounted to £200, cost parity would be achieved at 3.2 OGDs per 
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session or 38% capacity, and at 1.9 TNEs per session or 23% capacity. At £100 per 
capsule (£117 overall), MACE would be cheaper than OGD at baseline and on par with 
TNE when 5.3 procedures are performed per session or at 63% capacity, assuming no 
tissue biopsies are taken (Figure 20).  
 
In scenario analysis assuming tissue biopsies need to be performed using OGD and 
TNE after MACE, the cost of biopsies depends on conventional endoscopy capacity 
and cost of flexible endoscopy (Figure 21). If capsule endoscopes are discounted to 
£100, cost parity between MACE and OGD can be achieved at baseline (pre-COVID-
19, 100%) capacity, 70% capacity and 30% capacity, if 16%, 28% and 56% of MACE 
cases proceed to OGD for biopsies (Figure 21a). Cost parity between MACE and TNE 
can be achieved at 60% capacity and 30% capacity, if 9% and 39% of MACE cases 
proceed to TNE for biopsies (Figure 21b). 
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Figure 19: Process maps of flexible endoscopy (OGD and TNE) and magnet controlled capsule endoscopy (MACE) 
Processes in blue highlight differences between endoscopic modalities and are accounted for in the study. *Costs of personal protective equipment (PPE) are accounted for in post 
COVID-19 cost analyses. SB small bowel, CE capsule endoscopy. 
  
Advancing Capsule Endoscopy in the examination of the Upper Gastrointestinal Tract 
 
124  Foong Way David TAI- September 2020 
 
Table 15: Costs of Oesophagogastroduodenoscopy (OGD), transnasal endoscopy 
(TNE) and Magnet controlled capsule endoscopy (MACE) 
 
	 OGD	 TNE	 MACE	
a)	Fixed	cost	(£)	per	endoscopy	session	
Equipment	 92.30	 96.38	 20.54	
Maintenance	 38.10	 38.10	 4.80	
Staff	 316.90	 172.57	 147.25	





Equipment	 8.57	 8.57	 -	
Maintenance	 7.52	 7.52	 -	




	 46.00	 46.00	 -	
ii) Endoscopy	consumables	 	 	 	
Procedure	 8.00	 8.00	 309.10	
Sedation	 2.48	 -	 -	
Biopsy	 6.12	 6.12	 *	
PPE	 13.50	 9.00	 -	
	 30.10	 23.12	 309.10	
	 	 	 	
								iii)								Complications	 13.84	 	 	
	 	 	 	
Total	 £89.94	 £69.12	 £309.10	
 
a) Fixed costs per 4 hour endoscopy session, b) costs per procedure for i) reprocessing the endoscope and ii) 
endoscopy consumables, and iii) costs of complications requiring inpatient admission. PPE Personal 
protective equiptment. *Biopsies  after  MACE depend on cost of OGD, see Figure 21.
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Figure 20: Cost of OGD and TNE vary with endoscopy capacity 
Cost of flexible endoscopy (y axis) increases with reduction in endoscopy capacity (x axis). The current 
price of MACE capsules is £309. As MACE is a non-AGP, cost of procedure is dependant on price of 
capsule only. In two scenarios when prices of capsule endoscopes are discounted: at £200, cost parity 
between MACE and OGD can be achieved at 40% endoscopy capacity and when discounted to £100, cost 
parity between MACE and TNE can be achieved at 60% and cheaper than OGD at full capacity. 
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Figure 21: Cost parity analysis of OGD and TNE with MACE when tissue biopsies are required.  
Two scenarios model the cost of MACE presently (£309 capsule) and discounted capsules (£100 capsule) when A) OGD and B) TNE are subsequently performed for tissue biopsies. 
Shaded areas show range of cost of MACE depending on percentage of cases proceeding to flexible endoscopy for tissue biopsies (from 0% - 80% requiring biopsies). The dark blue 
shaded areas depict where cost parity exists between a direct to OGD or TNE strategy, and a MACE followed by OGD or TNE for biopsies strategy assuming capsules are discounted to 
£100 and endoscopy capacity ranges from 30 – 70%. 
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This study examines the economic viability of alternative upper GI endoscopic 
techniques in comparison to conventional OGD. The costs of increasing miniaturisation 
of non-invasive technologies like TNE and MACE may mean that compared to 
conventional OGD, these technologies might be cost-prohibitive. At baseline, prior to 
the COVID-19 pandemic, TNE was cheaper than conventional OGD predominantly 
because numerous more staff members were required to run a conventional OGD 
session to provide for airway support and recovery of sedated procedures. Capsule 
endoscopy obviates the need for both reprocessing of endoscopes and additional 
support staff in the endoscopy room and recovery, however despite this at the present 
prices of single-use capsule endoscopes, MACE is more expensive and not 
economically comparable to conventional OGD. 
 
We examined the effect of a reduction in endoscopy capacity as a result of the global 
COVID-19 pandemic on the costs of flexible endoscopy. IPC policies to establish risk 
of infection (by screening patients prior to endoscopy with throat swabs and relevant 
exposure and symptoms history), followed by separation of patients flows and the use 
of PPE commensurate with their risk of infection all add to the logistical complexity of 
an endoscopy service and ultimately reduces capacity. 196 In endoscopy units where 
screening capacity is limited, or there are local outbreaks of COVID-19 cases or in 
patients with known or suspected COVID-19, heightened IPC policies are advised. 
These measures, including strict donning and doffing of PPE for staff and separation 
and isolation of patients by risk of contagion, can mean endoscopy capacity can be 
expected to be a low as a third. 200 Even where patients have a low risk of infection, 
estimates have suggested that only up to 75% of pre-pandemic endoscopy capacity 
could be achieved. 196 At these current estimates for post pandemic endoscopy capacity, 
we estimate that the cost of OGD will increase by 30% to 112% and TNE by 27% to 
103%. Our study suggests that at current prices of capsule endoscopes, MACE is not 
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economically viable even where conventional endoscopy capacity is reduced to as low 
as 30%. However, where the price of capsule endoscopes is reduced by a third, there 
begins an opportunity consider MACE, and if prices are further reduced to a third of 
their current price, the cost of MACE and biopsies can be considered on par with 
conventional OGD.  
 
Aerosols can harbour viable coronavirus for up to three hours 201 and actively 
replicating and transmissible viruses can be detected in airway secretions of, in 
particular, asymptomatic or mildly symptomatic individuals. 202 As such AGPs are an 
infection risk to inappropriately prepared patients and staff. Joystick-controlled MACE 
can be performed on a patient in a separate room with audio-visual links to endoscopist, 
control station and monitor, and furthermore the physical separation between the patient 
and the staff therefore eliminates the need for PPE. 203 Another, less obvious factor 
limiting the endoscopy capacity of aerosol generating endoscopies are the periods of 
time required for air recirculation in environments which can range from 20 minutes to 
an hour depending on adequacy of room ventilation. 204 MACE is not known to 
generate aerosols and so it is envisaged that MACE endoscopy capacity can be 
maintained compared to aerosol generating flexible endoscopies.  
  
Studies which estimate costs of OGD by a ‘bottom up’ aggregation of  component costs 
from Canada in 2019 205 and Spain in 2014 206 report a wide range in costs for an 
unsedated OGD (inflation adjusted cost of between £39 and £89). f  These studies 
however do not report the costs and time required for high level disinfection during 
endoscope reprocessing. Crott et al. (2002) performed a micro costing analysis of 
OGDs which included endoscope reprocessing and report that in Canada, OGDs cost 
                                                
f UK Inflation adjustments and exchange rates are calculated to July 2019 and sourced from 
https://www.bankofengland.co.uk/monetary-policy/inflation/inflation-calculator and http://www.xe.com 
respectively 
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between 103.09 and 130.11 Canadian $ or between £75.40 and £95.06 in 2019 after 
inflation. 207 They report the cost of reprocessing an endoscope to be $13.40 (£9.83 in 
2019). A detailed micro costing of endoscope reprocessing from the United States 
however showed that reprocessing costs can in fact be more involved. 208 Reprocessing 
one endoscope took 76 minutes and between US $114 and 280 per endoscope to 
reprocess. The majority of this cost was between US$ 63 and $128 in endoscope repairs 
after failed leak testing. Locally in this study, such a cost is covered by maintenance 
contracts and therefore, excluding endoscope repairs, we report a cost of reprocessing 
(£46) within the range reported by Ofstead et al (in 2019: £39 – 117).  
 
Several assumptions have been made which warrant discussion. We estimate the cost of 
performing upper GI endoscopy by examining the impact of diagnostic OGD, TNE or 
MACE only sessions. In reality many endoscopy lists are mixed with lower GI and or 
therapeutic or more complex procedures. Nevertheless, separating AGP from less 
aerosol generating procedures where possible would seem sensible in limiting risk of 
cross-contamination from infections. 195 Furthermore pre-pandemic, where theoretical 
demand and capacity allow, performing all diagnostic OGDs sequentially in one 
endoscopy room would be likely to yield significant cost savings and therefore felt to be 
a reasonable representation of full endoscopy capacity. The costs presented in this study 
do not represent a full economic costing but only costs which differ between 
endoscopic modalities. Costs not included in the analysis (including those related to 
COVID-19 screening and risk stratification, general hospital overheads, administration 
and histology) are therefore assumed to be similar between the different upper GI 
endoscopy procedures and not required for the purposes of a cost parity analysis. 
Nevertheless, there may be costs which we have not considered such as adverse events 
related to MACE and TNE, which we assume are negligible. Capsule retention in small 
bowel capsule endoscopy is estimated at 1% and although experience is limited in 
MACE, no cases of retention have been reported in 3182 upper GI MACE procedures. 
124  Capsule aspiration is rare occurring in 0.1%. 93 Finally, epistaxis occurs after TNE 
in 2%, however the far majority of cases are self-limiting and do not need 
hospitalisation. 21  On the other hand, adverse events related to conventional OGD are 
more significant than previously thought. In a study of routine outpatient OGDs from 
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the USA, the rate of infections 30 days after OGD was 1.08% higher than of screening 
mammography, of which 64% of OGD related infections required hospital admission. 79 
At this rate, locally this would have accounted for 31 admissions at an estimated cost of 
£61,000 per annum or £13.84 per OGD. 
 
Finally, this is a cost minimisation study which assumes that MACE, OGD and TNE 
are clinically equivalent. Dysphagia is a contraindication for capsule endoscopy and 
therefore limit a group of patients undergoing MACE. In our study, 11% of patients had 
OGD for dysphagia increasing to 15% most recently in the year 2019. Otherwise, 
MACE has potential in detecting gastric and oesophageal pathologies compared to 
conventional OGD, 107,169 although larger studies, especially those examining a western 
population are warranted. This study suggests that the current prices of capsule 
endoscopes make MACE cost prohibitive, however in certain indications, MACE may 
offer added value to a patient’s diagnostic pathway and therefore the cost effectiveness 
(as opposed to cost parity) of MACE should be examined in these circumstances. 
Patients undergoing handheld MACE for recurrent or refractory anaemia and upper GI 
bleeding have been shown to have a greater diagnostic yield than conventional OGD. 
102,103 This may be in part because capsule endoscopes can further investigate the small 
bowel beyond D2 in the same examination, but also that MACE may be more able to 
detect certain lesions proximal to the D2 in reach of conventional OGD.  
 
There is evidence that patients are unwilling to attend hospitals for fear of COVID-19 
infection. 209 The optics of what was already an unpleasant procedure, has been further 
marred by the image of, and often imperceptible mumbles of, endoscopy staff dressed 
in PPE. The non-invasive and non-aerosol generating nature of MACE will therefore 
likely continue to be more preferable to patients than conventional OGD. Although 
MACE is currently more expensive than conventional OGD, the wider health economic 
cost effectiveness of MACE has not been considered. Most studies that examine the 
cost effectiveness of OGD in various settings utilise reimbursement costs which are 
often an inexact science, but are now increasingly used to reflect outcome and value-
based reimbursement, as opposed to volume based reimbursement. 210 In the UK 
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National Health Service, an OGD without biopsies is reimbursed at £454 to the 
provider. 199 Assuming the actual full economic cost for MACE in this study does not 
exceed this reimbursement account, with unaccounted costs amounting to less than 
£125 (38%), a MACE costing £329 per procedure can still be reimbursed fully. The 
economic value therefore, of patient experience and potential benefits of a small bowel 
examination and lack of aerosol generation should be further examined. 
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8 DISCUSSION 
This body of work aims to examine how capsule endoscopy can advance the quality of 
an upper gastrointestinal (GI) endoscopy. Capsule endoscopy is the gold standard 
endoscopic investigation of the small bowel 211 and a second line investigation of the 
colon in patients with an incomplete colonoscopy. 212 Capsule endoscopes designed to 
examine the upper GI tract are presently in limited use and has yet to be endorsed by 
societal guidance. However, with the recent Coronavirus disease 2019 (COVID-19) 
pandemic, there is push towards non-invasive endoscopic modalities such as capsule 
endoscopy.  
 
8.1 How gold is the gold standard? 
 
To advance capsule endoscopy in the investigation of the upper GI tract, we first 
examined the capabilities of the reference examination, conventional 
Oesophagogastroduodenoscopy (OGD) in Chapter 2. In a retrospective case control 
study of 627 oesophagogastric (OG) cancers we show that 48 cases (7.7%) have had 
previous OGDs up to 3 years prior to diagnosis, which have failed to identify the 
neoplastic lesion at its early stages. We further observe that missed upper GI cancer 
occurrence is associated with an increasing number of procedures during the endoscopy 
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session, but not the use of sedation, nor any metric related to the endoscopists 
procedural experience, background or types of and time of day of procedures.  
 
Accepting that early lesions should have been visible at the index OGD is an 
extrapolation from our historical understanding of early gastric cancer biology, 22 the 
finding in Chapter 2 supports a body of literature suggesting that conventional OGD has 
its diagnostic limitations. 4,11,12 Successive endoscopic examinations may yield more 
pathology. In between 40 and 60% examined with push enteroscopy after conventional 
OGD for obscure GI bleeding have culprit pathologies proximal to D2 and therefore in 
reach of, and presumably missed by their initial OGD. 213,214 Similarly, when examined 
with small bowel CE, around 10% of patients have culprit upper GI pathology not 
originally reported on OGD. 167 
 
That OGD, the gold standard endoscopic investigation of the upper GI tract, is not a 
completely sensitive test is perhaps not surprising. A meta-analysis of studies where 
colonoscopies were done in tandem by different or the same colonoscopist show that 
the sensitivity of colonoscopy reduces with the size of adenoma, the overall miss rate of 
adenomas is 26% and significant and advanced adenomas are often missed in 9%. 215 
Furthermore, studies comparing an alternative test, computed tomography (CT) 
colonoscopy, to optical colonoscopy show that between 12-17% of significant (>1cm) 
adenomas are detected on CT but not optical colonoscopy when compared to a 
composite diagnostic yield of both investigations, as opposed to assuming optical 
colonoscopy is the gold standard. 216,217  
 
Early stage OG malignancies are morphologically flat and more subtle than typical 
colonic adenomas which are commonly polypoid and more obvious. Accepting there 
are differences between the shape and adequacy in bowel preparation of a distended 
colon, oesophagus and stomach, the wealth of data from tandem studies of colonoscopy 
support the notion that subtle lesions like sessile serrated polyps and flat adenomas have 
high miss rates (27% and 34% respectively in a recent metanalysis). 215 Our finding that 
endoscopist procedural experience did not associate with missed cancer occurrence in 
the upper GI tract should therefore be interpreted cautiously. It is likely that ‘procedural 
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competence’ irrespective of background and training is just the beginning of a journey, 
as Gotoda et al. aptly puts in a precis of gastric cancer screening techniques, ‘(our) eyes 
can only see what the brain knows’ . 218    
 
In the efforts to increase the sensitivity of endoscopic examinations, perhaps the most 
significant, but yet intuitive finding, has been that pathology detection improves with 
increased examination time. 36,37,219 The finding that missed OG cancer occurrence is 
associated with an increasing number of procedures on endoscopy list perhaps suggest 
that an increasing workload affects endoscopists ability to perform a careful 
examination. With each additional procedure adds an additional turnover period, time 
which may reduce overall examination between patients. That increasing workload 
affects endoscopists may also be due to fatigue. It may be important to examine the 
effect of endoscopy session workloads on examination times to ensure endoscopists are 
given sufficient time to examine patients thoroughly. However, it is likely that as 
endoscopists gain knowledge and experience in detecting subtle lesions, examination 
times will consequently increase.  
 
8.2 Effectiveness of capsule endoscopy in the upper GI tract 
 
Upper GI Magnet controlled capsule endoscopy (MACE) requires minimal time 
between patients and with no need for conscious sedation could afford the endoscopist 
more time to examine the patient. In Chapter 3 we performed a self-controlled 
comparative trial of conventional OGD and MACE to examine patients experiences of 
both techniques. Patients tolerated MACE significantly better than conventional OGD 
with or without conscious sedation. Using two patient reported experience measures 
(PREM), the Universal patient centredness questionnaire (UPC-Q) and Endoscopy 
concern scale (ECS) scores, we show that patients are more accepting of MACE than 
OGD with or without sedation. Overall examination time was 8 times longer with 
MACE than OGD, although overall agreement in results between modalities was only 
65%. In Chapter 4 we examined the use of an ultra-thin transnasal endoscope (TNE), 
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which is better tolerated and preferred by patients than conventional OGD. We showed 
in this unblinded study that both MACE and TNE are highly acceptable. However 
patient tolerance and acceptability marginally favoured MACE than TNE.  
 
In both studies of conventional OGD and TNE we highlight that patient tolerance to 
MACE was superior to flexible endoscopy as the distresses of endoscope 
instrumentation (swallowing a capsule endoscope versus per oral or nasal intubation) 
were near absent with MACE, along with typical oro-pharyngeal distresses which 
accompany flexible endoscope intubation such as gagging, choking and vomiting. 
Consequent to these typical oro-pharyngeal reactions, both conventional OGD and TNE 
(both transnasal intubation and topical nasal spray application), have been shown to 
also be aerosol generating. 195,197 Robot controlled MACE can be performed on a 
patient at a distance, with audio-visual links to endoscopist, control station and monitor 
in a different room. 203 Therefore robot controlled MACE may have a further advantage 
in the future as the recent COVID-19 pandemic has put aerosol generating procedures 
(AGP) under considerable scrutiny 196.  
 
One of the major limitations of capsule endoscopy is its inability to obtain tissue 
biopsies and although the preference for MACE was almost unanimous (bar one patient 
undergoing TNE), we hypothesised that the need for tissue biopsies and the requirement 
for another appointment for flexible endoscopy may mean that patients might prefer to 
have just a single examination with a flexible endoscope. However, somewhat 
surprisingly, we show that having experienced both examinations, in retrospect, patients 
would still have preferred to have MACE followed by conventional OGD or TNE in 
83% and 64% respectively, even if biopsies were required in half of the cases. This 
goes to further support the superior tolerance and acceptance of MACE over 
conventional flexible endoscopy.  
 
Our studies reported in Chapter 3 and 4 are in support of previous comparative studies 
between upper GI MACE and conventional OGD 101-105,107 and oesophageal capsule 
endoscopy and TNE 175 which suggest that capsule endoscopy is better tolerated and 
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accepted. There are clearly patients who benefit from sedation during conventional 
OGD and the current literature points towards greater patient satisfaction and 
willingness to repeat investigations with sedation. 55 Overall the acceptability of OGD 
is high when patients are sedated adequately, more so than when compared to 
colonoscopy for example. 65 However, consistent with comparisons of TNE and 
conventional OGD, 21 we show that patients would still prefer a more non-invasive 
option, and in this case even if there is a chance that a further invasive endoscopy is 
required for tissue biopsies. This may have implications in improving uptake of 
population based screening investigations which have been ongoing in China for gastric 
cancer. 124  
 
By using the UPC-Q we examine aspects which patients determine to be important 
during their endoscopy experience. Patients prioritised procedural tolerance in between 
54 – 67% of procedures, the proportion of which decreased with increasingly less 
invasive modalities (i.e 67% OGD, 53% TNE and 53% MACE). Therefore, as 
procedural tolerance improves, it seems tolerance in itself becomes less important and 
other factors become more important. This has important implications in examining 
patient experience with capsule endoscopy. PREMs such as the ECS have been created 
to examine conventional flexible endoscopy, and not other endoscopic paradigms like 
capsule endoscopy. Although, the ECS was adapted for MACE in this study (for 
example by including swallowing the capsule and abdominal bloating from water 
ingestion), PREMs are mostly designed based on literature review, which are often 
clinician derived and uncommonly patient centric. 57 Therefore, the ECS may lack 
content validity in so far as patient experiences in capsule endoscopy are concerned and 
could explain why distresses to capsule endoscopy are distributed so tightly (IQRs 
mostly between 0 and 1) and skewed towards no distress. Semi-structured interviews of 
patients who have experienced capsule endoscopy better inform the context in which 
questions are asked in PREMs and thus assures content validity, however this was 
beyond the scope of this body of work. The Newcastle ENDOPREM is one such 
endeavour which aims to create a PREM to cover the breadth of endoscopic paradigms. 
220 
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The results of MACE and OGD agreed in two thirds of cases and where they did not, 
they missed pathology equally (5/30 lesions each) in our study. Although our 
comparative study of robot controlled MACE and OGD was not designed to examine 
the effectiveness of MACE in detecting pathology, our current experience suggests that 
further advancements in the capsule imaging technology could make it more capable in 
detecting oesophageal pathologies and further experience and training in the technique 
would make examinations more consistent, for example in improving transpyloric 
transit into the duodenum.  
8.3 Improving on the clinical effectiveness of upper GI capsule 
endoscopy 
 
Limited by its ability to take tissue biopsies, the ability of capsule endoscopy to 
routinely investigate the GI tract beyond the reach of the conventional flexible 
endoscope may be of some advantage. An 8 hour fast is the recommended pre-
procedure preparation for MACE of the upper GI tract, 221 however the ideal 
preparation for the small bowel is still debatable. 182 In Chapter 6 we examine ways to 
optimise small bowel mucosal views, specifically examining the need for and timing of 
polyethylene glycol (PEG) laxative. In a randomised control trial of pre-procedure 
preparation for small bowel capsule endoscopy we randomised participants between a 
clear liquid diet group, of what would also normally be used for upper GI capsule 
endoscopy- fasting and clear fluids, and two groups of PEG laxatives given as a single 
dose of PEG laxative on the morning of the procedure, or a split dose (evening before 
and morning of) before the procedure. On reviewer assessment of bowel cleansing, we 
found that PEG laxative offered a cleaner distal quartile of the small bowel and initial 
results suggest that at least a 1 litre dose of PEG consumed during the morning of the 
procedure is beneficial. No conclusions can yet be reached about relative benefit of 
dosing interventions (single vs split dose) at present. 
 
 For the purposes of combining an upper GI and small bowel assessment in 
capsule endoscopy, further assessment of the timing of the morning dose of PEG prior 
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to the MACE should be examined. For example, if a single dose of 2 litres PEG is 
beneficial, would it be just as beneficial splitting a litre in the morning at 6am and a 
further litre just prior to the upper GI MACE, and what are the effects of a litre of clear 
liquid just prior to the MACE in comparison? As fluids are also required to distend the 
gastric lumen, understanding the effect of PEG or clear fluids just prior to upper GI 
MACE on mucosal views can inform ways to improve patient experience as the volume 
of liquid and frequency of pre-procedure doses of PEG reduce.  
 
The utility of an upper GI MACE with a small bowel examinations should be 
considered. In patients with refractory and recurrent anaemia, a repeat upper GI 
investigation with MACE along with a small bowel examination have been suggested to 
be beneficial. 102 Only 20-30% of patients with iron deficiency anaemia have a normal 
OGD and colonoscopy, prompting a small bowel investigation. However two thirds of 
those refractory to iron after normal intubational endoscopies have small bowel 
pathology, 134 suggesting that at least 10% of anaemic patients would benefit from 
having a small bowel investigation in addition to an OGD and colonoscopy in the first 
instance. Pathology in the small bowel is considered to account for only 5% of all 
gastrointestinal causes of anaemia in historical fluoroscopic studies. 132 The endoscopic 
prevalence of lesions which cause occult small bowel bleeding amongst patients with 
initial presentations of anaemia are unknown and subject to an ongoing clinical trial.  
 
8.4 Cost implications of upper GI capsule endoscopy 
 
Having demonstrated how capsule endoscopy can offer a better patient experience than 
flexible endoscopic examination, and how MACE could be used to deliver greater 
clinical effectiveness by optimising bowel preparation for both investigations of the 
upper GI tract and small bowel, we acknowledge that the cost of novel technologies can 
often limit their advancement in clinical practice. In Chapter 6 we examine the 
economic impact of alternative technologies like MACE and compare them to flexible 
endoscopy. We perform a cost minimisation analysis between MACE, TNE and OGD. 
Chapter 8: Discussion 
Foong Way David TAI - September 2020   139 
 
This study concludes that the cost of MACE with present prices of capsule endoscopes 
is too dear to deliver an efficient service; that is, we found the cost of MACE to be at 
par with OGD and TNE only if between one to two flexible endoscopes were performed 
per four-hour endoscopy session. Scenarios where reductions in endoscopy capacity 
occurred in line with evolving post - COVID-19 pandemic recovery guidance suggest 
that the reduction in endoscopy capacity by 30 – 70% could increase the cost of 
performing OGD and TNE by between 30 and 112%. If prices of capsule endoscopes 
were to fall to a third, there would be potential to perform MACE with further 
conventional OGD and biopsies in between 28 to 56% of cases and still achieve cost 
parity between MACE and OGD.  
 
 
8.5 Upper GI capsule endoscopy: a look to the future 
 
The overall uptake of MACE will then depend on a number of factors. The clinicians 
and patients acceptance of MACE will largely be driven by accuracy of the device in 
the future. There are a number of technological advancements which would be required 
to improve the diagnostic accuracy of upper GI capsule endoscopy in this era of virtual 
chromoendoscopy and near focus imaging. Analogous to the initial difficulties with 
early generation transnasal endoscopes, capsule endoscopes would need to leverage 
novel imaging technology to improve resolution of images and provide greater mucosal 
detail. By comparison to transnasal endoscopy, the difficulties facing capsule 
endoscopy will be greater. Untethered to the physical ‘boxes’ of an endoscope stack, 
the capsule endoscope would need to be able to generate sufficient light to provide 
enough detail to a more sensitive image sensor, both supplied by a smaller but more 
efficient battery.    
 
Finally, the cost of the device would be also an important factor. When capsule 
endoscopes are able to output images with a significantly greater image resolution there 
will be an opportunity to leverage artificial intelligence. Neural networks can now 
recognise anatomy of the upper GI tract during conventional flexible endoscopy and 
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feedback ‘blind spots’, informing an endoscopist in real time what areas have not yet 
been fully examined.222 The Ankon Navicam MACE is presently able to automatically 
pilot the capsule in a preprogramed manner, but without feedback from inputs (i.e live 
endoscopy). In the future when capsule endoscopy image resolution allows neural 
networks to recognise capsule images of the upper GI tract, a truly ‘smart’ automated 
MACE examination can then be envisaged. This may help to develop workflow 
efficiencies which could offset the cost of capsule endoscopes.  
 
One challenge for advancing capsule endoscopy in the upper GI tract remains finding a 
clinical pathway where MACE or other upper GI capsule endoscopy technologies can 
be clinically effective. The most common indication for upper GI endoscopy is 
dyspepsia, but as significant pathology is uncommonly found 146 and in fact other 
strategies such as a helicobacter test and treat strategy have been found more cost 
effective than straight to endoscopy strategies, 223 it is unlikely non-invasive MACE 
will make a measurable difference in the investigation of dyspepsia, especially 
considering current costs. In Western countries, one such area may be in the screening 
and surveillance of Barrett’s oesophagus, however advancements in technology will 
require better control and improvements in image resolution of the capsule endoscope, 
to mirror that of transnasal endoscopy for example. Another area may be in the 
investigation of anaemia, where an upper GI and small bowel investigation could be 
both non-invasive and have the added value of an enteroscopy compared to 
conventional OGD alone. The additional value of such an approach would likely 
depend on both the prevalence of, and significance of, detecting flat vascular 
angioectasias not previously detected in historical radiological studies of small bowel 
pathology causing anaemia. 132  Nevertheless, the most significant causes of anaemia 
are still found in the colon in up to a third, 131 and with a quarter having pathology in 
both the upper and lower GI tract, 129 the most aspirational investigation would be a 
completely panenteric capsule endoscopy investigation. Battery technology and 
software would need to advance significantly to allow for a wide variation in panenteric 
transit time.  However, in the management of Crohn’s disease, such advanced capsule 
endoscopes which examine both small and large bowel disease have so far been shown 
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to be feasible, effective and more recently shown to be cost effective compared to 
conventional small bowel magnetic resonance imaging and ileocolonoscopy. 224,225  
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8.6 Concluding remark 
 
Capsule endoscopy remains a promising alternative upper GI endoscopic modality. We 
show in this body of work that it is a non-invasive examination that is accepted and 
preferred by patients over flexible endoscopy. It has a superior tolerance profile which 
may lend itself as being a non-aerosol generating diagnostic alternative during viral 
pandemics. Although conventional flexible endoscopy can be poorly tolerated it is 
necessary for tissue biopsies. Patients are however more inclined towards a capsule 
endoscopy prior to more invasive flexible endoscopy to acquire tissue only if required. 
However, this approach is presently too expensive with current cost of capsule 
endoscopes and further value based cost effectiveness studies of upper GI capsule 
endoscopy technologies are warranted.  
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APPENDIX 2: PATIENT QUESTIONNAIRE BEFORE AND AFTER 
MACE, CONVENTIONAL OGD AND TNE 
Items on these questionnaires are adapted in part or adopted in whole from the Universal Patient 
Centeredness Questionnaire, 68 the Endoscopy Concerns Scale, 65 and the Hospital Anxiety and 










Your experiences with the pill camera test - in the areas that are most important to you 
You will be having a pill camera test soon. We would like you to think of 3 things that are most 
important to you when you have the pill camera test. You can decide which things to include but they 
should be areas where changes can be made. 
 
Importance and experiences 
Please start by writing down the three things that are most important to you when you have your pill 
camera test: 
Please write your first area here:  
__________________________________________________________________________________ 
Please write your second area here:  
__________________________________________________________________________________ 
Please write your third area here:  
__________________________________________________________________________________ 
Prioritise area 
You have written down the things of importance to you when you have your pill camera test. We 
would now like you to rate how important each of these things were for you.  
You have a total of 6 points. Divide these 6 points between the things above based on how important 
they are to you. The sum must be 6. If you have only written down two things then divide the 6 points 
between the two things.  
I give the first area:         ☐points 
I give the second area:    ☐points  
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Section 1: Before capsule endoscopy (continued) 
This part of the questionnaire helps doctors to understand how you are feeling currently. Read every 
sentence. Circle the answer that best describes how you have been feeling during the LAST WEEK. 
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Section 1: Before capsule endoscopy (continued) 
Expectations: 
In regards to your upcoming pill camera test, how much, if any, have you been distressed by concerns 
about: 
 Not at all                                                                      Extremely 
Telling friends/colleagues the nature 
of my upcoming test 
1        2        3        4        5        6        7        8        9        10 
Fasting prior to the test 1        2        3        4        5        6        7        8        9        10 
Gagging during the test 1        2        3        4        5        6        7        8        9        10 
Sensations of choking during the test 1        2        3        4        5        6        7        8        9        10 
Sensation of bloating during the test 1        2        3        4        5        6        7        8        9        10 
Vomiting during the test 1        2        3        4        5        6        7        8        9        10 
Doctor seeing my food in the 
stomach during the test 
1        2        3        4        5        6        7        8        9        10 
Expressing emotions during the test 1        2        3        4        5        6        7        8        9        10 
Having to swallow the pill camera 1        2        3        4        5        6        7        8        9        10 
Potentially needing an injection of 
medication 1        2        3        4        5        6        7        8        9        10 
Discomfort during the procedure 1        2        3        4        5        6        7        8        9        10 
Discomfort after the procedure 1        2        3        4        5        6        7        8        9        10 
Pain during the procedure 1        2        3        4        5        6        7        8        9        10 
Pain after the procedure 1        2        3        4        5        6        7        8        9        10 
 
Current feeling: 
Please rate how anxious you are at present and how much discomfort and pain, if any, you are in 
before the test: 
 Not at all                                                                      Extremely 
Anxiety 1        2        3        4        5        6        7        8        9        10 
Discomfort 1        2        3        4        5        6        7        8        9        10 
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Section 2: After capsule endoscopy 
Your experiences with the pill camera test - in the areas that are most important for you 
You have just had a pill camera test. We would like you to list 3 things that were most important to 
you while you were having the pill camera test, and then to rate them. You can decide which things to 
include but they should be areas where changes can be made. 
Importance and experiences 
Please start by writing down the three things that were most important to you when you were having 
your pill camera test (on the left), and rate your experience by ticking one box for each thing (on the 
right)  
Please write your first area here:                 What was your experience with the pill camera in this 
area? 
Poor      Fairly Good      Good     Very Good      Excellent 
_________________________                       ☐        ☐        ☐       ☐         ☐ 
 
Please write your second area here:                     What was your experience the pill camera in this 
area? 
Poor      Fairly Good      Good     Very Good      Excellent 
_________________________                       ☐        ☐        ☐       ☐         ☐ 
 
Please write your third area here:                        What was your experience the pill camera in this 
area? 
Poor      Fairly Good      Good     Very Good      Excellent 
_________________________                       ☐        ☐        ☐       ☐         ☐ 
Prioritise area 
You have written down the things of importance to you when you had your pill camera test. We 
would now like you to rate how important each of these things were for you.  
You have a total of 6 points. Divide these 6 points between the things above based on how important 
they were to you. The sum must be 6. If you have only written down two things then divide the 6 
points between the two things.  
I give the first area:         ☐points  I give the third area:       ☐points 
 
I give the second area:    ☐points  
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Section 2: After capsule endoscopy (continued) 
 
Experience: 
In regards to the pill camera test you just had, how much distress, if any, did you experience from: 
 Not at all                                                                      Extremely 
Gagging during the test 1        2        3        4        5        6        7        8        9        10 
Sensations of choking during the test 1        2        3        4        5        6        7        8        9        10 
Sensation of bloating during the test 1        2        3        4        5        6        7        8        9        10 
Vomiting during the test 1        2        3        4        5        6        7        8        9        10 
Doctor seeing my food in the 
stomach during the test 1        2        3        4        5        6        7        8        9        10 
Expressing emotions during the test 1        2        3        4        5        6        7        8        9        10 
Having to swallow the pill camera 1        2        3        4        5        6        7        8        9        10 
Potentially needing an injection of 
medication 1        2        3        4        5        6        7        8        9        10 
Discomfort during the procedure 1        2        3        4        5        6        7        8        9        10 
Discomfort after the procedure 1        2        3        4        5        6        7        8        9        10 
Pain during the procedure 1        2        3        4        5        6        7        8        9        10 
Pain after the procedure 1        2        3        4        5        6        7        8        9        10 
 
Patient  
Comfort of procedure overall…………………………………… 
Ø None: no discomfort – resting comfortably throughout  
Ø Minimal: one or two episodes of mild discomfort, well tolerated  
Ø Mild: more than two episodes of discomfort, adequately tolerated  
Ø Moderate: significant discomfort, experienced several times during the procedure 
Ø Severe: extreme discomfort, experienced frequently during the procedure 
 
Would you: 
1. Undergo same test again given the same medical circumstances?                                Y          N  
 
2. Advise a friend to undergo the same test with the same medical circumstances?         Y          N 
 
3. Have the same test again in 1to 2 years if well and without any symptoms but if medical advice 
was that it’s a useful test to screen for cancer?                                                              Y         N   
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Section 3: Before oral or transnasal OGD 
Your experiences with OGD (the flexible tube camera) - in the areas that are most important 
for you 
You will be having a OGD soon. We would like you to think of 3 things that are most important to 
you when you have the gastroscopy, and then to rate them. You can decide which things to include 
but they should be areas where changes can be made. 
Importance and experiences 
Please start by writing down the three things that are most important to you when you have your 
gastroscopy: 
Please write your first area here:  
 
__________________________________________________________________________________ 
Please write your second area here:  
 
__________________________________________________________________________________ 




You have written down the things of importance to you when you have your gastroscopy. We would 
now like you to rate how important each of these things were for you.  
You have a total of 6 points. Divide these 6 points between the things above based on how important 
they are to you. The sum must be 6. If you have only written down two things then divide the 6 points 
between the two things.  
I give the first area:         ☐points 
I give the second area:    ☐points  
I give the third area:       ☐points 
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Section 3: Before oral or transnasal OGD 
Expectations: 
In regards to your endoscopy test, how much, if any, have you been distressed by concerns about: 
 Not at all                                                                      Extremely 
Telling friends/colleagues the nature 
of my upcoming test 1        2        3        4        5        6        7        8        9        10 
Fasting prior to the test 1        2        3        4        5        6        7        8        9        10 
Gagging during the test 1        2        3        4        5        6        7        8        9        10 
Sensations of choking during the test 1        2        3        4        5        6        7        8        9        10 
Sensation of bloating during the test 1        2        3        4        5        6        7        8        9        10 
Vomiting during the test 1        2        3        4        5        6        7        8        9        10 
Doctor seeing my food in the 
stomach during the test 1        2        3        4        5        6        7        8        9        10 
Expressing emotions during the test 1        2        3        4        5        6        7        8        9        10 
Insertion of the scope into my nose 
or mouth 1        2        3        4        5        6        7        8        9        10 
Insertion of intravenous line into my 
hand 1        2        3        4        5        6        7        8        9        10 
Discomfort prior to the test 1        2        3        4        5        6        7        8        9        10 
Discomfort during the procedure 1        2        3        4        5        6        7        8        9        10 
Discomfort after the procedure 1        2        3        4        5        6        7        8        9        10 
Pain prior to the test 1        2        3        4        5        6        7        8        9        10 
Pain during the procedure 1        2        3        4        5        6        7        8        9        10 
Pain after the procedure 1        2        3        4        5        6        7        8        9        10 
 
Current feeling: 
Please rate how anxious you are at present and how much discomfort and pain, if any, you are in 
before the test: 
 Not at all                                                                      Extremely 
Anxiety 1        2        3        4        5        6        7        8        9        10 
Discomfort 1        2        3        4        5        6        7        8        9        10 
Pain 1        2        3        4        5        6        7        8        9        10 
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Section 4: After oral or transnasal OGD 
Your experiences with the OGD (the flexible tube camera) - in the areas that are most 
important for you 
You have just had an OGD. We would like you to list 3 things that were most important to you while 
you were having the gastroscopy, and then to rate them. You can decide which things to include but 
they should be areas where changes can be made. 
Importance and experiences 
Please start by writing down the three things that were most important to you when you were having 
your OGD (on the left), and rate your experience by ticking one box for each thing (on the right)  
Please write you first area here:                 What was your experience with the OGD in this area? 
Poor      Fairly Good      Good     Very Good      Excellent 
_________________________                       ☐        ☐        ☐       ☐         ☐ 
 
Please write you second area here:                     What was your experience the OGD in this area? 
Poor      Fairly Good      Good     Very Good      Excellent 
_________________________                       ☐        ☐        ☐       ☐         ☐ 
 
Please write you third area here:                        What was your experience the OGD in this area? 
Poor      Fairly Good      Good     Very Good      Excellent 
_________________________                       ☐        ☐        ☐       ☐         ☐ 
Prioritise area 
You have written down the things of importance to you when you had your OGD. We would now like 
you to rate how important each of these things were for you.  
You have a total of 6 points. Divide these 6 points between the things above based on how important 
they were to you. The sum must be 6. If you have only written down two things then divide the 6 
points between the two things.  
I give the first area:         ☐points 
I give the second area:    ☐points  
I give the third area:       ☐points 
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Section 4: After oral or transnasal OGD (continued) 
Experience: 
In regards to the gastroscopy you just had, how much distress, if any, did you experience from: 
 Not at all                                                                      Extremely 
Gagging during the test 1        2        3        4        5        6        7        8        9        10 
Sensations of choking during the test 1        2        3        4        5        6        7        8        9        10 
Sensation of bloating during the test 1        2        3        4        5        6        7        8        9        10 
Vomiting during the test 1        2        3        4        5        6        7        8        9        10 
Doctor seeing my food in the 
stomach during the test 1        2        3        4        5        6        7        8        9        10 
Expressing emotions during the test 1        2        3        4        5        6        7        8        9        10 
Insertion of the scope into my nose 
or mouth 
1        2        3        4        5        6        7        8        9        10 
Insertion of intravenous line into my 
hand 1        2        3        4        5        6        7        8        9        10 
Discomfort during the procedure 1        2        3        4        5        6        7        8        9        10 
Discomfort after the procedure 1        2        3        4        5        6        7        8        9        10 
Pain during the procedure 1        2        3        4        5        6        7        8        9        10 
Pain after the procedure 1        2        3        4        5        6        7        8        9        10 
 
Patient  
Comfort of procedure overall…………………………………… 
Ø None: no discomfort – resting comfortably throughout  
Ø Minimal: one or two episodes of mild discomfort, well tolerated  
Ø Mild: more than two episodes of discomfort, adequately tolerated  
Ø Moderate: significant discomfort, experienced several times during the procedure 
Ø Severe: extreme discomfort, experienced frequently during the procedure 
 
Section 4: Post-OGD                                                                           
Would you: 
1. Undergo same test again given the same medical circumstances?                                Y          N  
 
2. Advise a friend to undergo the same test with the same medical circumstances?         Y          N 
 
3. Have the same test again in 1to 2 years if well and without any symptoms but if medical advice 
was that it’s a useful test to screen for cancer?                                                              Y         N  
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Section 5: After both capsule endoscopy and OGD. 
 
1. If you needed investigation for symptoms again, would you prefer to have the capsule 
endoscopy (CE) or tube camera (OGD) to examine your upper GI tract?  
Circle one [ CE  /   OGD ]  
 
2. If after a capsule endoscopy, you were told you needed to have biopsies taken you would 
require a tube camera (OGD) to obtain the biopsies.  
 
a. If after CE the chance was of requiring a further OGD was 1 in 20 would you prefer 
to have the CE or OGD initially?   Circle one [ CE / OGD] 
 
b. If after CE the chance was of requiring a further OGD was 1 in 10 would you prefer 
to have the CE or OGD initially?   Circle one [ CE / OGD] 
 
c. If after CE the chance was of requiring a further OGD was 1 in 5 would you prefer to 
have the CE or OGD initially?    Circle one [ CE / OGD] 
 
d. If after CE the chance was of requiring a further OGD was 1 in 4 would you prefer to 
have the CE or OGD initially?    Circle one [ CE / OGD] 
 
e. If after CE the chance was of requiring a further OGD was 1 in 2 would you prefer to 
have the CE or OGD initially?    Circle one [ CE / OGD] 
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APPENDIX 3: BLINDED REVIEWER ASSESSMENT OF BOWEL 
CLEANSING 
This is an example template of the pseudoanonymised cases (columns) and the quantitative index (QI), 
qualitative evaluation (QE) and overall adequacy of assessment (OAA) used by the blinded reviewer. 
This method of assessment has been adopted in whole from Brotz et al. (2009)190 and remain the 
intellectual property of the respective owners. 
 
	 0c4d1w33	 0DUhNQ33	 0GfJPA33	 0O0qww33	 13EemQ33	
Quartile	1	 	 	 	 	 	
%	of	mucosa	visualised	 	 	 	 	 	
Fluid	and	Debris	 	 	 	 	 	
Bubbles	 	 	 	 	 	
Bile/chyme	staining	 	 	 	 	 	
Brightness	 	 	 	 	 	
	 	 	 	 	 	
QE	 	 	 	 	 	
OAA	 	 	 	 	 	
	 	 	 	 	 	
Quartile	2	 	 	 	 	 	
%	of	mucosa	visualised	 	 	 	 	 	
Fluid	and	Debris	 	 	 	 	 	
Bubbles	 	 	 	 	 	
Bile/Chyme	 	 	 	 	 	
Brightness	 	 	 	 	 	
	 	 	 	 	 	
QE	 	 	 	 	 	
OAA	 	 	 	 	 	
	 	 	 	 	 	
Quartile	3	 	 	 	 	 	
%	of	mucosa	visualised	 	 	 	 	 	
Fluid	and	Debris	 	 	 	 	 	
Bubbles	 	 	 	 	 	
Bile/Chyme	 	 	 	 	 	
Brightness	 	 	 	 	 	
	 	 	 	 	 	
QE	 	 	 	 	 	
OAA	 	 	 	 	 	
	 	 	 	 	 	
Quartile	4	 	 	 	 	 	
%	of	mucosa	visualised	 	 	 	 	 	
Fluid	and	Debris	 	 	 	 	 	
Bubbles	 	 	 	 	 	
Bile/Chyme	 	 	 	 	 	
Brightness	 	 	 	 	 	
	 	 	 	 	 	
QE	 	 	 	 	 	
OAA	 	 	 	 	 	
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APPENDIX 4: PARTICIPANT CLINICAL RESEARCH FORM FOR 
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APPENDIX 5: PARTICIPANT PRE-PROCEDURE 





































	 	 	 	 	
Dizzy	
	
	 	 	 	 	
Nausea	
	
	 	 	 	 	
Vomiting	
	
	 	 	 	 	
Abdominal	pain	
	
	 	 	 	 	
Poor	sleep	
	
	 	 	 	 	
Bad	taste	
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APPENDIX 6: ITEMS COSTED IN ECONOMIC IMPACT STUDY 




     
Endoscopy room  Endoscopy consumables   
Olympus GIF HQ 290 or GIF- XP 290N [10]  Galipot (1)  50ml syringe (1) 
Olympus EVIS Lucera Elite video system [1]  Gloves (2 pairs)  Yankauer suction and tube (1) 
CO2 cylinder holder, cables and accessories [1]  Mouth guard (1)  Stack suction tube and liner (2 per session) 
CO2 insufflator [1]  Xylocaine and spray catheter (1)  Water (sterile; 3L per session) 
Endogator EGP-100 [1]  Phenylephrine and lidocaine nasal spray (1, TNE only)  Simethicone 80mg/ml 
A set of air channel connectors, tubes, blocker and leak test 
connectors [1] 
 Nonenzymatic pre clean (1)  Disposable face shield * 
Various IT equipment  Blood pressure cuff (disposable per session)  Hair cap* 
Observations machine [1]  Endogator water jet connector (per session)  Waterproof gown* 
Portable airway suction unit [1]  CO2 tubing (per session)  Face mask respirator (FFP) 3* 
Patient trolley [1]  Biopsy valve (1)   
Plastic trays and lids [10]  Biopsy forceps   
Maintenance contracts [per scope and per stack]  Sample pot, formalin solution and transport bag   
     
Reprocessing unit  Reprocessing consumables  Sedation 
Multichamber Washer disinfector [8]  Hats (two / cycle)  Blue IV cannula (1) 
Drying cabinet [4]  Gloves (3 pairs/ cycle)  Disposable tourniquet (1) 
Vapour phase Hydrogen peroxiade sterilisers [1]  Gown (3 pairs / cycle)  5ml Luer slip syringe (1) 
Trolley washer [1]  Pre-cleaning pod (one / cycle)  Drawing up filtered needle (1) 
Reverse osmosis unit and connectors [1]  Leak test filter (one / 10 cycles)  10ml Luer slip syringe (1) 
Vacuum packer [1]  Detergent for leak tester (one/ 750 cycles)  Clinell alcohol wipe (1) 
Maintenance contracts  Sink detergent (one /400 cycles)  Kidney dish (1) 
• Sterilising and quality management systems  Brushes (one / cycle)  Cotton ball (1) 
• Trolley washer  Red and green plastic bags (two / cycle)  Nasal cannula and O2 tube 2m (1) 
• Washer disinfector  Vacuum pack (one / cycle)  Midazolam 2mg/2ml (1) 
• Reverse osmosis unit  Washer: water, electricity, disinfectant and detergent (per 
cycle) 
 10ml saline (1) 
• Drying cabinets     
• IT equipment  MACE room  MACE consumables 
• Parts and additional callouts (once a month)  Ankon NaviCam system and capsule locator [1]  AKT-1 Capsule endoscope (1) 
  Data recorders [15]  Simethicone 80mg/ml 
  Maintenance contract   
 
